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FUNCTIONALIZATION OF PYRIDINES AND OTHER AZINES VIA PHOSPHORUS 
LIGAND-COUPLING REACTIONS 
 
  Nitrogen heterocycles are ubiquitous in pharmaceutical compounds with pyridine being 
one of the most frequently occurring examples. The discovery and development of new drugs rely 
heavily on our ability to modify these commonly occurring structures.  The functionalization of 
pyridine has a long history but despite this, there remain some deficiencies in this area of synthesis.  
Reactions which expand upon the known methodologies are of tremendous value to medicinal 
chemists who frequently work with pyridines and similar azines.  
 Chapter one will cover the relevance of pyridines in pharmaceuticals and will explain how 
structural features contribute to their presence in drugs. Conventional and newer methods to 
functionalize pyridine are also addressed. Chapter two will describe the work of the McNally lab 
in the development of heterocyclic phosphonium salts as reagents to selectively functionalize 
pyridines. An application of these salts is as precursors to form C−O bonds from alkoxide 
nucleophiles.  
 Chapter three presents the development of a strategy to construct bis-heterobiaryls using 
phosphorus ligand-coupling. This method offers an alternative to the widely used metal-catalyzed 
approaches which often struggle in the synthesis of bis-heterobiaryls. Lastly, chapter four will 
expand upon this work showing a new approach to prepare bis-heterobiaryls using heteroaryl 
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The Relevance of Azines in Pharmaceuticals and Methods of Functionalization 
1.1 Occurrence of Electron-Deficient Nitrogen Heterocycles in Drug Compounds  
 Electron-deficient nitrogen heterocycles are some of the most common motifs found in 
drug compounds. In a 2014 survey of FDA approved small molecule drugs, pyridine was found to 
be the second most common nitrogen heterocycle with 62 unique examples out of a total of 1035.1 
Only piperidine with 72 examples was featured in more drugs. Other common electron-deficient 
nitrogen heterocycles include pyrimidines, pyrazines, quinolines, and quinazolines which account 
for a combined 37 examples (Figure 1.1). 
 
 Figure 1.1: Occurrence of Electron-Deficient Nitrogen Heterocycles in Pharmaceuticals   
These heterocycles are present in some of the most well-known drugs on the market 
(Figure 1.2). Claritin, Lunesta, and Nexium, which are household names, and all feature a 
pyridine.2 Velcade3 and Tasigna,4 which are both cancer treatments, contain a pyrazine and 
pyrimidine, respectively. Ibrance, a treatment for breast cancer and one of the top-selling drugs in 




Figure 1.2: Pharmaceuticals Featuring an Electron-Deficient Nitrogen Heterocycle 
1.2 General Properties of Pyridine  
Heteroaromatics, a subset of heterocycles, are aromatic compounds with at least one 
heteroatom (non-carbon atom) incorporated in the ring. When the heteroatom is nitrogen this can 
have a pronounced effect on the properties of the aromatic ring and this is best illustrated by 
comparing benzene and pyridine.6 Nitrogen is significantly more electronegative than carbon, and 
consequently the -system of pyridine has less electron density. Additionally, the nitrogen lone 
pair is orthogonal to the -system and thus cannot donate electrons into the ring. A greater amount 
of electron density is weighted towards the nitrogen atom causing pyridine to have a dipole 
moment of 2.2 D. The electron density of benzene, on the other hand, is evenly distributed within 
the ring and thus the ring has no dipole moment. 
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The reactivity of pyridine is also influenced by the presence of the electron-withdrawing 
nitrogen which causes the  system to be less reactive towards electrophiles when compared with 
benzene and electron rich arenes such as phenol or aniline (Figure 1.3).6 Pyridine can react though 
the -system via electrophilic aromatic substitution but generally requires harsh conditions (vide 
infra). Another important consequence of the nitrogen is that it makes the 2- and 4-positions 
electrophilic and thus nucleophiles can add into the ring.7 Examples of this reactivity include the 
Chichibabin and nucleophilic aromatic substitution (SNAr) reactions which will be discussed later 
in this dissertation. Lastly, the orthogonal lone pair of the nitrogen can enable pyridine to act as a 
Brønsted or Lewis base.  
 
Figure 1.3: Reactivity of Pyridine as A) -nucleophile B) electrophile C) base 
1.3 Influence on Drug Design 
 Pyridine and other electron-deficient nitrogen heteroaromatics can have a large influence 
on the pharmacodynamics and pharmacokinetics of a drug. These heterocycles affect the 
solubility of a drug, its metabolism in the body, and lastly its ability to bind to a specific target. 
The aqueous solubility of a drug can impact on the oral absorption and the rate which it is taken 
into the body.8 A drug which is too hydrophobic will have a low concentration in the 
bloodstream and thus will be poorly circulated throughout the body requiring higher dosing. 
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Addition of polar functionality will increase the hydrophilicity of the compound making the drug 
more water soluble. Pyridine and other nitrogen heterocycles can be incorporated onto a drug 
scaffold for this purpose.9   
A common way for the body to remove a drug is through its oxidation to a more polar 
intermediate which is easier to excrete. This process generally involves CYP450 enzymes which 
can introduce polar hydroxyl groups making the drug more water soluble.10 Drugs with electron-
rich aromatics are more susceptible to this process and thus will be removed from the body at a 
quicker rate. To slow the rate of metabolism, electron-deficient aromatics such as pyridine can be 
used instead.9  
Nitrogen heterocycles can also be incorporated onto drugs to influence its binding to a 
biologic target. The lone pair on the nitrogen can serve as a hydrogen bond acceptor in this regard, 
allowing for binding to the polar functionality commonly found in drug targets. An example of 
this can be seen in Figure 1.4 with Gleevec where the nitrogen atom of pyridine hydrogen bonds 
with a specific methionine present in the Abl kinase.13 In addition, ring systems can improve 
selective binding by filling a hydrophobic pocket within the enzyme.11 In the example with 
Gleevec, the pyridine and pyrimidine serve this purpose through hydrophobic interactions with the 
enzyme. An additional benefit of a ring system is that it provides rigidity, limiting possible 





Figure 1.4: Hydrogen Bonding Between Gleevec and a Methionine Residue  
1.4 Functionalization of Pyridine  
1.4.1 Conventional Methods of Pyridine Functionalization  
 As pyridines are common in drug compounds, it is important to be able to synthesize new 
examples with a range of functional groups at different positions on the ring. A common approach 
to modify pyridine is through a versatile functional group such as a halogen. Halogens are 
commonly used in metal-catalysis and as precursors for radicals and anions. A halide can be 
installed on an aromatic by reacting it with an electrophilic halogen source via an electrophilic 
aromatic substitution (EAS) reaction. Halogenation via EAS on electron-rich arenes can be carried 
out at room temperature but for pyridine this process  is extremely difficult given the −deficient 
ring and thus requires harsher conditions.6 For example, the bromination of pyridine requires 
heating in elemental bromine and sulfuric acid at elevated temperatures (Scheme 1.1, A).14 These 
conditions are not applicable on pyridines with acid sensitive functionality or with groups which 
can preferential react with bromine. While 3-bromopyridne is the major product, dibromination 
can also occur. To increase the electron density in the ring, the N-oxide can be formed using an 
oxidant such as peroxide.15 The lone pairs of the oxygen can donate into the ring causing pyridine 
to react with bromine at the 4-position (Scheme 1.1, B).6 The N-oxide is removed using a reductant 
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such as triphenylphosphine or dimethyl sulfide. The additional steps to install and then remove the 
N-oxide lessen the practicality of this route. 
 
Scheme 1.1: Halogenation via EAS: A) 3-Bromination B) 4-Bromination via N-Oxides 
 Chlorination on pyridine N-oxides is carried out using phosphoryl chloride (Scheme 1.2).16 
The mechanism of this reaction involves the oxygen of the N-oxide attacking the phosphorus of 
the phosphoryl chloride releasing a chloride anion which then attacks either the 2- or 4-position of 
the pyridine. Subsequent base elimination provides the chloropyridine. Thionyl chloride has also 
been used in a similar manner as a chlorinating agent.17  
 
Scheme 1.2: Chlorination of Pyridine N-oxide 
 Direct metalation using strong bases followed by trapping with an electrophile is a common 
approach to install a halogen or to make a C−C bond on the pyridine ring.18 Common bases for 
this process include alkyl lithiums and lithium amides. For substituted pyridines, selectivity is 
typically controlled using directing groups which can coordinate with the lithium ion. Depending 




Scheme 1.3: Examples of Direct Metalation Followed by Trapping with an Electrophile  
 One of the oldest methods to functionalize pyridine is the Chichibabin reaction (Scheme 
1.4). First disclosed in 1914, this method enables the 2-position amination of pyridine from sodium 
amide.21 The mechanism of this reaction involves an addition-elimination where sodium amide 
attacks into the ring resulting in a Meisenheimer intermediate, which then subsequently loses 
hydride to regain aromaticity. Amination is a useful transformation as the 2-aminopyridine motif 
is present in various drug compounds such as Sonidegib22 and Netupitant.23  
 
Scheme 1.4: Example of the Chichibabin Reaction 
 Pyridines are known to react with radicals via the Minisci reaction (Scheme 1.5).24 In this 
process, a radical, typically an alkyl or aryl, is generated from a carboxylic acid precursor. The 
radical will add into the ring of a protonated pyridine forming a radical cation.25 Abstraction of the 
adjacent hydrogen atom regains aromaticity of functionalized pyridine. The radical will selectively 





Scheme 1.5: Example of the Minisci Reaction  
1.4.2 New Approaches to Functionalize Pyridine  
 A recent trend in pyridine functionalization is the incorporation of photocatalysis into the 
Minisci reaction. By using photocatalysis one circumvents the need for strong chemical oxidants 
and higher temperatures to generate the required radical.26 The Merck process group took this 
approach when developing a mild set of conditions for the late-stage alkylation of pharmaceuticals. 
An iridium photocatalyst and blue light (450 nm) cause a peroxide precursor to decompose 
releasing an alkyl radical at room temperature. The alkyl radical then reacts with the protonated 
azine via a Minisci reaction. An example of this process applied to loratadine can be seen in 
Scheme 1.6. Other examples utilizing photoredox chemistry includes the important work from the 
Molander,27 MacMillan,28,29 and Stephenson30 groups.  
 
Scheme 1.6: Late-Stage Functionalization of Pharmaceuticals  
9 
 
 The use of C−H activation has been a recent development in pyridine functionalization. 
One of the most commonly used methods is iridium-catalyzed borylation developed by Ishiyama, 
Miyaura, and Hartwig (Scheme 1.7).31,32 The Ir(I) complex reacts with B2pin2 and the bipyridine 
ligand to form the active Ir(III) catalyst. C−H activation followed by reductive elimination yields 
the C−B bond. The reaction on unsubstituted pyridine gives a mixture of 3- and 4-borylated 
products with a 2:1 ratio, respectively. On substituted pyridines, the regioselectivity is largely 
influenced by sterics. The Bpin group is a versatile functional handle and thus its installation on 
pyridine is an important transformation. Jin Quan Yu’s palladium-catalyzed C−H activation on 
pyridines should also be mentioned as an important finding in this area.33 
 
Scheme 1.7: Iridium Catalyzed Borylation of Pyridine  
 2-Fluoropyridines can easily be accessed by reacting a pyridine with silver(II) fluoride 
(AgF2) in acetonitrile at room temperature. (Scheme 1.8).34 This method, developed by the 
Hartwig group, installs a fluoro selectively at the 2-position of pyridine, and ortho to the nitrogen 
of other azines such as quinoline and diazines. 2-Fluoropyridnes are valuable precursors for SNAr 
reactions providing easy access to C−O and C−N bonds when reacted with alcohols and amines, 
respectively. The mechanism of fluorination is believed to first involve the coordination of AgF2 
to the pyridine followed by the addition of one the fluorides to the 2-position. The abstraction of 




Scheme 1.8: Hartwig’s 2-Fluorination of Pyridine  
 The 2-position cyanation of pyridine can be accomplished using an activating group such 
as a triflyl or oxime.35,36 Addition of a cyanide anion into the pyridine ring followed by a base 
elimination of the activating group yields the 2-cyano product. Examples of these processes can 
be seen in Scheme 1.9.  
 
Scheme 1.9: Cyanation of Pyridine: A) Trifyl Activation B) Oxime Activation 
1.4.3 4-Selective Methods 
 When compared with the 2- and 3-positions, methods to selectively functionalize the 4-
position of pyridine are relatively scarce. One approach to selectively access the 4-position is to 
react the pyridine nitrogen with an electrophile to form a pyridinium which makes the ring more 
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electrophilic. Addition of a carbon nucleophile followed by an oxidant can introduce a C−C bond 
on the ring. The use of acyl pyridiniums in this application has been extensively studied by Daniel 
Comins and an example of this process can be seen in Scheme 1.10 showing the 4-
functionalization of nicotine.37 Nicotine is first reacted with pivaloyl chloride to activate the 
pyridine. A Grignard is reacted with copper(I) bromide to form a cuprate which adds selectively 
to the 4-position to form an N-pivaloyl-1,4-dihydronicotine. Subjecting this dearomatized species 
to elemental sulfur in toluene at reflux forms the 4-functionalized product.  
 
Scheme 1.10: Comins’ 4-Functionalization of Nicotine  
 A similar approach was developed by the Kanai group to install perfluoroalkyl and 
perfluoroaryl groups to the 4-position of pyridine as well as other azines (Scheme 1.11).38 A bulky 
borane Lewis acid is used to form the more electrophilic pyridinium and also prevents nucleophilic 
attack at the 2-positon due to its steric influence. Tetrabutylammonium difluorotriphenylsilicate 
(TBAT) reacts with the silane to release a trifluoromethyl anion which then attacks the 4-position 
of the activated pyridine. The resulting dearomatized species is then oxidized using an iodonium 
salt. While the reaction is selective for the 4-position, the presence of groups at the 3-position led 




Scheme 1.11: Kanai’s Trifluoromethylation of Pyridines and Azines  
 A bulky Lewis acid was also employed by the Nakao group in their 4-selective alkylation 
of pyridine (Scheme 1.12).39 A bulky aluminum Lewis acid, methylaluminum bis (2, 6-di-t-butyl-
4-methylphenoxide) (MAD), coordinates to the nitrogen of pyridine and then the nickel catalyst 
with an NHC ligand, IPr, undergoes oxidative addition into the para C−H bond. Migratory 
insertion across the alkene followed by reductive elimination yields the alkylated product with 
minor amounts of the secondary isomer.  
 
Scheme 1.12: Nakao’s 4-Selective Alkylation of Pyridine 
 In 2019, Rubin Martin developed a selective silylation of pyridine using Et3SiBPin and 
KHMDS (Scheme 1.13).40 The silyl group has seen some interest due to its potential application 
in drugs, but can also be used as a functional handle for subsequent transformations. The reaction 
is believed to proceed by the formation of a distinct silyl anion which then attacks the pyridine 
ring. Interestingly, the selectivity can be controlled by solvent. When the solvent is dimethylethane 
(DME) the reaction favors the 4-position over the 2-position (10:1 for pyridine). When dioxane is 
used the selectivity switches to favor the 2-position (6:1). The process can be applied to 




Scheme 1.13: Selectivity of Silylation of Pyridine Controlled by Solvent 
1.5 Conclusion  
 The functionalization of pyridine remains an important topic in synthesis given its 
relevance in pharmaceuticals. Despite being studied extensively, there remain deficiencies in this 
area. There are numerous methods to selectively functionalize the 2- and 3-positions of pyridine, 
but relatively few methods which target the para C−H bond. In subsequent chapters, the McNally 
group provides a solution to this problem by the selective installation of a phosphonium group to 
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Heteroaryl Ether Synthesis using Heterocyclic Phosphonium Salts 
2.1 Chapter Overview  
 The development of a new strategy to synthesize heteroaryl ethers is presented in this 
chapter. The heteroaryl ether motif is common in pharmaceuticals but is difficult to construct 
without prefunctionalized starting material, such as heteroaryl halides. As shown in section 1.4.1, 
pyridines are difficult to halogenate beyond simple examples, thus more complex heteroaryl ethers 
cannot easily be accessed. Our two-step approach circumvents this requirement, allowing C−O 
bond formation from the C−H bond of a pyridine or diazine. Regioselective formation of a 
heterocyclic phosphonium salt followed by a reaction with an alkoxide yields the heteroaryl ether. 
This strategy was applied to a variety of pyridines ranging in complexity from building blocks to 
pharmaceuticals. My co-worker, Ryan Dolewski, developed the reaction to make the heterocyclic 
phosphonium salts and prepared most of the examples that would be used in this process. Professor 
Robert Paton carried out the computational analysis to help us understand the mechanism. Work 
presented in this chapter lead to a publication in the Journal of American Chemical Society1 and 
subsequent publications using a similar approach.2,3  
2.2 Background  
2.2.1 Heteroaryl Ethers in Pharmaceuticals  
A heteroaryl ether is a heteroaromatic featuring an ether linkage. This motif is common in 
pharmaceuticals with numerous examples featuring an azine, specifically. (Figure 2.1). 
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Sulfadoxine, a malaria treatment, and Bedaquline, a tuberculosis drug, are on the World’s Health 
Organization’s list of essential medicines and both contain the heteroaryl ether motif.4 Two 
additional examples include Simeprevir and Grazoprevir which are treatments for hepatitis C.5 
Nexium, one of the top-selling drugs in 2012, has an ether linkage at the 4-position of the pyridine 
ring (Figure 1.2).6 Other proton pump inhibitors such as Prevacid and Protonix are structurally 
similar to Nexium, having this heteroaryl ether motif.7  
 
Figure 2.1: Heteroaryl Ethers Found in Pharmaceuticals 
2.2.2 Conventional Methods to Prepare Heteroaryl Ethers  
Heteroaryl ethers are typically prepared from heteroaryl halide and alcohol precursors.8 
Pyridines with a halogen or pseudo-halogen at the 2- or 4-position can react with alcohols or 
alkoxides via a nucleophilic aromatic substitution (SNAr) process (Scheme 2.1, A).9 Reactions at 
the 3-position of pyridine are generally more difficult often requiring additional withdrawing 
groups on the ring or high temperatures. The SNAr reaction begins with the nucleophilic attack of 
the alkoxide on the ipso position of a leaving group (I) resulting in a charged intermediate known 
as a Meisenheimer complex (II). Elimination of the leaving group yields the rearomatized product 
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with an ether linkage (III). More recent studies show that the SNAr reaction on pyridine could also 
be concerted, forgoing a charged intermediate.10 The rate-determining step of a SNAr reaction is 
the attack of the nucleophile on the pyridine ring. Since electron-deficient rings have faster reaction 
rates, pyridines with electron-withdrawing groups such as fluoro, chloro, and nitro groups are 
typically used. In examples featuring more than one halide at an SNAr active position, such as 2,4-
dichloropyidine, there may be a lack of regiocontrol depending on the nucleophile and the 
conditions.11 
 
Scheme 2.1: Conventional Methods to Synthesize Heteroaryl Ethers: A) SNAr Reactions B) 
Metal-Catalysis C) Alkylation reactions 
 Heteroaryl ethers are also prepared using transition metal-catalysis (Scheme 2.1, B).12–15 
A metal catalyst, typically palladium or copper, oxidatively inserts into the carbon-halogen bond 
(V). Next there is a ligand exchange at the metal center between an alcohol or alkoxide and the 
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halide (VI). Reductive elimination forms the C−O bond (III) while reducing the metal and 
regenerating the catalyst. 
 Alkylation is another approach to construct heteroaryl ethers but requires the preinstalled 
hydroxyl functionality (Scheme 2.1, C).16 In this process, a base is used to deprotonate the 
hydroxyl group (VIII) which is then alkylated using an alkyl halide via an SN2 mechanism (IX). 
Competing reactivity at the nitrogen atom complicates this process.  
2.2.3 Recent Methods to Prepare Heteroaryl Ethers 
A novel method from MacMillan uses nickel catalysis in combination with photochemistry 
to construct C−O bonds (Scheme 2.2, A).17 Like previous methods using metal-catalysis, this 
requires a heteroaryl halide and an alcohol, but in this case, nickel is used instead of palladium or 
copper. Nickel is generally not used as a catalyst in heteroaryl ether formation because the resulting 
nickel(II) aryl alkoxide complex will not easily undergo reductive elimination. Using 
photocatalysis, the Ni(II) complex can be oxidized to a more reactive Ni(III) species making 
reductive elimination more facile.  
A medicinal chemistry group from Pfizer developed a straightforward approach to install 
a heteroaryl ether linkage at the 2-position of a pyridine from the corresponding N-oxide (Scheme 
2.2, B).18 Using a phosphonium activating group known as PyBroP, this reaction is carried out 
under mild conditions. The oxygen of the pyridine N-oxide attacks PyBroP displacing a bromide. 
The resulting activated complex is then attacked at the 2-position of pyridine by an alcohol, and 




Scheme 2.2: Recent Examples of Heteroaryl Ether Synthesis: A) MacMillan’s Aryl Ether 
Synthesis using Photoredox Catalysis B) Pfizer’s Heteroaryl Ether Synthesis from N-oxides 
 
2.2.4 Anders’ Initial Findings on Heterocyclic Phosphonium Salts 
 A seminal report from Ernst Anders provided a framework for the synthesis of heterocyclic 
phosphonium salts (Scheme 2.3).19 Pyridine (X) was reacted with triflic anhydride (Tf2O) at low 
temperatures in dichloromethane to form a triflyl pyridinium salt (XI). Addition of 
triphenylphosphine into the ring results in a dearomatized intermediate (XII). Triethylamine 
(NEt3) enables elimination of the triflyl group to regain aromaticity and form the phosphonium 
salt (XIII). The triflyl ammonium byproduct is removed in a water workup.  
 
Scheme 2.3: Mechanism of Heterocyclic Phosphonium Salt Formation 
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 One of the most important aspects of this reaction was its regioselectivity. The 
phosphonium group was installed with complete selectivity at the 4-position of pyridine (Scheme 
2.4). When applied to pyrazine this method worked reasonably well, with a yield of 71%. For 
quinoline, the selectivity worsens with 47% of the 4-position isomer versus 13% of the 2-position. 
A large deficiency in this method was its application on 3- and 5-substituted pyridines. 3-
Methylpyidine, for example, gave a low yield of 21%. 
 
Scheme 2.4: Anders’ Method of Phosphonium Salt Formation 
 The reactivity of the heterocyclic phosphonium salts was explored by Anders although 
most of this work focused on transformations from the bis-phosphonium salt. These salts featuring 
a second phosphonium group are inherently more reactive, but the additional step to synthesize 
them make them significantly less practical. Sodium azide could be reacted with 4-pyridyl 
phosphonium salt to form an iminophosphorane in 3% yield (Scheme 2.5, A), however, when the 
bis-salt was used, the yield increases to 81% (Scheme 2.5, B).19 A heteroaryl ether could also be 




Scheme 2.5: Initial Examination of Reactivity by Anders: A) Iminophosphorane from the 
Phosphonium Salt, B) Iminophosphorane from the Bis-Phosphonium Salt C) Methoxylation 
from the Bis-Phosphonium Salt 
 
2.2.5 C−O Bond Construction via Phosphorus Ligand-Coupling  
 Aryl ethers could be formed from a phosphorane through a process known as ligand-
coupling. By heating methoxy-tetraphenylphosphorane to 190-200 °C, anisole and 
triphenylphosphine can be produced (Scheme 2.6).21 It has been proposed that this transformation 
proceeds via a concerted mechanism where the C−O bond is formed while the C−P and C−O bonds 
are broken.22 The hypervalent P(V) phosphorus is reduced to the lower P(III) oxidation state in 




Scheme 2.6: C−O Bond Formation via Apical-Apical Ligand-Coupling  
2.3. Results and Discussion  
2.3.1 Improved Conditions to Make Heterocyclic Phosphoniums Salts 
 Since Anders’ initial findings in the late 1980s, the heterocyclic phosphonium salts found 
no practical use in synthesis. Given the medicinal relevance of pyridines and the difficulty in 
functionalizing these structures regioselectivity, the McNally lab looked at using the phosphonium 
group as a functional handle to carry out subsequent transformations. To make this approach 
synthetically useful we had to expand the scope of the phosphonium salts. Ryan Dolewski, a co-
worker in the McNally lab, was able to improve the generality of the reaction by changing the 
base. Use of triethylamine gave low to no yields when the pyridine had a substituent at the 3- or 
5-position. It was found that 1,8-Diazabicyclo(5.4.0)undec-7-ene (DBU) would give high yields 
on these same substrates. For example, when triethylamine is used as the base in making the 
phosphonium salt on 3-methylpyridine, it was found to give a 0% yield in our hands versus 21% 
that Anders reported. Triethylamine is believed to have failed because of a steric clash between its 
alkyl groups and the 3-methyl group on pyridine. When DBU is used, the yield increases to 78% 




Scheme 2.7: Importance of Base in the Phosphonium Salt Reaction  
 The reaction is compatible with a wide range of pyridines (Table 2.1) with complete 
selectivity for the 4-position in the large majority of examples.1 The salts are typically free-flowing 
powders, benchtop stable, and only in a few rare cases did we observe decomposition over time. 
The purification of these compounds involves precipitation from diethyl ether, avoiding the need 
for column chromatography. Pyridines with a halogen at the 2- or 4-position (2a-2c, 2j, and 2n) 
undergo the reaction without concerns of halide displacement. The method can tolerate bulky 
substituents such as phenyl (2f) or trifluoromethyl groups (2l) at the 3- or 5-position despite a 
potential steric clash with triphenylphosphine. Examples of 2,3- (2g and 2h), 2,5 (2i-2l), and 3,5-
disubstituted2,23 pyridines have all been shown to work well, and only in a few examples did we 
observe minor amounts of regioisomers (2k and 2p). For 4-substituted pyridines, the phosphonium 
is instead installed at the 2-position (2m-2o), and diazines such as pyrazines (2p) and pyrimidines 
(2q) are also compatible. More complex structures such as the 2,3,4-trisubstituted example 2o can 







Table 2.1: Conditions and Scope of Heterocyclic Phosphonium Salts  
 
 Reproduced with permission from J. Am. Chem. Soc. 2016 , 138, 13806. Copyright 2016 American Chemical Society. 
2.3.2 Development of a Heteroaryl Ether Synthesis using Phosphonium Salts 
 To install a carbon-heteroatom bond on pyridine, we proposed reacting the phosphonium 
salt with a nucleophile, such as an alkoxide, to displace triphenylphosphine via an SNAr reaction. 
An initial successful result came when the phosphonium salt of pyridine was reacted with two 
equivalents of potassium tert-butoxide in tetrahydrofuran (THF) at room temperature to form 4-
(tert-butoxy)pyridine in 47% yield after 30 minutes (Scheme 2.8). Phosphonium salts of pyrazine 
and 2-bromopyridine were subjected to the same conditions and both gave reasonable yields of the 
corresponding heteroaryl ether in 40% and 66%, respectively. Different alkoxides were reacted 
with the 2-phenylpyridine phosphonium salt and the primary, secondary, and tertiary examples all 
gave good yields ranging from 69% to 78%. Notably, potassium tert-butoxide consumed all the 
phosphonium salt after only 5 minutes. The sodium alkoxides were prepared by deprotonation of 
the corresponding alcohol with NaH. Other solvents were explored but THF proved to provide the 




Scheme 2.8: Initial Survey of Reactivity A) Azine Phosphonium Scope B) Alcohol Scope 
  The reaction of the 2-phenylpyridine phosphonium salt (2d) with cyclohexanol and NaH 
was optimized by vary the conditions (Table 2.2). The amount of alkoxide (entry 1-3) had a small 
influence with 1.5 equivalents giving the highest yields. Excess alcohol or NaH did not improve 
the yield (entry 4 and 5), while concentration was found to be the most important factor as can be 
seen in entries 6-8. Diluting the reaction from 0.25 M to 0.125 M lowered the yield while 








Table 2.2. Optimization of Reaction Conditions for Heteroaryl Ether Synthesis 
 
Entry NaH (equiv) CyOH (equiv) Concentration (M) % Product 
1 1.0 1.0 0.25 76 
2 1.5 1.5  0.25 81 
3 3.0 3.0 0.25 70 
4 1.0 1.5 0.25 76 
5 3.0 1.5 0.25 70 
6 1.5 1.5 0.125 61 
7 1.5 1.5 0.5 89 
8 1.5 1.5 1.0 89 
 
 We next examined the scope of alcohols compatible in this reaction (Table 2.3). Primary, 
secondary, and tertiary alcohols all work well despite the potential steric clash of the bulkier 
alkoxides. Use of benzyl alcohol yields 3db which can be hydrogenated to introduce hydroxyl 
functionality. Metal hydroxides have been shown to decompose the salts and thus a direct 
hydroxylation is not applicable. Despite reduced nucleophilicity, trifluoroethanol (3dd) can be 
used to form the corresponding heteroaryl ether in high yield. Propargyl alcohol (3de) allows for 
installation of an alkyne for potential application in click chemistry. Alcohols featuring other 




Table 2.3: Conditions and Scope of Heteroaryl Ethers using Different Alcohols  
 
Reproduced with permission from J. Am. Chem. Soc. 2016,  138, 13806. Copyright 2016 American Chemical Society. 
 
 The scope of the heterocyclic phosphonium salts was then examined using sodium hexan-
1-olate as our nucleophile (Table 2.4).1 The reaction is chemoselective over halogens at the 2-
position of pyridine. Phosphonium salts of 2-chloro (3aa) and 2-bromopyridine (3ba) showed only 
trace halide displacement. Examples with a 2-fluoro group (3ca and 3ja) gave only minor amounts 
(<10%) of the undesired product from SNAr processes. Bulky substituents (3fa and 3ha) at the 3- 
or 5-positions do not impede attack of the alkoxide. Pyridines featuring donating (3ka) or 
withdrawing groups (3la) work in reasonable yield despite changes in electronics on the ring, and 





Table 2.4: Conditions and Scope of Heteroaryl Ethers using Different Phosphonium Salts 
 
Reproduced with permission from J. Am. Chem. Soc. 2016,  138, 13806. Copyright 2016 American Chemical Society. 
 
2.3.3 Late-Stage Functionalization of Pharmaceuticals and Bioactive Molecules 
 Late-stage functionalization is the introduction of new functionality on a complex substrate 
later in its synthesis.24–26 This approach can significantly reduce the amount of work required to 
access derivatives by circumventing the need to design a different route for each new product. 
Late-stage functionalization can be applied to compounds which are already bioactive to 
potentially discovery a new drug. The phosphonium group can be installed on various 
pharmaceuticals which contain a pyridine and reacting these salts with an alkoxide provides an 
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easy route to install an ether linkage and thus accomplish late-stage functionalization (Table 2.5).1 
Nicotine worked well in this 2-step process despite the aliphatic amine within its structure (4,5). 
The methoxy derivative was found to take upwards to 5 steps from a literature synthesis.27 The 
carbamate group in Loratadine did not interfere with salt (6) or heteroaryl ether formation (7). 
Installing the phosphonium on Chlorphenamine failed initially, which we suspected was due to the 
presence of the amine. To solve this problem one equivalent of triflic acid was added to protonate 
the amine. A protected version of Chantix could be used in this process but the salt formation on 
a quinoxaline requires higher temperatures. The reaction with the alkoxide was relatively low 
yielding for this substrate (11). The acyl group of the Zytiga phosphonium salt underwent 
transesterification when reacted with alkoxides. Converting the acyl to an OTBS group resolved 
this problem. The hydroxyl of Cinchonidine could be protected with a benzyl group enabling both 












Table 2.5: Late-Stage Functionalization of Pharmaceuticals and Bioactive Molecules  
 
Reproduced with permission from J. Am. Chem. Soc. 2016,  138, 13806. Copyright 2016 American Chemical Society. 
 
2.4 Mechanism  
2.4.1 Proposed Mechanism of C−O Bond Formation 
 Heteroaryl ether formation from the phosphonium salt is thought to go through one of two 
different mechanisms. This transformation could be an SNAr mechanism where the alkoxide 
nucleophile attacks the ipso position of the phosphonium salt.8 By either a stepwise or concerted 
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process, triphenylphosphine is displaced providing the heteroaryl ether (Scheme 2.9). 
 
Scheme 2.9: Heteroaryl Ether Formation via SNAr 
 Another possible mechanism for heteroaryl ether formation is phosphorus ligand-coupling 
(Scheme 2.10). In this process, the alkoxide nucleophile directly attacks the phosphorus atom of 
the phosphonium salt, leading to a P(V) phosphorane. This intermediate can couple two of its 
ligands while reducing the phosphorus atom to a P(III) oxidation state.22 This pathway yields the 
same products as the SNAr process, a heteroaryl ether and triphenylphosphine.  
 
Scheme 2.10: Heteroaryl Ether Formation via Phosphorus Ligand-Coupling 
 Unlike the SNAr mechanism, ligand-coupling is relatively unexplored. To provide evidence 
of this pathway we attempted to observe the phosphorane intermediate in-situ via 31P NMR 
analysis. We carried out the reaction between the 2-phenylpyridine salt and sodium hexan-1-olate 
at −80 °C in deuterated THF and progressively increased the temperature. Initially, only the 
resonances of the phosphonium (25.25 ppm) and triphenylphosphine oxide (28.09 ppm) were 
observed. The oxide was attributed to undesired side reactions when setting up the experiment. 
Once the reaction was warmed to −30 °C a new peak was observed at −70.64 ppm (Scheme 2.11). 
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This chemical shift falls in the range of a phosphorane species.29 Warming to 0 °C and then to 
room temperature showed this peak growing in intensity. Detection of this intermediate provides 
evidence that this reaction was going through ligand-coupling. At room temperature, 
triphenylphosphine is detected as a byproduct of heteroaryl ether formation and after several hours 
the phosphorane peak disappears and the triphenylphosphine peak increases in size.  
  
  
Scheme 2.11: Detection of Phosphorane Intermediate by in-situ 31P NMR at −30 °C  
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A computational study from Professor Robert Paton provided additional evidence that this 
reaction is proceeding through a step-wise ligand-coupling mechanism. After phosphorane 
formation, the alkoxyl group occupying an apical position is thought to migrate onto the pyridine 
occupying one of the equatorial positions, leading to a dearomatized intermediate. This migration 
proceeds through a 3-center-4-electron bond between the phosphorus, ipso carbon of pyridine, 
and the oxygen of the alkoxyl group (Scheme 2.12). DFT calculations indicate that the energy 
barrier for this process is relatively low at 22.9 kcal/mol and the G of the resulting 
dearomatized intermediate is −21.1 kcal/mol. Phenyl migration is a possible outcome, but the 
energy barrier is 7.4 kcal/mol higher and it is not observed experimentally. Elimination of 
triphenylphosphine gives the heteroaryl ether product.  
 
Scheme 2.12: DFT Calculated Transition State 
2.4.2 Undesired Pathways 
 The reaction between the heterocyclic phosphonium salts and an alkoxide can lead to some 
undesired products such as triphenylphosphine oxide and the C−H product (the result of the 
phosphonium group being replaced with a hydrogen atom). One possible explanation for these 
compounds is the presence of hydroxide from water contamination. Hydroxides are known to 
decompose phosphonium salts by forming a phosphorane (Scheme 2.13, A). Deprotonation of the 
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hydroxyl group forms triphenylphosphine oxide while releasing a discrete pyridyl anion. The 
anion, which is the most electron withdrawing ligand on the phosphorus atom, is subsequently 
protonated leading to the C−H product.  Other potential pathways involve the formation of the 
alkoxyphosphorane. By either an SN2 or E2 mechanism triphenylphosphine oxide and the C−H 
product are formed (Scheme 2.13, B and C) 
 
Scheme 2.13: Potential Decomposition Pathways: A) Hydroxide Attack B) E2 C) SN2 
2.5 Other Nucleophiles  
 After successfully demonstrating heteroaryl ether formation from alkoxides, we next 
explored the viability of other nucleophiles in this reaction manifold. Thiolates were found to work 
in comparable yields using the same method. In our first publication we showed one example on 
nicotine (Scheme 2.14),1 and Ryan Anderson, a co-worker in the McNally lab, has since expanded 
upon this work.  
 
Scheme 2.14: Initial Result for Thioether Formation  
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 Ryan optimized the reaction for thiolate nucleophiles and expanded the scope (Scheme 
2.15).2 Like the reaction with alkoxides, thioether formation can occur on 2-halopyridines with 
minimal displacement of the halide via an SNAr process. 3,5-Disubstituted examples work with 
selectivity for the 4-position despite potential issues from the steric influence of the 3- and 5-
position substituents. This method can be applied to pharmaceuticals as demonstrated on the 
example with Etoricoxib. 
 
Scheme 2.15: Optimized Conditions and Scope of Thioethers 
 As Anders showed in his original work, azides can react with the phosphonium salts to 
form an iminophosphorane (Scheme 2.4).19 This reaction proceeds by nucleophilic attack on the 
phosphonium salt either through an SNAr reaction or by ligand-coupling to displace 
triphenylphosphine. The resulting heteroaryl azide then reacts with the triphenylphosphine via a 
Staudinger reaction. Anders’ initial attempt to make an iminophosphorane from the phosphonium 
salts was low yielding (3%). An optimization of this reaction showed that we could achieve much 
higher yields. Heating the phosphonium salt of 2,2’-bipyridine in DMSO with one equivalent of 
sodium azide at 100 °C yields the iminophosphorane. In-situ hydrolysis of the iminophosphorane 




Scheme 2.16: Iminophosphorane Formation and Hydrolysis  
 Chirag Patel, a co-worker in the McNally lab, optimized this reaction further, expanded the 
scope, and demonstrated the utility of the iminophosphorane through derivatization (Scheme 
2.17).3 The iminophosphorane formation is high yielding on electron-deficient substrates such as 
diazines and pyridines with electron-withdrawing groups. The iminophosphorane can be alkylated 
and then hydrolyzed to form a secondary amine. This functional group can also be reacted with 
carbon disulfide to install an isothiocyanate.  
 





 The two-step approach of making a heterocyclic phosphonium salt and subsequent C−O 
bond formation is a useful tool in synthesizing heteroaryl ethers. This strategy is compatible with 
a range of pyridines and diazines. Avoiding the requirement of pre-installed halogens, this method 
can be applied to substrates which are difficult to halogenate and on pharmaceuticals as a way to 
carry out late-stage functionalization. The mechanism of heteroaryl ether formation is believed to 
be a stepwise ligand-coupling reaction involving the formation of a phosphorane intermediate 
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Bis-Heterobiaryl Formation using Phosphorus Ligand-Coupling 
3.1 Chapter Overview  
 This chapter describes the development of a new method to prepare bis-heterobiaryls 
through the use of phosphorus ligand-coupling. Despite the bis-heterobiaryl motif being prevalent 
in pharmaceuticals, their synthesis remains a challenge using conventional synthetic methods. In 
a three-step sequence, two heteroaromatics can be coupled together from their C−H bonds by 
selectively installing them on to a phosphorus reagent. By exploiting the reactivity of hypervalent 
phosphorus, this strategy represents one of the first synthetically useful applications of phosphorus 
ligand-coupling. Ben Boyle and Xuan Zhang assisted in synthesizing the bis-heterobiaryl 
examples to demonstrate the scope of this process. Ben Boyle performed the kinetic studies on the 
phosphorus ligand-coupling reaction. Professor Robert Paton and Juan Alegre-Requena carried 
out the computational analysis. The work presented in this chapter culminated in a publication in 
the journal Science.1 
3.2 Background  
3.2.1 Significance of Bis-Heterobiaryls  
  A bis-heterobiaryl is a structure possessing two heteroaromatics linked directly together 
through a C−C bond. This motif can be found in various pharmaceuticals and other bioactive 
molecules such as natural products (Figure 3.1). Imatinib, used in the treatment of myelogenous 
Leukemia, has a pyridine and pyrimidine linked directly together. Etoricoxib, used as a non-
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steroidal anti-inflammatory, has a 2,3’-bipyridine within its structure.2 MK-1064, a drug being 
developed for insomnia, has three pyridines linked in succession.3 AMG-319, a potential treatment 
for human papillomavirus, has a quinoline and pyridine bonded together.4 Streptonigrin5 and 
Nemertelline6 are both natural products of interest which contain this motif. 
 
Figure 3.1: Examples of Pharmaceuticals and Bioactive Molecules Containing a Bis-Heterobiaryl 
3.2.2. Synthesis of Bis-Heterobiaryls using Metal-Catalysis 
 An important disconnection when considering the synthesis of bis-heterobiaryls is the 
carbon-carbon bond connecting the two rings (Figure 3.2). The most common approach to 
construct this bond is through metal-catalysis using an electrophilic coupling partner paired up 
with a nucleophilic coupling partner.7,8 The electrophilic partner is typically a (hetero)aryl halide 
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or triflate while the nucleophilic partner can a (hetero)aryl boronic acid, zinc, or stannane. This 
section will specifically cover the Suzuki-Miyaura, Negishi, and Stille cross-coupling methods.   
 
Figure 3.2: Synthesis of Bis-Heterobiaryls and Common Precursors used in Metal-Catalysis  
In a Suzuki-Miyaura reaction, a (hetero)aryl halide and (hetero)aryl boronic acid are 
coupled using a metal catalyst.9,10 Specific bases and ligands are generally required for the reaction 
to be high yielding. A representative example from the Fu group showing the synthesis of a 2,4’-
bipyridine can be seen in Scheme 3.1, A.10 The Suzuki-Miyaura reaction is one of the most widely 
used methods in the pharmaceutical industry,11 but despite its popularity, limitations exist, 
especially in the synthesis of molecules containing basic functionality, such as amines. These 
motifs are known to interfere with catalysis by binding to the metal catalyst.12 This issue is 
especially problematic when coupling two complex substrates, such as drug fragments which 
might have several basic nitrogen atoms. Another significant issue is the availability of the cross-
coupling precursors. Building block heteroaryl halides are largely commercially available, but 
beyond these examples the availability is severely limited. Without required halide starting 
material, one is forced to carry out a halogenation reaction, which is particularly challenging on 
pyridines as described earlier (see 1.4.1).13 Heteroaryl boronic acids and similar derivatives such 
as boronic esters, tetrafluoroborates and MIDA boronates are significantly less available 
commercially when compared with the heteroaryl halide.14 Installation of the boronic acid 
functionality on a heteroaromatic from the C−H bond often relies on a two-step protocol where 
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you must first halogenate and then convert the halogen to the desired C−B bond.15 Lastly, boronic 
acids can decompose in the basic conditions typically used for a Suzuki-Miyaura coupling. This is 
especially true for 2-pyridyl boronic acids which are well known to be highly unstable (see 4.2.2).16
 Alternative metal-catalyzed cross-coupling methods include the Negishi and Stille 
reactions. The Negishi reaction is similar to a Suzuki-Miyaura coupling in that it utilizes heteroaryl 
halides and a metal catalyst but differs in the use of heteroaryl zinc reagents as an alternative to 
boronic acids.17,18 The heteroaryl zinc is commonly prepared from a heteroaryl halide precursor 
using zinc metal or a zinc halide. While the Negishi reaction is robust, heteroaryl zincs generally 
suffer from a poor shelf-life and are typically prepared shortly before use.19 A representative 
example from the Merck process group shows a coupling between a 2-pyridyl zinc and a 
chloroquinoline in Scheme 3.1, B.17 The Stille reaction20 also differs in the nucleophilic coupling 
partner, requiring an organostannane. Heteroaryl stannanes, which are commonly prepared from a 
halide precursor,21 are more stable than their boronic acid counterparts but are toxic.22 An example 
from the Schubert group shows the coupling of a 2-pyridylstannane with a 2-bromopyridine in 
Scheme 3.1, C.23 While metal-catalyzed cross-couplings are essential reactions for the modern 
organic chemist, these methods are limited in their use to synthesize bis-heterobiaryls and thus 




Scheme 3.1: Representative Examples of Metal-Catalyzed Cross-Couplings used in Bis-
Heterobiaryl Synthesis 
 
3.2.3 Synthesis of Bis-Heterobiaryls using Phosphorus Ligand-Coupling  
 An alternative approach to metal-catalysis and significantly less explored method to 
synthesize bis-heterobiaryls is through phosphorus ligand-coupling. Examples from the literature 
typically involve the formation of 2,2’-bipyridines. Unlike metal-catalyzed reactions, phosphorus 
ligand-coupling requires the formation of a precursor where both the heteroaromatics are already 
attached to the phosphorus atom. This precursor can be a phosphonium salt or phosphine oxide 
with two or three pyridyl groups. The mechanism of ligand-coupling proceeds with the phosphorus 
atom being attacked by a nucleophile to form a P(V) phosphorane intermediate.20 From this 
intermediate, two of the pyridyl groups couple while breaking their bonds to phosphorus, in a 
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manner akin to reductive elimination in metal-catalysis. A detailed description of this mechanism 
is presented later in this chapter (see section 3.4). 
 The first report of bipyridine synthesis through phosphorus ligand-coupling came from 
Mann in 1948 (Scheme 3.2, A).21 In this process, 2-bromopyridine undergoes lithium-halogen 
exchange and then is reacted with phosphorus trichloride to form a tripyridylphosphine. The 
resulting phosphine is then reacted with methyl iodide in methanol to yield a bis-methylated 
bipyridinium. This transformation likely occurs by methyl iodide alkylating both of the nitrogen 
atoms of the pyridines and the phosphorus atom to form a phosphonium salt. Methanol attacks the 
phosphonium salt to form a phosphorane intermediate, which then undergoes ligand-coupling to 
give the bipyridinium product. Thirty years later, Newkome would report a different approach for 
phosphorus ligand-coupling (Scheme 3.2, B).22 In this example, a dipyridylphosphine is formed 
from dichlorophenylphosphine reacting with a lithiated pyridine. The resulting phosphine is then 
oxidized with hydrogen peroxide to form a phosphine oxide. An alkoxide attacks the phosphine 
oxide to form an alkoxy-phosphorane intermediate which then undergoes ligand-coupling.  
 In 1989, Uchida and Oae demonstrated an approach involving the formation of a 
tripyridylphosphine, which was then alkylated with benzyl bromide to yield a phosphonium salt 
(Scheme 3.2, C).23 Addition of acidic water forms a phosphorane intermediate after the attack of 
water on the phosphorus atom. The phosphorane then selectively couples the pyridyl groups. A 
year later, Uchida and Oae developed another route to the bipyridine by reacting lithiated pyridine 
with phosphoryl chloride. A tripyridylphosphine oxide forms and undergoes attack by another 
lithiated pyridine to form a phosphorane before yielding the bipyridine via ligand-coupling 
(Scheme 3.2, D). While these seminal reports showed potential use in organic synthesis, little was 
done in this area. These methods are limited with the use of highly reactive butyl lithium and have 
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only been demonstrated to work to form dimer products. Our group believed that phosphorus 
ligand-coupling could be developed beyond these initial reports into a viable alternative to metal-
catalyzed cross-couplings in the synthesis of bis-heterobiaryls.  
 




3.3 Results and Discussion  
3.3.1 Initial Ligand-Coupling Results 
 In our initial report on heterocyclic phosphonium salts, we were able to selectively make 
C−P bonds on various pyridines and diazines (see 2.3.1).24 With the knowledge of the previously 
reported phosphorus ligand-coupling reactions in mind, we next looked at installing a second 
heteroaryl group onto the phosphorus atom. We envisioned this was achievable replacing 
triphenylphosphine, used in stage 2, with a heteroaryl phosphine (P). By sequential addition of 
triflic anhydride (Tf2O), 2-pyridyl phosphine, and 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) to 
2-phenylpyridine, a bis-heterobiaryl phosphonium salt was formed in 62% yield (Scheme 3.3). 
The heteroaryl phosphines were found to work in comparable yields to the reactions using 
triphenylphosphine.  
 
Scheme 3.3: Initial Bis-Heterobiaryl Phosphonium Synthesis  
 Following the synthesis of the bis-heterobiaryl phosphonium salt, we next looked towards 
developing the ligand-coupling reaction. Initially, the bis-heterobiaryl phosphonium salt was 
reacted in 1:1 acetone/water mixture25 at 80 °C (Scheme 3.4). This resulted in the formation of 2'-
phenyl-2,4'-bipyridine in 25% yield and a pyridyl phosphine oxide in 65% yield through an 
undesired pathway similar to the decomposition of a phosphonium salt shown in Scheme 2.13, 




Scheme 3.4: Initial Ligand-Coupling Result 
3.3.2 Development of the Ligand-Coupling Conditions 
 Our initial result for phosphorus ligand-coupling had provided the desired bipyridine 
product and showed that ligand-coupling could be developed further. We next reacted the bis-
heterobiaryl phosphonium salts with methanol, but this gave no product formation and little to no 
conversion of the phosphonium salt starting material. When two equivalents of anhydrous HCl 
was used in combination with methanol the product yield increased to 76%.  To optimize the 
reaction, we first tested a variety of alcohols (Table 3.1). Isopropyl alcohol, tertbutyl alcohol, 
trifluoroethanol, and hexafluoroisopropanol were all found to be effective, albeit in lower yields 
ranging from 51% to 68%. Lowering the amount of acid to 1.0 and 0.5 equivalents gave lower 
yields of 62% and 48%, respectively. Lowering the temperature to 60 °C gave a yield of 44%, at 
40 °C gave a yield of 12% and at room temperature there was no reactivity. Ethanol was found to 
give a comparable yield of 70% and was preferable to methanol due to the higher boiling point. A 
further improvement in yield to 80% was achieved by increasing the concentration from 0.2 M to 
0.4 M. Increasing the concentration further was not found to improve the reaction. Triflic acid 
(TfOH) was found to work in a comparable yield to HCl while weaker acids such as trifluoroacetic 
acid performed poorly. The optimized conditions for ligand-coupling were found to be 80 °C in 
ethanol (0.4 M) with two equivalents of acid (HCl or TfOH).  
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Table 3.1: Optimization of the Ligand-Coupling Reaction  
 
Entry Solvent HCl (equiv) Temperature (°C) Concentration (M) % Product 
1 MeOH - 80 0.2 0 
2 MeOH 2.0 80 0.2 76 
3 IPA 2.0 80 0.2 57 
4 TBA 2.0  80 0.2 51 
5 TFE 2.0 80 0.2 59 
6 HFIPA 2.0 80 0.2 68 
7 MeOH 1.0 80 0.2 62 
8 MeOH 0.5 80 0.2 48 
9 MeOH 2.0 60 0.2 44 
10 MeOH 2.0 40 0.2 12 
11 EtOH 2.0 80 0.2 70 
12 EtOH 2.0 80 0.4 80 
13 EtOH 2.0 80 1.0 80 
Yields based on 1H NMR using 1,3,5-trimethoxybenzene as an internal standard 
3.3.3 Development of the Fragmentable Phosphine 
 After our initial result using 2-pyridylphosphine, we sought to make different heteroaryl 
phosphines which were not commercially available. Pyridyl phosphines can be prepared by 
reacting a pyridyl lithium with chlorodiphenylphosphine27 or through metal-catalysis using a 
pyridyl halide and diphenylphosphine as the coupling partners.28 To avoid the requirement a pre-
functionalized starting material that would limit the reaction scope, we developed a new method 
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where we could form the phosphine from the C−H bond of the azine. Our approach centers around 
the ability of certain alkyl phosphonium salts to fragment under basic conditions to form an alkene 
and a phosphine. An example of this fragmentation can be seen in Scheme 3.5.29 
 
Scheme 3.5: Example of Fragmentation Under Basic Conditions 
 We imagined that by using a phosphine with the right alkyl linker in our salt synthesis we would 
form an alkyl phosphonium. This phosphonium salt could then undergo a fragmentation pathway 
to make a heteroaryl phosphine. A report from Alonso showed that various alkyl phosphines could 
be prepared from a neat reaction between diphenylphosphine and Michael acceptors (Scheme 
3.6).30 We believed these acrylate derived phosphines could be an effective route for heteroaryl 
phosphines via a modified phosphonium salt synthesis procedure. 
 
Scheme 3.6: Synthesis of a Fragmentable Phosphine  
 With modifications in our standard set of conditions for the phosphonium salt synthesis,24 
we could instead form the heteroaryl phosphine. Replacing triphenylphosphine with methyl 3-
(diphenylphosphaneyl)propanoate, a phosphine derived from methyl acrylate, and increasing the 
equivalents of DBU, we could form the heteroaryl phosphine in good yield (Scheme 3.7). DBU 
has a dual role of rearomatizing the azine (see Int-I in Scheme 3.8) after phosphine attack to form 
54 
 
an alkyl phosphonium salt (see Int-II in Scheme 3.8) and then initiating an elimination reaction 
likely via an E1CB mechanism to form the desired heteroaryl phosphine. Methyl acrylate is released 
as a byproduct from this reaction. Development of these conditions allowed us to leverage our 
previous scope of heteroaryl phosphonium salts as heteroaryl phosphines. 
 
Scheme 3.7: Heteroaryl Phosphine Synthesis using the Fragmentable Phosphine  
3.3.4 Scope of Bis-Heterobiaryl Synthesis  
 From the C−H bonds of two different pyridines or diazines we could make a bis-
heterobiaryl in a 3-step process (Scheme 3.8). In step A, a heteroaryl phosphine is formed from 
the sequential addition Tf2O, fragmentable phosphine (1), and DBU to a pyridine. In step B, a 
different pyridine can be used. Sequential addition of Tf2O, the heteroaryl phosphine (2a) and 
DBU forms the bis-heterobiaryl phosphonium salt. In step C, the salt is subjected to 2 equivalents 




From Science, 2018, 362, 799. Reprinted with permission from AAAS 
Scheme 3.8: Optimized Conditions to Make Bis-heterobiaryls  
 
 Using an optimized set of conditions, we then examined the scope of bis-heterobiaryls 
(Scheme 3.9). From our initial result, we demonstrated that we could make 2,4’-bipyridines. We 
next showed that this strategy could be applied to make 4,4’ and 2,2’ systems with pyridines or 
quinolines. Given the highly selective nature of the phosphonium salt reaction, the 4-position of 
the pyridine or quinoline must be blocked to gain access to the 2-position. Pyrimidines and 
pyrazines worked as well, but in a lower yield for the coupling step. The reaction allows for 
electron-donating groups (4d) as well as electron-withdrawing groups (4c) on the azine ring. 
Importantly, we can have halogens such as bromines (4b) and chlorines (4i) which is significant 
because they can be competing sites of reactivity in metal-catalyzed cross-couplings. Medicinally 




From Science, 2018, 362, 799. Reprinted with permission from AAAS 
Scheme 3.9: Bis-heterobiaryls from Building Block Substrates  
 
 After applying this process on various building block substrates, we sought to demonstrate 
the method on substrates where metal-catalysis would be challenging, or the coupling partners 
would be difficult to synthesize. We prepared four azines which are similar to drug fragments that 
a medicinal chemist might encounter (4l-4o). These azines have a high number of basic 
functionality and would pose a problem for metal-catalysis via poisoning of the catalyst. In 
addition, halogenating or borylating these structures to make the required coupling precursors 
would be extremely challenging. An additional complication is the multiple reactive sites, which 
would make it difficult to control selectivity. Using our method, we can selectively make C−P 
bonds to both the heteroaromatics to form the bis-heterobiaryl phosphonium salt, and through 
ligand-coupling, we can construct a bis-heterobiaryl. By utilizing this convergent coupling 
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strategy, one could quickly generate a library from a small number of fragments. 
 
From Science, 2018, 362, 799. Reprinted with permission from AAAS 
Scheme 3.10: Coupling of Complex Fragments and Bioactive Molecules 
 
 The three-step process to make bis-heterobiaryls is also applicable on pharmaceuticals and 
drug candidates themselves (Scheme 3.10). While installing a heteroaryl group on a preexisting 
pharmaceutical would likely not be useful in a late-stage functionalization strategy, this process 
could see use later in a drug’s synthesis. Late-stage functionalizations are most useful when small 
incremental changes can be made to the bioactive compound. Addition of a pyridine, for example, 
would represent a relatively large change to the molecule. Using ligand-coupling in a drug’s 
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synthesis is advantageous in that it circumvents issues of metal contamination which is relevant in 
many cross-coupling methods. Use of metals is generally not detrimental in the early steps of a 
route as there could be multiple subsequent purifications. Later in the synthesis, this is problematic 
as the metal could be difficult to remove completely.  
3.3.5 Important Considerations in Reaction Planning   
 The order of addition onto the phosphorus atom can be vital when making the bis-
heterobiaryl phosphonium salt. This is relevant when there is a large steric difference at the 2-
position of two different pyridines. In example 4b, the 2-arylpyridine was made into a pyridyl 
phosphine which was then reacted with 3-chloropyridine to make the bis-heterobiaryl 
phosphonium salt in 82% yield. When the order is switched and the 3-chloropyridine is made into 
the pyridyl phosphine first, the following reaction fails to yield the phosphonium salt (Scheme 
3.11). The explanation for this result is that the triflyl group can exchange between the pyridines. 
The steric influence at the 2-position causes there to be an unfavorable equilibrium where the triflyl 
group is activating the wrong pyridine, and thus the reaction cannot proceed. In example 4b it is 
necessary to make the 2-substituted pyridine the phosphine first for there to be a favorable 




From Science, 2018, 362, 799. Reprinted with permission from AAAS 
Scheme 3.11: Importance of the Order of Addition onto the Phosphorus Atom  
 
 Another important consideration when carrying out ligand-coupling is the choice of acid 
and the number of equivalents used. In many examples, HCl and TfOH worked to give comparable 
yields, but in some cases, there was a large difference. When a pyridine has a bulky substituent at 
the 3- or 5-position or electron withdrawing groups an undesired chlorination reaction could occur 
during step C when HCl was used. In an example featuring Loratadine, chlorination was a 




Yields based on 1H NMR using 1,3,5-trimethoxybenzene as an internal standard 
Scheme 3.12: Unexpected Chlorination in the Ligand-Coupling Step from HCl  
 
In some cases, the chlorination product was not observed, but instead, a heteroaryl ether formed 
from a sequential SNAr reaction with ethanol and the chloropyridine (Scheme 3.13). To prevent 
these undesired pathways, TfOH can be used instead of HCl, as triflate is a non-nucleophilic 
counter anion.  Lastly, the equivalents of acid used should equal the number of basic nitrogen 
atoms. For example, in 4l we used three equivalents of triflic acid. A lower number will result in 
a slower rate for the reaction.  
 
Yields based on 1H NMR using 1,3,5-trimethoxybenzene as an internal standard 





3.3.6 Limitations of the Bis-Heterobiaryl Synthesis 
 While the method to synthesize bis-heterobiaryls was found to be relatively robust, we did 
encounter some examples which were low yielding or failed outright (Figure 3.3). Steps A and B 
have the same limitations as they go through a similar mechanism. 2,6-Disubstituted pyridines are 
low yielding (<5%) for phosphonium salt formation, which is thought to be due to the influence 
of the ortho groups on the formation of the trifyl pyridinium. 2-Trifluoromethylpyridines also do 
not work well for similar reasons. Alkyl amides are not suitable for these reactions as they can 
react with the Tf2O. 4-Alkyl and 4-arylpyridines generally work poorly (<25%) but the reason for 
this is not fully understood. 
 In step C, 2-halopyridines did not work well as there was competing an SNAr reaction with 
the alcohol. 2-Methoxypyridine suffered from dealkylation when HCl and ethanol were used. 
When TfOH and TFE were used instead, the reaction rates were found to be slow and full 
conversion of the starting material was not achieved after several days. Cyano groups were also 
found to react in HCl and ethanol and coupling was slow in TfOH and TFE. Esters could be 
tolerated but would undergo transesterification. 3-Bromo and 3-iodopyridines would dehalogenate 




Figure 3.3: Difficult Substrates for Bis-Heterobiaryl Synthesis  
3.4 Mechanism  
3.4.1 Experimental and Computational Probe of the Mechanism   
 The mechanism of phosphorus ligand-coupling was probed through experiment and 
computation. A coupling to make a 4,4’-bipyridine was used as the model system. To begin the 
investigation, we wished to understand the role of acid in this process. The reaction begins with 
the protonation of both the pyridines. This makes the phosphorus atom of the phosphonium salt 
more electrophilic, allowing for an alcohol to attack forming a phosphorane intermediate. The 
effect of the acid on the electrophilicity of the phosphorus atom can be observed by 31P NMR. 
Each additional equivalent of acid causes the peak of the phosphonium to shift further downfield 




From Science, 2018, 362, 799. Reprinted with permission from AAAS 
Scheme 3.14: Influence of Acid on the Phosphorus Chemical Shift 
 
Without acid, the phosphorane does not form and ligand-coupling does not occur. This result led 
us to believe that the attack of the alcohol is the rate-determining step of the reaction and changing 
the electronics of the phosphonium salt should impact the rate of the reaction. By installing 
different groups at the 4-position of the aryl substituents of the phosphine we could make the 
phosphorus more or less electrophilic (Scheme 3.15). When this group is chloro the rate increases 
with a krel of 1.89. When this group is methoxy the rate of the reaction decreases with a krel of 0.16. 
This result agrees with our hypothesis that the nucleophilic attack of the alcohol is the rate-




From Science, 2018, 362, 799. Reprinted with permission from AAAS 
Scheme 3.15: Influence of Electronics on the Rate of the Reaction 
 
 Additional evidence that the attack of the alcohol is the rate-determining step comes from 
reacting the phosphonium salt with an alkoxide (Scheme 3.16). When this alternative method is 
used, the phosphorane forms at room temperature and the ligand-coupling reaction is complete 
within 5 minutes. When the acidic conditions are used ligand-coupling does not occur until 40 °C 
and the rate is relatively slow even at 80 °C requiring several hours to go to completion.  
 
From Science, 2018, 362, 799. Reprinted with permission from AAAS 
Scheme 3.16: Ligand-Coupling via an Alkoxide Nucleophile  
 
 To gain further insight, we collaborated with the Paton lab to probe the mechanism using 
computation. Their study indicates that once the phosphorane (Int-III) forms, there is a trans-
effect that weakens the C−P bond of the apical pyridine and there is a buildup of electron density 
on this ring. This weakening is reflected in the computed bond lengths with the apical pyridine 
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C−P bond being 1.99 Å vs the equatorial pyridine C−P bond being 1.86 Å (Scheme 3.17). The 
apical pyridine can migrate on to the protonated equatorial pyridine as electron density from the 
C−P  bond is donated in the  of the aromatic ring. The protonated equatorial pyridine serves 
as a good acceptor for this buildup of negative charge. This migration goes through a transition 
state (TS-1) with three-center, four-electron bonding between the pyridyl groups and the 
phosphorus atom. The energy barrier of this process is 14 kcal/mol and after the migration, a 
dearomatized intermediate (Int-IV) forms and elimination of methyl diphenylphosphinite regains 
aromaticity by forming the bis-heterobiaryl.  
 
From Science, 2018, 362, 799. Reprinted with permission from AAAS 
Scheme 3.17: DFT Calculated Transition State for Ligand-Coupling Reaction  
 
3.4.2 Rationalization of Selectivity During Phosphorus Ligand-Coupling 
 The computational study also provided insight into the selectivity of the reaction. From the 
phosphorane intermediate (Int-III) it is possible for a phenyl or the alkoxy group to migrate but 
experimentally only the heteroaryl groups were observed to couple. The phosphorane can have 
different conformations which can interchange through a Berry pseudorotation.31,32 The most 
stable phosphorane has the most electron-withdrawing groups in the apical positions.33 The lowest 
energy conformation places a protonated pyridine and alkoxy group in these apical positions and 
the two phenyls and the other protonated pyridine occupy the equatorial positions. A trans-effect 
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weakens the C−P of the aromatic opposite the alkoxy group, resulting in a buildup of negative 
charge on the ring. The protonated pyridine is more effective at stabilizing the electron density as 
opposed to a phenyl group. The apical pyridine can be viewed as the donor group which will then 
migrate on to the acceptor group in the equatorial position. The acceptor can be the other 
protonated pyridine or one of the phenyls. For the migration to occur the electron density of the 
apical C−P  bond donates into the  of the equatorial group. The protonated pyridine can 
stabilize the negative charge from this donation and thus it is the acceptor group.  
 The selectivity was also examined through computation. The G‡ for different migrations 
was determined using DFT calculations (Figure 3.4). The energy of migration which leads to the 
desired bis-heterobiaryl formation was found to be 14 kcal/mol. When acid is removed from the 
system, G‡ increases to 30 kcal/mol. This increase in energy is rationalized by the loss of 
stabilization that results from protonation of the two pyridines. Phenyl migration is disfavored by 
11 kcal/mol over pyridyl migration. Alkoxy migration was surprisingly close with a G‡ of 18 
kcal/mol. Despite heteroaryl ether formation being known from our previous work, we did not 
observe this product when bis-heterobiaryl phosphonium salts were used.  
 




3.5 Conclusion  
 The synthesis of bis-heterobiaryls using phosphorus ligand-coupling offers an alternative 
to metal-catalysis. Some of the challenges associated with catalysis such as precursor synthesis, 
catalyst poisoning, and metal contamination can be avoided using this method. The significance 
of this approach was demonstrated on complex fragments and pharmaceuticals where the use of 
metal-catalysis would likely not be an option. The mechanism of phosphorus ligand-coupling in 
the synthesis of a 4,4’-bipyridines was probed through experiment and computation. Phosphorane 
formation by the attack of the alcohol was determined through experiments to be the rate-
determining step of the reaction. Computation suggests that from the phosphorane, ligand-coupling 
occurs through a stepwise migration of the apical pyridine onto the equatorial pyridine followed 
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Bis-Heterobiaryl Formation from Chloroazines 
4.1 Chapter Overview  
 Building from our previous work on phosphorus ligand-coupling, this chapter describes an 
alternative approach to synthesize bis-heterobiaryls using chloroazines as coupling partners. From 
diphenylphosphine, two sequential SNAr reactions on chloroazines yields a bis-heterobiaryl 
phosphonium salt. A new set of conditions were then employed to induce ligand-coupling to form 
the bis-heterobiaryl. Importantly, this approach gives access to 2,2’-bipyridines which were 
difficult to synthesize using our previous ligand-coupling method. This work represents an 
advancement to the area of heterobiaryl synthesis by enabling a general and convenient coupling 
of abundant chloroazines without the need for specialized sets of conditions often required when 
using metal-catalyzed cross-couplings. Ben Boyle contributed to the discovery and optimization 
of this process, as well as, the preparation of a number of bis-heterobiaryl examples presented in 
the scope. This work has been published on the preprint server ChemRxiv.1  
4.2 Background  
4.2.1 Importance of 2,2’-Bipyridines 
 The 2,2’-bipyridine motif is a privileged motif in a variety of areas in chemistry (Figure 
4.1). As mentioned previously, bis-heterobiaryls are found in pharmaceuticals and specifically a 
2,2’-bipyridine can be found in the structure of the drug candidate MK-1064 (Figure 3.1).2 
Caerulomycin C, an antibiotic natural product produced by Streptomyces caeruleus, features this 
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motif.3 Bipyridines can also be found in a variety of different material applications such as 
OLEDs,4 metallosupramolecular assemblies,5 and nanomaterials.6 Importantly, 2,2’-bipyridines 
are ligands in metal complexes commonly used in organic synthesis.7  
 
Figure 4.1: 2,2’-Bipyridines Found in Different Areas of Chemistry 
4.2.2 New Approaches to 2,2’-Bipyridine Synthesis  
 The most common approach to synthesize unsymmetrical 2,2’-bipyridines is through 
metal-catalyzed cross-couplings.6 While the Suzuki–Miyaura, Negishi and Stille couplings are 
some of the most widely used reactions for biaryl synthesis, their application in the synthesis of 
2,2’-bipyridine has not been as extensively studied. The Suzuki-Miyaura coupling has the most 
difficulties in this aspect as the required 2-pyridyl boronic acid is often unstable in the typical 
reaction conditions. This creates a significant challenge in applying this reaction for 2,2’-
bipyridine synthesis. The mechanism for this decomposition has been extensively studied by the 
Lloyd-Jones group. They found that in neutral conditions at 70 °C the half-life of the 2-pyridyl 
boronic acid is just 27 seconds (Scheme 4.1).8 The decomposition occurs via protodeboronation 
where the carbon-boron bond is cleaved and subsequently protonated via a zwitterionic 
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intermediate.9 The N-H bond of the pyridine interacts with the borate to stabilize the zwitterionic 
intermediate, promoting this decomposition pathway. 
 
Scheme 4.1: Protodeboronation of 2-Pyridyl Boronic Acids via Zwitterionic Intermediate   
 The unreliability of 2-pyridyl boronic acids has been an issue in the pharmaceutical 
industry where the Suzuki-Miyaura coupling is commonly used. In a survey of electronic 
notebooks from Pfizer, couplings using these reagents showed a very poor success rate with only 
28 out of 358 reactions giving a yield higher than 20%.10 
 To address this deficiency in the Suzuki-Miyaura coupling, many groups have worked 
towards creating boronic acid equivalents. One example is the MIDA boronate developed by the 
Burke group.11 This benchtop stable reagent slowly releases a boronic acid in-situ, limiting the 
time it can decompose in the reaction. A heteroaryl MIDA boronate can be prepared by carrying 
out lithium-halogen exchange on a heteroaryl halide. The resulting organolithium intermediate is 
then trapped with boron isopropoxide followed by N-methyliminodiacetic acid (MIDA). A 2,2’-




Scheme 4.2: MIDA Boronate used in Bis-Heterobiaryl Synthesis 
 A different approach, pioneered by the Molander group, utilizes potassium trifluoroborate 
salts as boronic acid equivalents in metal-catalyzed cross-couplings.12 These air-stable salts are 
prepared by reacting a boronic acid or ester with aqueous KHF2. While Molander’s original work 
indicated that the 2-pyridyl variant did not work generally, Wu later showed successful couplings 
involving 2-pyridyl trifluoroborates which were also 6-substituted.13 It should be noted that 6-
substituted boronic acids show much greater stability when compared with other examples 
(Scheme 4.3).10 
 
Scheme 4.3: 2-Pyridyl Trifluoroborate used in Bipyridine Synthesis 
 Besides boronic acid derivatives, alternative partners have also been developed. An 
emerging method comes from the Willis group using pyridine sulfonates.14 The sulfonates can be 
prepared from 2-mercapto or 2-halopyridine precursors and are benchtop stable. An example of a 
bipyridine synthesis using this method can be seen in Scheme 4.4. Despite recent advancements, 
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2,2’-bipyridine synthesis remains a significant challenge requiring the development of new 
methods.  
 
Scheme 4.4: Pyridine Sulfonate used in Bipyridine Synthesis 
4.2.3 Synthesis of Heteroaryl Phosphonium Salts via an SNAr Mechanism  
 Phosphonium salts can also be prepared via a nucleophilic aromatic substitution (SNAr) 
reaction between a heteroaryl halide and triphenylphosphine. In a paper from Toma, 2-
halopyridines were reacted neat with triphenylphosphine at elevated temperatures (120-180 °C) to 
give 2-pyridyl phosphonium salts (Scheme 4.5).15 While chloro, bromo, and iodopyridines worked 
using this method, 2-fluoropyridines failed to form the phosphonium salt. This result goes against 
typical SNAr reactivity, which suggests that 2-fluoropyridines should be the most active. Inorganic 
salts such as LiBr and LiPF6 were found to improve the yield of the reaction, although their role is 
not completely understood.  
 





4.3 Results and Discussion  
4.3.1 Tandem SNAr-Ligand-Coupling Results 
 From our initial findings utilizing bis-heterobiaryl phosphonium salts to make bis-
heterobiaryls (see chapter three), we sought to apply the ligand-coupling reaction in a new way to 
access compounds that we previously could not synthesize. We proposed that an SNAr reaction 
would form the phosphonium salt, and then through ligand-coupling, we would make a bis-
heterobiaryl. Initially, we reacted 4-chloropyridine hydrochloride with two equivalents of 2-
pyridylphosphine in ethanol at 60 °C leading to the formation of a bis-heterobiaryl phosphonium 
salt. Protonation of the 4-chloropyrdine significantly lowers the temperature required to carry out 
the SNAr reaction. After the salt formation, additional acid was then added, and the reaction was 
warmed to 80 °C. After 14 hours approximately 60% of the bis-heterobiaryl was formed by 1H 
NMR analysis (Scheme 4.6). 
 
Scheme 4.6: Sequential SNAr Ligand-Coupling Initial Result 
4.3.2 Optimized Conditions for 2,4’- and 4,4’-Bipyridines  
 The two-stage process involving phosphonium salt formation by an SNAr reaction followed 
by ligand-coupling was later optimized by Ben Boyle, a co-worker in the McNally lab. To improve 
the atom economy of this reaction the pyridyl phosphine was changed to the limiting reagent. In 
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the first stage, ethanol was replaced with 1,4-dioxane, sodium triflate was used as an additive, and 
the reaction was heated to 120 °C. While ethanol could be used to make the bis-heterobiaryl 
phosphonium salt at much lower temperatures, the competing ethanolysis posed a problem when 
more SNAr active substrates are used. In the second stage HCl, water, and trifluoroethanol (TFE) 
were added and the reaction was heated to 80 °C. Triflic acid (TfOH) was found to give nearly 
identical yields to HCl. This set of conditions were found to be optimal for 2,4’- and 4,4’-couplings 
(Scheme 4.7). For 2,4’-couplings it is best to use the 2-pyridyl phosphine as the donor as opposed 
to using a 4-pyridyl phosphine. Fluoro and bromopyridines can be used as well, but generally, give 
lower yields of the heterobiaryl product when compared with the chloropyridine.  
 





4.3.3 Optimized Conditions for Quinolines and Diazines 
 The initial set of conditions to make 2,4’ and 4,4’-bipyridines failed when applied to 
chloroquinolines and diazines. It was found that phosphonium salt formation was not going to 
completion after stage one. This was an unexpected result as chloroquinolines and diazines are 
significantly more reactive in SNAr reactions. It was later observed that the reverse reaction, 
chlorination via an SNAr process, was occurring and preventing the reaction from going to 
completion (Scheme 4.8).  
 
Scheme 4.8: Quinolines and Diazines Failed to go to Competition in Salt Formation 
 To solve this problem, we proposed trapping the phosphonium salt in-situ. If the 
nucleophile which initiates ligand-coupling was in the reaction from the start, then it could 
intercept the phosphonium salt before the reverse reaction could occur. Initially, we used 1.2 
equivalents of HCl, 10 equivalents of H2O, and trifluoroethanol as the solvent. Heating to 80 °C 
was sufficient to form the phosphonium which was subsequently reacted with H2O to give the bis-
heterobiaryl via ligand-coupling (Scheme 4.9). When coupling a pyridine to a quinoline (5f-j) it 
is best to use the quinoline as the acceptor (i.e. the chloroazine) and the pyridine as the donor (i.e. 
the heteroaryl phosphine). Diazines (5k and 5l) were found to work well when paired with other 
diazines but can also be paired with a pyridine or quinoline based on our previous work.16 While 
pyrimidines and quinazolines worked in reasonably yield, pyrazines were either low yielding or 




Scheme 4.9: Initial Result and Scope of Quinoline and Diazine Couplings 
4.3.4 Optimized Conditions for 2,2’-Bipyridines  
 The initial set of conditions to make 2,4’ and 4,4’-bipyridines failed when applied to 
synthesize 2,2’-bipyridines as the formation of the phosphonium salt was also not going to 
completion. The SNAr reaction was found to be more difficult at the 2-position than at the 4-
position and thus a different set of conditions were required (Table 4.1). Stage one was optimized 
to improve phosphonium salt formation and 2,5-chloropyridine and 2-pyridyl phosphine were 
chosen as coupling partners. Initially, it was found that switching from dioxane to a less polar 
solvent such as toluene (tol.) or chlorobenzene (PhCl) considerably improved the yield. Triflic 
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acid performed better than HCl and changing the additive to KPF6, increased the yield further. 
Temperature proved to be one of the most important factors; heating to 130 °C gave the best yields, 
whereas heating to 140 °C would give unwanted side products (Scheme 4.15).  
Table 4.1: Optimization of Phosphonium Salt for 2,2’-Coupling 
 
Entry Solvent Additive Temp. oC Conc. (M) Acid Yield (%)* 
1 dioxane/tol. (1:1) NaOTf 120 2 HCl 43 
2 dioxane/tol. (1:1) KPF6 120 2 HCl 49 
3 dioxane/tol. (1:1) NaOTf 120 2 TfOH 42 
4 dioxane/tol. (1:1) none 120 2 TfOH 57 
5 dioxane none 120 2 TfOH 46 
6 tol. none 120 2 TfOH 60 
7 tol. KPF6 120 2 TfOH 66 
8 tol. none 130 2 TfOH 70 
9 PhCl none 120 2 TfOH 51 
10 PhCl none 130 2 TfOH 67 
11 PhCl none 140 2 TfOH 69† 
12 PhCl KPF6 130 2 TfOH 81 
13 PhCl KPF6‡ 130 2 TfOH 73 
14 PhCl NaPF6 130 2 TfOH 79 
15 PhCl LiPF6 130 2 TfOH 78 
*1H NMR yields shown using triphenylmethane as an internal standard. †Undesired 
phosphonium salt observed. ‡1.5 equivalents of KPF6 was used instead of 1.0 equivalents. 
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 After improving the salt yield in stage one, stage two was found to require no change. This 
two-stage process was applied to a range of 2-chloropyridines and 2-pyridyl phosphines to make 
2,2’-bipyridines (Scheme 4.10). Tertiary amines (5n), amides (5q) and halogens (5r) can be 
tolerated in this process. Other examples feature medically relevant SF5 (5o), CF3 (5p), and OCF3 
(5e) groups.  It was found that 2,2’-couplings were generally lower yielding (35-58%) than that of 
2,4’- or 4,4’-couplings. The reason for this difference is currently being investigated by the 
McNally and Paton labs.  
 




4.3.5 Synthesis of Heteroaryl Phosphines via Acidic SNAr Conditions 
 After our initial findings showed that bis-heterobiaryl phosphoniums could be prepared 
using acidic SNAr conditions, Ben Boyle discovered that a similar approach could be applied to 
prepare the heteroaromatic phosphines. It was found that diphenylphosphine could be reacted 
with 1.2 equivalents of 2-chloropyridine and 1.0 equivalent of triflic acid in dioxane at 120 °C. 
Triflic acid served to make the 2-chloropyridine more reactive towards the SNAr process. After 
19 hours, 2-pyridyl phosphine was formed in 67% yield (Scheme 4.11).   
 
Scheme 4.11: Pyridyl Phosphine Synthesis by SNAr Initial Result 
 The reaction was later optimized to be more general and operationally simpler. The first 
change was making the chloroazine the limiting reagent as separating the excess chloroazine from 
the heteroaryl phosphine proved difficult. Changing the solvent to chlorobenzene and increasing 
the temperature to 130 °C significantly improved the yields. The optimized conditions and scope 
of the pyridyl phosphines can be seen in Scheme 4.12. The phosphines are typically benchtop 
stable powders but for long-term storage, the phosphines can be kept in a −20 °C fridge to slow 




Scheme 4.12: Scope of Pyridyl Phosphines  
 For the more electron-deficient azines such as quinolines and diazines, milder conditions 
were used. Heating the chloroazine with 1.2 equivalents of diphenylphosphine in trifluoroethanol 
at 80 °C was sufficient to get high yields. Acid was not required in these examples and the harsher 
conditions would lead to dehalogenation of the starting material. The optimized conditions and 




Scheme 4.13: Scope of Heteroaromatic Phosphines (Quinolines and Diazines) 
4.3.6 One-Pot Conditions for Bis-Heterobiaryl Synthesis  
 Ben Boyle found that the bis-heterobiaryl could be formed in a one-pot reaction from the 
respective chloroazines. Heteroaryl chloride 1 was reacted with diphenylphosphine and triflic acid 
at 130 °C for 16 hours (Scheme 4.14). Heteroaryl chloride 2 was then added along with sodium 
triflate and the reaction was heated to 130 °C for 12 hours. Lastly, 10 equivalents of water and 
TFE were added. Heating to 80 °C for 22 hours lead to a 2,4’-bipyridine in 67% yield. The other 





Scheme 4.14: One-Pot Synthesis of 2,4’-Bipyridine from Chloropyridines  
4.3.7 Problematic Substrates and Undesired Pathways 
 While this process to make heterobiaryls could be applied to a range of pyridines and other 
azines it is inherently limited in that we must carry out an SNAr reaction to make the phosphines 
and phosphoniums. Only the 2- and 4-halopyridines are suitable for this process while the 3-
halopyridines are unreactive under these conditions. Chloropyridines with electron-donating 
groups show poor reactivity as well (Figure 4.2). Pyridines with multiple halogens at SNAr active 
positions are not tolerated due to poor selectivity and over-reactivity. Both 2-chloro-5-
fluoropyridine and 2-chloro-3-fluoropyridine performed poorly when making the phosphine due 
to poor reactivity and oxidation of the resulting phosphine, respectively. Bromo and iodo atoms at 
the 3- or 5-positions on pyridine were avoided due to dehalogenation as noted in the previous 
chapter. Similarly, alkoxyl groups at the 2-positon were avoided due to dealkylation.  
 
Figure 4.2: Difficult Chloropyridines for Phosphine and Phosphonium Salt Formation  
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 In some examples the phosphine and subsequent phosphonium salt formation would 
succeed, but ligand-coupling would fail (Figure 4.3). This was the case when trying to carry a 
4,4’-coupling between two quinolines. After salt formation, no ligand coupling products were 
observed even after heating to elevated temperatures. A similar result was observed when making 
a 2,2’-bipyridine when one of the pyridines featured a 2- or 4-amino group.  
 
Figure 4.3: Examples Where Ligand-Coupling Failed 
 In a few rare cases, we would observe a chloro-phosphine metastasis between the two 
azines. In this undesired process the phosphonium salt forms but then subsequently reacts with a 
chloride ion via an SNAr reaction. If the chlorination is unselective, this leads to a mixture of two 
different heteroaryl chlorides and two different heteroaryl phosphines. From this mixture, three 
different phosphonium salts could form leading to three different bis-heterobiaryl products after 




Scheme 4.15: (A) Undesired Dimerization Observed Experimentally. (B) Formation of Three 
Different Phosphonium Salts via Chlorination 
 
4.4 Comparisons with Other Cross-Coupling Methods 
4.4.1 Improvements to Previous Ligand-Coupling Method 
 When compared with our previous method16 to make bis-heterobiaryls, the tandem SNAr-
ligand-coupling approach has some clear advantages (Figure 4.3). The ability to make the bis-
heterobiaryl phosphonium salt from the C−H bond of the azines using triflyl activation is desirable, 
but the high selectivity of the reaction for the 4-position of pyridine limits the different types of 
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couplings which can be achieved. From the C−Cl bond, you can access phosphoniums which 
cannot be made using the previous method. For example, to carry out a 2,2’-coupling this would 
require the 4-position to be blocked for each pyridine to access the 2-position C−H bonds. Using 
the tandem SNAr-ligand-coupling approach, a 2,2’-bipyridine can be synthesized from two 
different chloropyridines without concerns of selectivity.  
 Another advantage of this method is that it can tolerate substitution patterns and 
functionality that were problematic in our previous strategy. 2,6-Disubstituted and 2-
trifluoromethylpyridines presented issues for triflyl activation but do not interfere with the SNAr 
reaction when making the phosphonium salt. Functional groups such as alkyl amides, alcohols, 
and phenols react with triflic anhydride and thus were previously avoided. All these functional 
groups are tolerated in the SNAr reaction and the subsequent ligand-coupling reaction.   
 
Figure 4.3: Issues which are Addressed using the Tandem SNAr-Ligand-Coupling Approach 
4.4.2 Comparison with Metal-Catalyzed Cross-Coupling 
 An important consideration in cross-coupling is halide selectivity in structures featuring 
two or more halogens. In many examples, the metal will not discriminate, and this will lead to a 
mixture of products. The tandem SNAr-ligand-coupling approach avoids this issue as it is 
selective for the halide at the most SNAr active position. To demonstrate this utility, we carried 
out a comparison study of the two methods using 4,7-dibromoquinoline as a model substrate 
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(Scheme 4.16). Using 2-pyridylstannane and standard conditions for a bis-heterobiaryl Stille 
coupling we observed a mixture of products. When the tandem SNAr-ligand-coupling approach 
was used we observed exclusive reactivity at the 4-position.  
 
Scheme 4.16: Comparison Study Between Cross-Coupling Strategies 
4.5 Conclusion  
 The tandem SNAr-ligand-coupling approach provides a new way to access bis-
heterobiaryls that are difficult to prepare using our previous method or through metal-catalyzed 
cross-couplings. Specifically, the 2,2’-bipyridine motif is an important structural feature in various 
areas of chemistry and being able to easily access these compounds is an advancement to current 
synthetic methods. This method is operationally simple and can be applied to a range of 
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The work described in this dissertation shows the development and application of 
heterocyclic phosphonium salts in the selective functionalization of pyridines and other azines. 
The abundance of pyridines in pharmaceuticals and the difficulty in selectively functionalizing 
these structures make this research appealing to the field of medicinal chemistry. The 
phosphonium is installed selectively to the 4-position of pyridine and subsequent transformations 
can be carried out on this group. We were able to show that carbon-heteroatom bonds could easily 
be accessed by reacting phosphonium salts with various nucleophiles such alkoxides, thiolates, 
and azides. This method provides an alternative approach to SNAr and metal-catalyzed processes 
which are limited by the requirement of a heteroaryl halide which can be difficult to synthesize. 
Additionally, this dissertation describes the development of a new approach to synthesize 
bis-heterobiaryls using phosphorus ligand-coupling. Through the preparation of bis-heterobiaryl 
phosphonium salts, we could selectively couple two different azines by reacting them with acid in 
either alcohol or water. Importantly, this approach addresses some of the problems associated with 
metal catalysts and coupling partners required in metal-catalyzed cross-couplings. While 
phosphorus ligand-coupling has been known process, it has seen little application in synthesis. Our 
method provides a convenient strategy to access bis-heterobiaryls which are commonly found in 







Heteroaryl Ether Synthesis using Heterocyclic Phosphonium Salts: Experimental  
(Combined Work of Ryan Dolewski and Michael Hilton) 
 
A 1.1 General Methods and Materials 
 PPh3 (99%) was purchased from Oakwood Chemical and is most effective when crushed 
to a powder before use. Tf2O (99%) was purchased from Oakwood Chemical and used without 
further purification but was routinely stored in a –20 ºC fridge. NEt3 and DBU were distilled before 
use. NaH (60% in mineral oil) was purchased from Sigma Aldrich and was typically distributed 
into vials and stored in a desiccator. All reactions were run under a nitrogen atmosphere unless 
otherwise noted.  
A 1.2 Instrumentation 
 1H NMR spectra were recorded using a Varian 400 MR spectrometer (400 MHz) or an 
Agilent Inova 400 (400 MHz) spectrometer. The chemical shifts (δ) were reported in ppm and 
referenced to the corresponding NMR solvent: CDCl3 (7.26 ppm), (CD3)2SO (2.50 ppm), or 
CD3OD (3.31 ppm). Coupling constants (J) were reported in Hertz (Hz) and the multiplicity was 
reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, qn = quintet, sext = sextet, sp 
= septet, m = multiplet, br = broad. 13C NMR spectra were recorded using a Bruker Ultrashield–
400, a Varian 400 MR or an Agilent Inova 400 spectrometer. The chemical shifts (δ) were reported 




ppm), or CD3OD (49.00 ppm). Low–resolution mass spectra were recorded on an Agilent 6310 
Quadrupole Mass Spectrometer. Infrared spectra were recorded on a Bruker Tensor 27 FT–IR 
spectrometer with absorptions reported in wavenumbers (cm–1). Melting points were recorded 
using a Büchi B–450 melting point apparatus.  
A 1.3. General Procedures 
A 1.3.1 General Procedure A (Preparation of Heterocyclic Phosphonium Salts) 
 
 An oven dried 8 mL vial (≤ 0.5 mmol scale) or a round bottom flask (> 0.5 mmol scale) 
equipped with a stir bar was charged with the heterocycle (1.0 equiv) and placed under a nitrogen 
atmosphere. CH2Cl2 (0.1 M) was added, the reaction vessel cooled to –78 ºC and Tf2O (1.0 equiv) 
was added dropwise over 5 minutes. The reaction was stirred for 30 minutes before PPh3 (1.1 
equiv) was added in one portion. The reaction was subjected to three rapid cycles of 
vacuum/nitrogen backfill and was stirred for a further 30 minutes at –78 ºC. The stated organic 
base (NEt3 or DBU, 1.0 equiv) was added dropwise via syringe, the cooling bath was removed, 
and the reaction was allowed to warm to room temperature while stirring (approximately 15-30 
minutes). The reaction mixture was quenched with H2O (approximately the same volume as 
CH2Cl2) and the mixture was transferred to a separatory funnel. The mixture was diluted CH2Cl2 
and the resulting organic layer was washed three times with H2O. The organic layer was dried 
(MgSO4), filtered and concentrated in vacuo to approximately 2-10 mL (depending on the scale of 




then placed in a –20 ºC refrigerator for approximately 1 hour. The resulting suspension was filtered 
on a frit, the solid washed with chilled Et2O (0 ºC) and dried in vacuo to provide the pure 
phosphonium salt. 
(2-Chloropyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (2a) 
 
 Prepared according to general procedure A using 2-chloropyridine (473 L, 5.00 mmol), 
Tf2O (845 L, 5.00 mmol), PPh3 (1.44 g, 5.50 mmol), NEt3 (697 L, 5.00 mmol) and CH2Cl2 (50 
mL). After the purification procedure, the title compound was isolated as a white solid (2.14 g, 
4.08 mmol, 82% yield). mp 158-160 ºC; IR max/cm-1 (film): 3087, 3061, 3028, 1459, 1264, 1137, 
1110, 1031, 749, 726, 634; 1H NMR (400 MHz, CDCl3) : 8.82 (1H, app t, J = 5.1 Hz, H1), 7.98-
7.89 (3H, m, H6), 7.86-7.77 (6H, m, H5), 7.75-7.62 (7H, m, H2 and H4), 7.40 (1H, d, J = 13.2 Hz, 
H3); 
13C NMR (100 MHz, CDCl3)  153.38 (d, J = 15.1 Hz), 152.31 (d, J = 11.3 Hz), 136.41 (d, 
J = 3.0 Hz), 134.49 (d, J = 10.4 Hz), 132.01 (d, J = 83.2 Hz), 131.11 (d, J = 13.0 Hz), 127.41 (d, 
J = 9.5 Hz), 126.28 (d, J = 8.4 Hz), 120.72 (q, J = 320.4 Hz), 115.02 (d, J = 90.0 Hz); 19F NMR 
(365 MHz, CDCl3)  -78.19; 31P NMR (162 MHz, CDCl3)  22.27; m/z LRMS (ESI + APCI) 
found [M - OTf]+ 374.1, C23H18ClNP





(2-Bromopyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (2b) 
 
 Prepared according to general procedure A using 2-bromopyridine (954 L, 10.00 mmol), 
Tf2O (1.69 mL, 10.00 mmol), PPh3 (2.89 g, 11.00 mmol), DBU (1.52 mL, 10.00 mmol) and 
CH2Cl2 (100 mL). After the purification procedure, the title compound was isolated as a white 
solid (4.84 g, 8.52 mmol, 85% yield). mp 129-136 ºC; IR max/cm-1 (film): 3099, 3059, 3027, 2996, 
1264, 1136, 1109, 1030, 634; 1H NMR (400 MHz, CDCl3) : 8.81 (1H, app t, J = 5.1 Hz, H1), 
7.99-7.89 (3H, m, H6), 7.87-7.73 (7H, m, H2 and H5), 7.72-7.60 (6H, m, H4), 7.54 (1H, d, J = 12.9 
Hz, H3); 
13C NMR (100 MHz, CDCl3)  152.63 (d, J = 10.8 Hz), 143.77 (d, J = 14.0 Hz), 136.15 
(d, J = 3.1 Hz), 134.47 (d, J = 10.6 Hz), 131.67 (d, J = 82.9 Hz), 131.11 (d, J = 13.2 Hz), 130.81 
(d, J = 9.2 Hz), 126.58 (d, J = 8.3 Hz), 120.71 (d, J = 320.9 Hz), 115.01 (d, J = 89.7 Hz); 19F NMR 
(365 MHz, CDCl3)  -78.19; 31P NMR (162 MHz, CDCl3)  22.00; m/z LRMS (ESI + APCI) 
found [M - OTf]+ 418.1, C23H18BrNP








(2-Fluoropyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (2c) 
 
 Prepared according to general procedure A using 2-fluoropyridine (859 L, 10.00 mmol), 
Tf2O (1.69 mL, 10.00 mmol), PPh3 (2.89 g, 11.00 mmol), DBU (1.52 mL, 10.00 mmol) and 
CH2Cl2 (100 mL). After the purification procedure, the title compound was isolated as a white 
solid (3.96 g, 7.80 mmol, 79% yield). mp 192-196 ºC; IR max/cm-1 (film): 3087, 3064, 1586, 1437, 
1388, 1262, 1227, 1142, 1108, 1031, 726, 718, 687, 634; 1H NMR (400 MHz, CDCl3) : 8.67 (1H, 
app t, J = 5.3 Hz, H1), 7.99-7.88 (3H, m, H6), 7.87-7.75 (6H, m, H5), 7.74-7.60 (7H, m, H2 and 
H4), 7.10 (1H, d, J = 13.4 Hz, H3); 
13C NMR (100 MHz, CDCl3)  163.28 (dd, J = 245.4, 16.9 
Hz), 150.63 (dd, J = 13.7, 12.7 Hz), 136.09 (d, J = 3.2 Hz), 134. 21 (d, J = 10.7 Hz), 133.95 (dd, 
J = 84.4, 6.6 Hz), 130.81 (d, J = 13.8 Hz), 125.18 (dd, J = 8.2, 5.1 Hz), 122.44 (q, J = 321.6 Hz), 
114.81 (d, J = 90.1 Hz), 114.19 (dd, J = 40.3, 10.2 Hz); 19F NMR (365 MHz, CDCl3)  -61.56 (d, 
J = 10.3 Hz), -78.20; 31P NMR (162 MHz, CDCl3)  22.15, (d, J = 9.9 Hz); m/z LRMS (ESI + 
APCI) found [M - OTf]+ 358.1, C23H18FNP







Triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (2d) 
 
 Prepared according to general procedure A using 2-phenylpyridine (2.57 mL, 18.00 mmol), 
Tf2O (3.04 mL, 18.00 mmol), PPh3 (5.19 g, 19.8 mmol), NEt3 (2.51 mL, 18.00 mmol) and CH2Cl2 
(180 mL). After the purification procedure, the title compound was isolated as a white solid (8.53 
g, 15.08 mmol, 84% yield). mp 169–171 ºC; IR max/cm-1 (film): 3087, 3066, 3011, 1584, 1570, 
1471, 1439, 1374, 1079, 997, 751; 1H NMR (400 MHz, CDCl3) : 9.01 (1H, app t, J = 5.1 Hz, H1), 
7.93–7.54 (18H, m, H3, H4, H5, H6, and H7), 7.50 (1H, ddd, J  = 17.8, 5.1, 1.1 Hz, H2), 7.42–7.36 
(3H, m, H8 and H9); 
13C NMR (100 MHz, CDCl3)  159.09 (d, J = 9.9 Hz), 151.63 (d, J = 10.7 
Hz), 136.74 (d, J = 1.5 Hz), 136.14 (d, J = 3.2 Hz), 134.30 (d, J = 9.8 Hz), 130.91 (d, J = 13.0 Hz), 
130.35, 129.23 (d, J = 84.1 Hz), 128.98, 127.00, 125.25 (d, J = 7.8 Hz), 123.08, (d, J = 8.4 Hz), 
120.68 (q, J = 321.1 Hz), 115.49 (d, J = 89.1 Hz); 19F NMR (365 MHz, CDCl3)  -78.1; 31P NMR 








[2,2'-Bipyridin]-4-yltriphenylphosphonium trifluoromethanesulfonate (2e) 
 
 Prepared according to general procedure A using 2,2'-bipyridine (929 mg, 5.95 mmol), 
Tf2O (1.00 mL, 5.95 mmol), PPh3 (1.73 g, 6.55 mmol), NEt3 (830 L, 5.99 mmol) and CH2Cl2 (60 
mL). After the purification procedure, the title compound was isolated as a white solid (2.92 g, 
5.15 mmol, 87% yield). mp 179-182 ºC; IR max/cm-1 (film): 3060, 3014, 1576, 1438, 1261, 1142, 
1106, 1030; 1H NMR (400 MHz, CDCl3) : 9.06 (1H, app t, J = 5.1 Hz, H1), 8.65 (1H, d, J = 13.8 
Hz, H3), 8.55 (1H, d, J = 4.4 Hz, H10), 8.46 (1H, d, J = 7.9 Hz, H7), 7.96-7.88 (3H, m, H6), 7.87-
7.74 (7H, m, H5 and H8), 7.72-7.55 (7H, m, H2 and H4), 7.35 (1H, dd, J = 7.7, 4.5 Hz, H9); 
13C 
NMR (100 MHz, CDCl3)  157.80 (d, J = 9.9 Hz), 153.36 (d, J = 2.3 Hz), 151.37 (d, J = 10.7 
Hz), 149.34, 137.34, 136.17 (d, J = 3.1 Hz), 134.42 (d, J  = 9.9 Hz), 130.97 (d, J = 13.0 Hz), 129.29 
(d, J = 83.9 Hz), 126.91 (d, J = 8.4 Hz), 125.08, 123.89 (d, J = 9.2 Hz), 121.65, 120.80 (q, J = 
321.2 Hz), 115.75 (d, J = 89.3 Hz); 19F NMR (365 MHz, CDCl3)  -78.10; 31P NMR (162 MHz, 






Triphenyl(3-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (2f) 
 
 Prepared according to general procedure A (except that the stirring time after addition of 
PPh3 was 1 hour instead of 30 minutes) using 3-phenylpyridine (400 mg, 2.58 mmol), Tf2O (435 
L, 2.58 mmol), PPh3 (744 mg, 2.84 mmol), DBU (285 L, 2.58 mmol) and CH2Cl2 (26 mL). 
After the purification procedure, the title compound was isolated as a white solid (1.05 g, 1.86 
mmol, 72% yield). mp 185-188 ºC; IR max/cm-1 (film): 3032, 2980, 2948, 1518, 1407, 1292, 1249, 
1186, 825; 1H NMR (400 MHz, CDCl3) : 8.95 (1H, app t, J = 4.7 Hz, H1), 8.74 (1H, d, J = 6.8 
Hz, H3), 7.85-7.73 (3H, m, H6), 7.73-7.40 (13H, m, H2, H4, and H5), 7.11 (1H, t, J = 7.6 Hz, H9), 
6.91 (2H, app t, J = 7.6 Hz, H8), 6.71 (2H, d, J = 7.5 Hz, H7); 
13C NMR (100 MHz, CDCl3) 
  (d, J = 8.0 Hz), 149.97 (d, J = 10.4 Hz), 141.68 (d, J = 7.3 Hz), 135.43 (d, J = 3.0 Hz), 
134.41 (d, J = 4.5 Hz), 134.18 (d, J = 10.3 Hz), 130.59 ( d, J = 13.0 Hz), 129.21, 128.89, 128.30, 
128.20, 126.35 (d, J = 83.4 Hz), 120.82 (q, J = 321.2 Hz), 116.89 (d, J = 89.2 Hz); 19F NMR (365 
MHz, CDCl3)  − 31P NMR (162 MHz, CDCl3)  21.73; m/z LRMS (ESI + APCI ) found 
[M - OTf]+ 416.2, C29H23NP






Triphenyl(5,6,7,8-tetrahydroquinolin-4-yl)phosphonium trifluoromethanesulfonate (2g) 
              
 Prepared according to general procedure A (except the product suspension was placed in a 
–20 ºC refrigerator for approximately 12 hours instead of 1 hour) using 5,6,7,8-tetrahydroquinoline 
(773 L, 5.95 mmol), Tf2O (1.00 mL, 5.95 mmol), PPh3 (1.73 g, 6.55 mmol), DBU (890 L, 5.95 
mmol) and CH2Cl2 (60 mL). After the purification procedure, the title compound was isolated as 
a pale tan solid (2.24 g, 4.13 mmol, 69% yield). mp 248-251 ºC; IR max/cm-1 (film): 3019, 2954, 
1442, 1259, 1144, 1029; 1H NMR (400 MHz, DMSO-d6) : 8.74 (1H, app t, J = 5.1 Hz, H1), 8.07-
7.93 (3H, m, H6), 7.92-7.71 (12H, m, H4 and H5), 6.94 (1H, dd, J = 15.3, 5.1 Hz, H2), 3.12-2.97 
(2H, m, H10), 2.21-2.04 (2H, m, H7), 1.84-1.71(2H, m, H9), 1.60-1.44 (2H, m, H8); 
13C NMR (100 
MHz, CDCl3)  160.25 (d, J = 8.4 Hz), 148.20 (d, J = 11.4 Hz), 135.48 (d, J = 7.6 Hz), 135.27 (d, 
J = 3.1 Hz), 134.06 (d, J = 10.7 Hz), 130.50 (d, J = 13.0 Hz), 126.18 (d, J = 9.9 Hz), 125.51 (d, J 
= 82.4 Hz), 120.40 (q, J = 322.0 Hz), 116.34 (d, J = 87.7 Hz), 32.01 (d, J = 2.3 Hz), 29.66 (d, J = 
5.3 Hz), 21.03, 20.54; 19F NMR (365 MHz, CDCl3)  -77.75; 31P NMR (162 MHz, 








 Prepared according to general procedure A (except that the stirring time after addition of 
PPh3 was 1 hour instead of 30 minutes and an additional hour of stirring at room temperature after 
addition of DBU) using 2-methyl-3-(thiophen-3-yl)pyridine (518 mg, 3.00 mmol), Tf2O (500 L, 
3.00 mmol), PPh3 (775 mg, 3.30 mmol), DBU (448 L, 3.00 mmol) and CH2Cl2 (30 mL). After 
the purification procedure,1 the title compound was isolated as a tan solid (1.04 g, 1.78 mmol, 59% 
yield). mp 182-185 ºC; IR max/cm-1 (film): 3112, 3072, 2976, 1272, 1262, 1168, 1153, 1027, 632; 
1H NMR (400 MHz, CDCl3) : 8.82 (1H, app t, J = 5.0 Hz, H1), 7.86-7.77 (3H, m, H5), 7.75-7.65 
(6H, m, H4), 7.63-7.52 (6H, m, H3), 7.28-7.18 (1H, m, H2), 6.85 (1H, dd, J = 5.1, 2.9 Hz, H8), 6.58 
(1H, dd, J = 2.9, 1.1 Hz, H6), 6.20 (1H, dd, J = 5.1, 1.2 Hz, H7), 2.31 (3H, s, H9); 
13C NMR (100 
MHz, CDCl3)  161.95 (d, J = 8.1 Hz), 149.44 (d, J = 10.8 Hz), 135.84 (d, J = 7.6 Hz), 135.21 (d, 
J = 3.0 Hz), 134.56 (d, J = 5.3 Hz), 133.80 (d, J = 9.9 Hz), 130.49 (d, J = 12.9 Hz), 128.05, 127.68 
(d, J = 84.8 Hz), 126.48, 125.97, 125.86 (d, J = 9.6 Hz), 120.69 (q, J = 320.9 Hz), 117.16 (d, J = 
                                                             
1 The concentrated CH2Cl2 solution of crude product was added dropwise to an excess of chilled Et2O (0 °C) instead 
of the order of addition in General Procedure A. The mixture was then placed in a -20 °C refrigerator for approximately 
1 hour. The resulting suspension was filtered on a frit and the solid was washed with chilled Et2O (0 °C). The solid 
was redissolved in approximately 10 mL of CH2Cl2 and was precipitated a second time via dropwise addition to an 
excess of chilled Et2O (0 °C). The resulting suspension was filtered on a frit, the solid washed with chilled Et2O (0 




89.6 Hz), 23.54 (d, J = 2.3 Hz); 19F NMR (365 MHz, CDCl3)  -78.03; 31P NMR (162 MHz, 




 Prepared according to general procedure A using 2-methyl-5-(phenylethynyl)pyridine (860 
mg, 4.45 mmol), Tf2O (749 L, 4.45 mmol), PPh3 (1.29 g, 4.90 mmol), DBU (619 mL, 4.45 mmol) 
and CH2Cl2 (40 mL). After the purification procedure, the title compound was isolated as an off-
white solid (1.60 g, 2.65 mmol, 60% yield). mp 188–190 ºC; IR max/cm-1 (film): 3098, 2214, 1584, 
1462, 1260, 1028, 761; 1H NMR (400 MHz, CDCl3) : 8.96 (1H, d, J = 2.8 Hz, H1), 7.86 (3H, m, 
H8), 7.80–7.68 (13H, m, H7, H6, and H5), 7.17 (2H, app t, J = 7.7 Hz, H4), 7.09 (1H, d, J  = 15.1 
Hz, H2), 6.66 (2H, d, J = 7.4 Hz, H3), 2.66 (3H, s, H9);
 13C NMR (100 MHz, CDCl3)  160.40 (d, 
J = 10.4 Hz), 154.04 (d, J = 7.1 Hz), 135.72 (d, J = 3.0 Hz), 134.22 (d, J = 10.5 Hz), 130.83, 130.67 
(d, J = 13.2 Hz), 129.87, 128.65 (d, J = 85.9 Hz), 128.32, 128.11 (d, J = 8.8 Hz), 120.75 (q, J = 
321.2 Hz), 120.37 (d, J = 4.5 Hz), 119.90, 115.82 (d, J = 90.3 Hz), 103.30, 83.97 (d, J = 6.1 Hz), 
24.83; 19F NMR (365 MHz, CDCl3)  -78.1; 31P NMR (162 MHz, CDCl3)  22.8; m/z LRMS 
(ESI + APCI) found [M - OTf]+ 454.2, C32H25NP





(2-Fluoro-5-methylpyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (2j) 
 
 Prepared according to general procedure A using 2-fluoro-5-methylpyridine (620 L, 5.98 
mmol), Tf2O (1.00 mL, 5.95 mmol), PPh3 (1.73 g, 6.55 mmol), DBU (890 L, 5.95 mmol) and 
CH2Cl2 (60 mL). After the purification procedure, the title compound was isolated as a white solid 
(2.54 g, 4.87 mmol, 82% yield). mp 160-161 ºC; IR max/cm-1 (film): 3066, 1438, 1261, 1142, 
1032, 720; 1H NMR (400 MHz, CDCl3) : 8.43 (1H, d, J = 6.8 Hz, H1), 7.96-7.88 (3H, m, H5), 
7.87-7.79 (6H, m, H4), 7.75-7.67 (6H, m, H3), 6.72 (1H, dd, 15.6, 2.8 Hz, H2), 2.00 (3H, s, H6); 
13C NMR (100 MHz, CDCl3)  162.44 (dd, J = 244.1, 17.6 Hz), 152.46 (dd, J = 13.7, 10.7 Hz), 
136.14 (d, J = 3.1 Hz), 134.41 (app t, J = 6.4 Hz), 134.11 (d, J = 10.7 Hz), 131.74 (dd, J = 83.1, 
6.9 Hz), 131.20 (d, J = 13.0 Hz), 120.71 (q, J = 320.4 Hz), 115.43 (dd, J = 40.4, 11.4 Hz), 115.26 
(d, J = 89.27 Hz), 18.97 (d, J = 3.8 Hz); 19F NMR (365 MHz, CDCl3)  -66.58 (d, J = 9.4 Hz), -
78.17; 31P NMR (162 MHz, CDCl3)  21.40 (d, J = 9.4 Hz); m/z LRMS (ESI + APCI) found [M 
- OTf]+ 372.2, C24H20FNP






(5-Methoxy-2-methylpyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (2k) 
and (3-methoxy-6-methylpyridin-2-yl)triphenylphosphonium trifluoromethanesulfonate 
(2k’) 
             
10:1 Mixture of Regioisomers 
 Prepared according to general procedure A using 5-methoxy-2-methylpyridine (397 mg, 
3.23 mmol), Tf2O (542 L, 3.23 mmol), PPh3 (931 mg, 3.35 mmol), DBU (482 L, 3.23 mmol) 
and CH2Cl2 (32 mL). After the purification procedure, the title compounds (10:1 mixture of 
regioisomers) were isolated as a white solid (1.29 g, 2.43 mmol, 75% combined yield). An 
analytically pure sample of the major regioisomer was obtained by recrystallization from CH2Cl2 
and Et2O.  





mp 211-212 ºC; IR max/cm-1 (film): 3069, 2952, 1486, 1438, 1261, 1224, 1108, 1031; 1H NMR 
(400 MHz, CDCl3) : 8.52 (1H, d, J = 6.9 Hz, H1), 7.95-7.40 (15H, m, H3, H4, and H5), 6.79 (1H, 
d, J = 15.0 Hz, H2), 3.62 (3H, s, H6), 2.46 (3H, s, H7); 
13C NMR (100 MHz, CDCl3)  153.72, 
153.05 (d, J = 10.7 Hz), 135.62 (d, J = 4.6 Hz), 135.46 (d, J = 3.1 Hz), 133.71 (d, J = 10.7 Hz), 
130.51 (d, J = 13.0 Hz), 127.12 (d, J = 6.9 Hz), 120.72 (q, J = 321.21 Hz), 116.46 (d, J = 91.6 Hz), 
115.62 (d, J = 87.0 Hz), 57.01, 23.55; 19F NMR (365 MHz, CDCl3)  -78.13; 31P NMR (162 MHz, 




 Prepared according to general procedure A using 2-butyl-5-(trifluoromethyl)pyridine (1.02 
g, 5.00 mmol), Tf2O (845 L, 5.00 mmol), PPh3 (1.44 g, 5.50 mmol), DBU (758 L, 5.00 mmol) 
and CH2Cl2 (50 mL). After the purification procedure, the title compound was isolated as a white 
solid (2.55 g, 4.16 mmol, 83% yield). mp 152-154 ºC; IR max/cm-1 (film): 3057, 2931, 1717, 1437, 
1414, 1260, 1222, 1147, 1105, 1029; 1H NMR (400 MHz, CDCl3) : 9.16 (1H, d, J = 6.8 Hz, H1), 
7.92–7.87 (3H, m, H5), 7.80–7.76 (6H, m, H4), 7.73–7.67 (6H, m, H3), 7.18 (1H, d, J = 17.2 Hz, 
H2), 2.93 (2H, t, J = 7.6 Hz, H6), 1.69–1.62 (2H, m, H7), 1.37–1.27 (2H, m, H8), 0.88 (3H, t, J = 




Hz), 134.41 (d, J = 10.4 Hz), 130.74 (d, J = 13.0 Hz), 129.77 (d, J = 8.5 Hz), 125.90 (d, J = 80.1, 
1.0 Hz), 124.42 (qd, J = 33.1, 4.0 Hz), 122.49 (qd, J = 275.1, 2.9 Hz), 120.76 (q, J = 321.2 Hz), 
116.40 (d, J = 90.4 Hz), 37.93, 30.35, 22.11, 13.63; 19F NMR (365 MHz, CDCl3)   -78.27, -
53.55; 31P NMR (162 MHz, CDCl3)   27.4 (d, J = 2.3 Hz); m/z LRMS found [M]+ 305.2, 
C28H26F3NP
+ requires 305.2. 
Triphenyl(4-(trifluoromethyl)pyridin-2-yl)phosphonium trifluoromethanesulfonate (2m) 
 
 Prepared according to general procedure A using 4-(trifluoromethyl)pyridine (926 L, 8.00 
mmol), Tf2O (1.35 mL, 8.00 mmol), PPh3 (2.31 g, 8.80 mmol), DBU (1.20 mL, 8.00 mmol) and 
CH2Cl2 (80 mL). After the purification procedure, the title compound was isolated as an off-white 
solid (3.69 g, 6.62 mmol, 83% yield). mp 110–112 ºC; IR max/cm-1 (film): 3071, 1588, 1485, 
1390, 1223, 1180, 998, 572, 535; 1H NMR (400 MHz, CDCl3) : 9.33 (1H, d, J = 2.8 Hz, H1), 8.02 
(1H, m, H2), 7.92 (3H, m, H6), 7.82–7.69 (13H, m, H3, H4, and H5); 13C NMR (100 MHz, CDCl3) 
 154.20 (d, J = 19.9 Hz), 147.00 (d, J = 121.0 Hz), 139.92 (qd, J = 35.8 Hz, 11.3 Hz), 136.02 (d, 
J = 2.9 Hz), 134.55 (d, J = 10.2 Hz), 130.70 (d, J = 13.1 Hz), 126.05 (dq, J = 25.9, 3.6 Hz), 124.36 
(m), 121.47 (qd, J = 274.1, 3.0 Hz), 120.70 (q, J  = 320.5 Hz), 115.93 (d, J = 90.0 Hz); 19F NMR 
(365 MHz, CDCl3)  − − ; 31P NMR (162 MHz, CDCl3)  16.2; m/z LRMS (ESI + 
APCI) found [M - OTf]+ 408.1, C24H18F3NP





(4-bromopyridin-2-yl)triphenylphosphonium trifluoromethanesulfonate (2n) 
 
 Prepared according to general procedure A2 using 4-bromopyridine (198 L, 2.00 mmol), 
Tf2O (338 L, 2.00 mmol), PPh3 (577 mg, 2.20 mmol), DBU (303 L, 2.00 mmol) and CH2Cl2 
(40 mL). After the purification procedure,3 the title compound was isolated as a tan solid (677 mg, 
1.20 mmol, 60% yield). mp 147-149 ºC; IR max/cm-1 (film): 3087, 3061, 1553, 1436, 1258, 1137, 
1110, 1028, 635; 1H NMR (400 MHz, CDCl3) : 8.88 (1H, d, J = 5.1 Hz, H1), 8.03-7.84 (4H, m, 
H3 and H6), 7.84-7.59 (13H, m, H2, H4, and H5); 
13C NMR (100 MHz, CDCl3)  153.28 (d, J = 
20.6 Hz), 146.37 (d, J = 119.1 Hz), 135.97 (d, J = 3.1 Hz), 135.16 (d, J = 14.4 Hz), 134.55 (d, J = 
10.8 Hz), 134.00 (d, J = 25.2 Hz), 131.88 (d, J = 3.1 Hz), 130.69 (d, J = 13.6 Hz), 120.80 (q, J = 
321.0 Hz), 116.21 (d, J = 89.2 Hz); 19F NMR (365 MHz, CDCl3)  − ; 31P NMR (162 MHz, 




                                                             
2 A solution of 4-bromopyridine in CH2Cl2 (20 mL) was added to a solution of Tf2O in CH2Cl2 (20 mL) at –78 ºC 
over 10 minutes instead of the order of addition in General Procedure A. 
3 Once the organic layer was separated, dried (MgSO4), filtered, and concentrated in vacuo, the title compound was 







 Prepared according to general procedure A using 2-butyl-3-(methoxymethyl)-4-(p-
tolyl)pyridine (483 mg, 1.79 mmol), Tf2O (300 L, 1.79 mmol), PPh3 (517 mg, 1.97 mmol), DBU 
(268 L, 1.79 mmol) and CH2Cl2 (60 mL). After the purification procedure, the title compound 
was isolated as a white solid (909 mg, 1.34 mmol, 75% yield). mp 149-150 ºC; IR max/cm-1 (film): 
3059, 2956, 2869, 1568, 1438, 1261, 1151, 1031 ; 1H NMR (400 MHz, CDCl3) : 7.91-7.82 (3H, 
m, H6), 7.78-7.62 (12H, m, H5 and H4), 7.35 (1H, d, J = 6.4 Hz, H1), 7.26-7.23 (4H, m, H3 and H2), 
4.35 (2H, s, H7), 3.38 (3H, s, H8), 3.06 (2H, t, J = 7.7 Hz, H10), 2.35 (3H, s, H9), 1.71 (2H, qn, J = 
7.7 Hz, H11), 1.33 (2H, sext, J = 7.6 Hz, H12), 0.87 (3H, t, J = 7.5 Hz, H13); 
13C NMR (100 MHz, 
CDCl3)  167.00 (d, J = 19.1 Hz), 152.58 (d, J = 11.4 Hz), 143.18, 141.99, 139.39, 135.63 (d, J 
= 3.1 Hz), 134.47 (d, J = 10.7 Hz), 133.60 (d, J = 1.5 Hz), 133.19 (d, J = 3.8 Hz), 130.42 (d, J = 
13.0 Hz), 129.91 (d, J = 25.2 Hz), 129.04 (d, J = 84.7 Hz), 120.83 (q, J = 321.2 Hz), 117.07 (d, J 
= 89.27 Hz), 67.93, 58.68, 34.27, 30.58, 22.31, 21.08, 13.83; 19F NMR (365 MHz, CDCl3)  -
78.07; 31P NMR (162 MHz, CDCl3)  14.49; m/z LRMS (ESI + APCI) found [M - OTf]+ 530.3, 
C36H37NOP





(5-(4-Methoxyphenyl)pyrimidin-4-yl)triphenylphosphonium trifluoromethanesulfonate (2p) 
and (5-(4-methoxyphenyl)pyrimidin-2-yl)triphenylphosphonium trifluoromethanesulfonate 
(2p’) 
 
24:1 Mixture of Regioisomers 
 Prepared according to general procedure A (except that the stirring time after addition of 
PPh3 was 1 hour instead of 30 minutes) using 5-(4-methoxyphenyl)pyrimidine (450 mg, 2.42 
mmol), Tf2O (409 L, 2.42 mmol), PPh3 (698 mg, 2.66 mmol), DBU (367 L, 2.42 mmol) and 
CH2Cl2 (24 mL). After the purification procedure,
4 the title compound was isolated as a tan solid 
(724 mg, 1.21 mmol, 50% combined yield). Both isomers, IR max/cm-1 (film): 3063, 2936, 1396, 
1258, 1222, 1146, 1105, 1028, 634; Major isomer, 1H NMR (400 MHz, CDCl3) : 9.44 (1H, s, 
H2), 8.98 (1H, d, J = 9.0 Hz, H1), 7.80-7.70 (3H, m, H5), 7.67-7.56 (12H, m, H3 and H4), 6.91 (2H, 
d, J = 8.7 Hz, H6), 6.55 (2H, d, J = 8.7 Hz, H7), 3.72 (3H, s, H8); Minor isomer, 
1H NMR (400 
                                                             
4 The concentrated CH2Cl2 solution of crude product was added dropwise to an excess of chilled Et2O (0 °C) instead 
of the order of addition in General Procedure A. The mixture was then placed in a -20 °C refrigerator for approximately 
1 hour. The resulting suspension was filtered on a frit and the solid was washed with chilled Et2O (0 °C). The solid 
was redissolved in approximately 10 mL of CH2Cl2 and was precipitated a second time via dropwise addition to an 
excess of chilled Et2O (0 °C). The resulting suspension was filtered on a frit, the solid washed with chilled Et2O (0 




MHz, CDCl3) : 9.23 (2H, s, H1), 7.80-7.70 (3H, m, H4), 7.70 (2H, d, J = 8.7 Hz, H5), 7.67-7.56 
(12H, m, H2 and H3), 7.09 (2H, d, J = 8.6 Hz, H6), 3.88 (3H, s, H7); Major isomer, 
13C NMR (100 
MHz, CDCl3)  161.84 (d, J = 5.3 Hz), 160.53, 156.97 (d, J = 16.8 Hz), 149.74 (d, J = 114.5 Hz), 
142.72 (d, J = 19.2 Hz), 135.22 (d, J = 3.1 Hz), 134.67 (d, J = 10.2 Hz), 130.60, 130.25 (d, J = 
13.1 Hz), 123.61, 120.82 (q, J = 321.3 Hz), 117.10 (d, J = 88.6 Hz), 114.37, 55.42; Both isomers,  
19F NMR (365 MHz, CDCl3)  -78.01; Major isomer, 31P NMR (162 MHz, CDCl3)  17.84; m/z 
LRMS (ESI + APCI) found [M - OTf]+ 447.2, C29H24N2OP
+ requires 447.2. 
Triphenyl(pyrazin-2-yl)phosphonium trifluoromethanesulfonate (2q) 
 
 Prepared according to general procedure A using pyrazine (120 mg, 1.50 mmol), Tf2O (252 
L, 1.50 mmol), PPh3 (432 mg, 1.65 mmol), DBU (224 L, 1.50 mmol) and CH2Cl2 (13.0 mL). 
After the purification procedure, the title compound was isolated as an off-white solid (525 mg, 
1.07 mmol, 80% yield). mp 185–188 ºC; IR max/cm-1 (film): 3066, 1587, 1484, 1395, 1186, 617, 
571; 1H NMR (400 MHz, CDCl3) : 9.09 (1H, br s), 9.06 (1H, br s), 8.86 (1H, br s), 7.91 (3H, m), 
7.82–7.71 (12H, m); 13C NMR (100 MHz, CDCl3)  149.72 (d, J = 24.0 Hz), 149.51 (d, J = 3.4 
Hz), 147.25 (d, J = 14.7 Hz), 141.37 (d, J = 115.4 Hz), 136.02 (d, J = 3.1 Hz), 134.54 (d, J = 10.4 
Hz), 130.71 (d, J = 13.1 Hz), 120.69 (q, J = 321.1 Hz), 115.71 (d, J = 89.3 Hz); 19F NMR (365 
MHz, CDCl3)  -78.2; 31P NMR (162 MHz, CDCl3)  13.9; m/z LRMS (ESI + APCI) found [M 
- OTf]+ 341.1, C22H18N2P








 Prepared according to general procedure A using (-)-nicotine (803 L, 5.00 mmol), Tf2O 
(845 L, 5.00 mmol), PPh3 (1.44 g, 5.50 mmol), DBU (748 L, 5.00 mmol) and CH2Cl2 (50 mL). 
After the purification procedure, the title compound was isolated as a tan solid (2.19 g, 3.82 mmol, 
76% yield). mp 178-181 ºC; IR max/cm-1 (film): 3066, 2971, 2758, 1338, 1264, 1223, 1142, 1108, 
1102, 1031, 719, 636; 1H NMR (400 MHz, CDCl3) : 9.37 (1H, d, J = 6.9 Hz, H3), 8.79 (1H, app 
t, J = 4.6 Hz, H1), 7.96-7.62 (15H, m, H4, H5, and H6), 7.12 (1H, dd, J = 15.5, 5.1 Hz, H2), 3.10-
2.93 (2H, m, H7 and H10), 1.99 (1H, app q, J = 8.5 Hz, H10), 1.87-1.67 (4H, m, H9 and H11), 1.49-
1.23 (2H, m, H8 and H9), 1.01-0.83 (1H, m, H8); 
13C NMR (100 MHz, CDCl3)  153.01 (d, J = 
8.1 Hz), 149.96 (d, J = 10.6 Hz), 144.24 (d, J = 6.7 Hz), 135.99 (d, J = 3.0 Hz), 134.39 (d, J = 10.2 
Hz), 131.05 (d, J = 13.0 Hz), 127.53 (d, J = 9.9 Hz), 126.24 (d, J = 81.6 Hz), 120.83 (q, J = 321.3 
Hz), 116.74 (d, J = 88.5 Hz), 66.03 (d, J = 4.9 Hz), 55.97, 39.39, 35.43, 22.93; 19F NMR (365 
MHz, CDCl3)  -77.01; 31P NMR (162 MHz, CDCl3)  20.69; m/z LRMS (ESI + APCI) found 
[M - OTf]+ 423.2, C28H28N2P









 Prepared according to general procedure A using Loratadine (ethyl-4-(8-chloro-5,6-
dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridine-11-ylidene)-1-piperidinecarboxylate) (750 
mg, 1.96 mmol), Tf2O (329 L, 1.96 mmol), PPh3 (565 mg, 2.15 mmol), DBU (300 L, 1.96 
mmol) and CH2Cl2 (20 mL). After the purification procedure, the title compound was isolated as 
a white solid (1.37 g, 1.72 mmol, 88% yield). mp 129-136 ºC; IR max/cm-1 (film): 3061, 2978, 
2908, 2868, 1437, 1261, 1221, 1147, 1106, 1029, 635; 1H NMR (400 MHz, CDCl3) : 8.73 (1H, 
app t, J = 5.0 Hz, H1), 7.97-7.87 (3H, m, H8), 7.86-7.74 (6H, m, H7), 7.73-7.60 (6H, m, H6), 7.16-
7.01 (3H, m, H2, H3, and H4), 6.71 (1H, s, H5), 4.14 (2H, q, J = 7.0 Hz, H15), 3.84-3.61 (2H, m, 
H13 or H14), 3.45-3.20 (3H, m, H10 and H13 or H14), 2.75 (1H, dt, J = 17.4, 4.7 Hz, H9), 2.58 (1H, 
dt, J = 14.9, 4.7 Hz, H10), 2.53-2.30 (3H, m, H11 or H12), 2.26-2.09 (1H, m, H11 or H12), 1.60-1.43 
(1H, m, H9), 1.25 (3H, t, J = 7.2 Hz, H16); 
13C NMR (100 MHz, CDCl3)  163.64 (d, J = 8.3 Hz), 




134.21 (d, J = 10.7 Hz), 133.95, 133.57, 132.37, 131.58, 131.13 (d, J = 13.0 Hz), 129.85, 127.22 
( d, J = 10.0 Hz), 127.01 (d, J = 82.2 Hz), 126.43, 120.78 (q, J = 321.3 Hz), 116.42 (d, J = 88.5 
Hz), 61.39, 44.65, 44.41, 30.74, 30.46, 30.39, 29.39, 14.59; 19F NMR (365 MHz, CDCl3)  -78.16; 
31P NMR (162 MHz, CDCl3)  21.17; m/z LRMS (ESI + APCI) found [M - OTf]+ 643.2, 
C40H37ClN2O2P
+ requires 643.2. 
(2-(1-(4-Chlorophenyl)-3-(dimethylamino)propyl)pyridin-4-yl)triphenylphosphonium 
trifluoromethanesulfonate (8) 
                                
 Chlorphenamine (1.64 g, 5.95 mmol) was dissolved in Et2O (10 mL) and cooled to 0 ºC. 
Trifluoromethanesulfonic acid (527 L, 5.95 mmol) was added dropwise, the ice bath was 
removed, and the solution was stirred for 10 minutes at room temperature. The solution was 
concentrated in vacuo and the resulting acid salt was subjected to general procedure A (expect that 
the product was precipitated a second time using the same protocol and the product suspension 
was placed in a -20 °C refrigerator for 12 hours instead of 1) using Tf2O (1.0 mL, 5.95 mmol), 
PPh3 (1.73 g, 6.55 mmol), DBU (1.78 mL, 11.90 mmol) and CH2Cl2 (60 mL). After the purification 




52-58 ºC; IR max/cm-1 (film): 3062, 2941, 2818, 2770, 1438, 1260, 1108, 1029; 1H NMR (400 
MHz, CDCl3) : 8.97 (1H, app t, J = 5.1 Hz, H1), 7.93-7.86 (3H, m, H6), 7.80-7.70 (6H, m, H5), 
7.61-7.50 (6H, m, H4), 7.39 (1H, ddd, J = 12.8, 5.1, 1.5 Hz, H2), 7.25-7.16 (5H, m, H3, H7, and 
H8), 4.28 (1H, app t, J = 6.8 Hz, H9), 2.56-2.43 (1H, m, H10), 2.32-2.11 (9H, m, H10, H11, and H12); 
13C NMR (100 MHz, CDCl3)  165.55 (d, J = 9.9 Hz), 150.97 (d, J = 9.9 Hz), 140.26, 135.82 (d, 
J = 3.1 Hz), 134.02 (d, J = 10.7 Hz), 132.25, 130.61 (d, J = 13.0 Hz), 128.92 (d, J = 85.5 Hz), 
128.75, 127.92, 126.26 (d, J = 8.4 Hz), 124.42 (d, J = 7.6 Hz), 120.46 (q, J = 321.2 Hz), 115.31 
(d, J = 89.3 Hz), 56.73, 49.77, 44.88, 31.99; 19F NMR (365 MHz, CDCl3)  -78.14; 31P NMR (162 
MHz, CDCl3)  22.38; m/z LRMS (ESI + APCI) found [M - OTf]+ 535.2, C34H33ClN2P+ requires 
535.2. 
((rac)-8-benzyl-7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxalin-2-
yl)triphenylphosphonium trifluoromethanesulfonate (10) 
 
 Prepared according to general procedure A (except that after the addition of PPh3 the 
reaction mixture was heated to 40 °C for 1 hour, followed by addition of DBU at 40 °C instead of 
–78 °C) using 8-benzyl-7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline (115 mg, 
0.38 mmol), Tf2O (64 L, 0.38 mmol), PPh3 (110 mg, 0.42 mmol), DBU (57 L, 0.38 mmol) and 
CH2Cl2 (3.8 mL). After the purification procedure,
5 the title compound was isolated as a tan solid 





(158 mg, 0.22 mmol, 58% yield). mp 101-106 ºC; IR max/cm-1 (film): 3061, 2949, 2900,2797, 
1439, 1262, 1148, 1109, 1029, 636; 1H NMR (400 MHz, DMSO-d6) : 9.09 (1H, s, H1), 8.10-7.72 
(17H, m, H2, H3, H7, H8, and H9), 7.20-7.05 (3H, m, H5 and H6), 6.92-6.80 (2H, m, H4), 3.55-3.27 
(4H, m, H15, H10, and H11), 3.03-2.87 (2H, m, H13 or H14), 2.66-2.42 (2H, m, H13 or H14), 2.29-2.15 
(1H, m, H12), 1.87 (1H, d, J = 10.8 Hz, H12); 
13C NMR (100 MHz, CDCl3)
6  144.90 (d, J = 23.5 Hz), 
144.21, 143.45 (d, J = 16.9 Hz), 137.51 (br s), 136.00 (d, J = 2.9 Hz), 134.55 (d, J = 10.9 Hz), 130.72 (d, J 
= 13.0 Hz), 129.20-126.21 (3C, m), 120.69 (br s), 120.67 (q, J = 321.5 Hz), 116.42 (d, J = 88.3 
Hz), 61.29, 57.90-56.06 (2C, m), 43.14-40.43 (3C, m); 19F NMR (365 MHz, DMSO-d6)  −; 




yl)triphenylphosphonium trifluoromethanesulfonate (12) 
 
                                                             
5 The concentrated CH2Cl2 solution of crude product was added dropwise to an excess of chilled Et2O (0 °C) instead 
of the order of addition in General Procedure A. The mixture was then placed in a -20 °C refrigerator for approximately 
1 hour. The resulting suspension was filtered on a frit and the solid was washed with chilled Et2O (0 °C). The solid 
was redissolved in approximately 10 mL of CH2Cl2 and was precipitated a second time via dropwise addition to an 
excess of chilled Et2O (0 °C). The resulting suspension was filtered on a frit, the solid washed with chilled Et2O (0 
°C) and dried in vacuo to provide the pure phosphonium salt. 
6 Please note that the 13C NMR contains a number of broad peaks that account for the lower than expected number of 




 Prepared according to general procedure A (except that the reaction was warmed to -50 ºC 
before the addition of PPh3, was stirred at -50 °C for 1 hour, and DBU was added at -50 °C instead 
of -78 °C. During the purification stage the product suspension was placed in a -20 ºC refrigerator 
for approximately 12 hours instead of 1) using 3-((8R,9S,10R,13S,14S)-3-((tert-
butyldimethylsilyl)oxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-
cyclopenta[a]phenanthren-17-yl)pyridine (295 mg, 0.64 mmol), Tf2O (107 L, 0.64 mmol), PPh3 
(184 mg, 0.70 mmol), DBU (95 L, 0.64 mmol) and CH2Cl2 (6.5 mL). After the purification 
procedure, the title compound was isolated as a white solid (412 mg, 0.47 mmol, 74% yield). mp 
158-163 ºC; IR max/cm-1 (film): 3062, 2929, 1442, 1259, 1096, 1030, 909, 725; 1H NMR (400 
MHz, CDCl3) : 9.02 (1H, d, J = 7.2 Hz), 8.75 (1H, t, J  = 4.6 Hz), 7.92-7.83 (3H, m), 7.83-7.73 
(6H, m), 7.72-7.61 (6H, m), 7.33-7.24 (1H, m), 5.57 (1H, br s), 5.24 (1H, d, J = 4.4 Hz), 3.49 (1H, 
m), 2.30-2.10 (2H, m), 1.89-1.66 (6H, m), 1.62-0.71 (22H, m), 0.65-0.51 (1H, dt, J = 11.7 Hz, 4.92 Hz), 
0.06 (6H, s), -0.12-(-0.23) (1H, m); 13C NMR (100 MHz, CDCl3)  150.77 (d, J = 7.6 Hz), 149.14 (d, J  = 
3.8 Hz), 148.73 (d, J = 10.7 Hz), 141.78, 139.29, 137.51 (d, J = 6.1 Hz), 135.66 (d, J = 3.1 Hz) 134.31 (d, 
J = 9.9 Hz), 130.93 (d, J = 13.0 Hz), 129.99 (d, J = 10.7 Hz), 125.29 (d, J = 83.9 Hz), 120.84 (q, J = 328.8 
Hz), 120.18, 118.03 (d, J = 90.0 Hz), 72.31, 55.45, 49.91, 48.91, 42.68, 37.24, 36.58, 33.70, 32.64, 31.92, 
31.17, 29.97, 25.92, 20.42, 19.20, 18.79, 18.24, -4.58; 19F NMR (365 MHz, CDCl3)  -78.11; 31P NMR 









yl)triphenylphosphonium trifluoromethanesulfonate (14) 
 
 Prepared according to general procedure A (except that the stirring time after addition of 
PPh3 was 1 hour instead of 30 minutes) using (1S,2S,4S,5R)-2-((R)-(benzyloxy)(quinolin-4-
yl)methyl)-5-vinylquinuclidine (472 mg, 1.23 mmol), Tf2O (207 L, 1.23 mmol), PPh3 (354 mg, 
1.35 mmol), NEt3 (171 L, 1.23 mmol) and CH2Cl2 (12 mL). After the purification procedure,7 
the title compound was isolated as a yellow solid (507 mg, 0.638 mmol, 52% yield). mp 92-98 ºC; 
IR max/cm-1 (film): 3062, 3031, 2940, 2866, 1144, 1108, 1029, 635; 1H NMR (400 MHz, CDCl3) 
: 8.54 (1H, d, J = 8.1 Hz, H5), 8.26 (1H, d, J = 8.6 Hz, H2), 7.94 (1H, t, J = 7.2 Hz, H3), 7.91-7.60 
(17H, m, H1, H4, H9, H10, and H11), 7.29-7.02 (3H, m, H7 and H8), 7.14-7.02 (2H, m, H6), 5.83-
5.45 (2H, m, H12 and H14), 5.07-4.89 (2H, m, H13), 4.60 (1H, d, J = 11.4 Hz, H15), 4.33 (1H, d, J 
= 11.4 Hz, H15), 3.52-3.06 (3H, m, H16, H20, and H22), 2.84-2.62 (2H, m, H20 and H22), 2.49-2.33 
                                                             
7 The concentrated CH2Cl2 solution of crude product was added dropwise to an excess of chilled hexanes (0 °C) instead 
of the order of addition in General Procedure A. The mixture was then placed in a -20 °C refrigerator for approximately 
1 hour. The resulting suspension was filtered on a frit and the solid was washed with chilled hexanes (0 °C). The solid 
was redissolved in approximately 10 mL of CH2Cl2 and was precipitated a second time via dropwise addition to an 
excess of chilled hexanes (0 °C). The resulting suspension was filtered on a frit, the solid washed with chilled hexanes 




(1H, br s, H21), 2.06-1.47 (5H, m, H17, H18, H19); 
13C NMR (100 MHz, CDCl3)  149.20 (d, J = 
22.1 Hz), 148.45, 145.10, 143.93, 139.54, 136.58, 135.68 (d, J = 3.0 Hz), 134.53 (d, J = 10.0 Hz), 
131.99-131.79 (3C, m), 131.23, 130.44 (d, J = 13.2 Hz), 128.40, 127.89, 127.22, 126.71 (d, J = 
3.1 Hz), 126.08, 123.78, 120.64 (q, J = 320.3 Hz), 116.99 (d, J = 87.7 Hz), 115.55, 71.81, 60.71, 
55.61, 43.04, 38.32, 26.89, 25.83; 19F NMR (365 MHz, CDCl3)  -78.15; 31P NMR (162 MHz, 
CDCl3)  14.92; m/z LRMS (ESI + APCI) found [M - OTf]+ 645.3, C44H42N2OP+ requires 645.3. 
A 1.3.2 General Procedure B (Preparation of Heteroaryl Ethers) 
 
 An oven dried 8 mL vial with a septa cap was charged with sodium hydride (60% 
dispersion in mineral oil, 1.5 equiv) and placed under a nitrogen atmosphere. THF (0.5 M) was 
added, the suspension was cooled to 0 ºC and the alcohol (1.5 equiv) was added dropwise over 5 
minutes (if the alcohol was a solid or viscous liquid, it was added as a 1.0 M solution in THF to 
an equivalent volume 1.0 M solution of NaH in THF). The reaction was stirred for 30 minutes 
before the septa cap was briefly removed and the phosphonium salt (1.0 equiv) was added in one 
portion. The reaction was subjected to three rapid cycles of vacuum/nitrogen backfill, the ice bath 
removed, and the reaction stirred for 12 hours while warming to room temperature. The reaction 
was quenched with H2O, the aqueous layer was separated and extracted with Et2O (3x). The 




filtered and concentrated in vacuo. The residue was purified by flash column chromatography 
under the stated conditions to provide the heteroaryl ether product.  
4-(Hexyloxy)-2-phenylpyridine (3da) 
 
 Prepared according to general procedure B using sodium hydride (60% dispersion in 
mineral oil, 30 mg, 0.75 mmol), n-hexanol (94 L, 0.75 mmol), triphenyl(2-phenylpyridin-4-
yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column 
chromatography (silica gel, gradient elution: 5% EtOAc in hexanes to 10% EtOAc in hexanes) 
afforded the title compound as a white amorphous solid (92 mg, 0.36 mmol, 72% yield). mp 36-
37 ºC; IR max/cm-1 (film):3068, 2942, 1563, 1467, 1323, 1219, 1021; 1H NMR (400 MHz, CDCl3) 
: 8.50 (1H, d, J = 5.5 Hz, H1), 7.97 (2H, d, J = 7.4 Hz, H4), 7.46 (2H, t, J = 7.4 Hz, H5), 7.40 (1H, 
t, J = 7.4 Hz, H6), 7.22 (1H, d, J = 2.4 Hz, H3), 6.74 (1H, dd, J = 5.7, 2.2 Hz, H2), 4.05 (2H, t, J = 
6.5 Hz, H7) 1.82 (2H, qn, J = 6.5 Hz, H8), 1.48 (2H, qn, J = 6.7 Hz, H9), 1.40-1.31 (4H, m, H10 and 
H11), 0.92 (3H, t, J = 7.0 Hz, H12); 
13C NMR (100 MHz, CDCl3)  165.83, 159.08, 150.79, 139.49 
128.84, 128.57, 126.87, 108.45, 107.25, 67.92, 31.45, 28.86, 25.57, 22.52, 13.95; m/z LRMS (ESI 
+ APCI) found [M+H]+ 256.2, C17H22NO






4-(benzyloxy)-2-phenylpyridine 2-phenylpyridin-4-ol (3db) 
 
 Prepared according to general procedure B (except that CH2Cl2 was used instead of Et2O 
for the extraction stage of the workup) using sodium hydride (60% dispersion in mineral oil, 30 
mg, 0.75 mmol), benzyl alcohol (78 L, 0.75 mmol), triphenyl(2-phenylpyridin-4-
yl)phosphonium trifluoromethanesulfonate (282 mg, 0.50 mmol) and THF (1.0 mL). Flash column 
chromatography (silica gel, gradient elution: 5% to 15% EtOAc in hexanes) to afford the title 
compound as a faintly purple amorphous solid (94 mg, 0.36 mmol, 72% yield). mp 71–73 ºC; IR 
max/cm-1 (film): 3030, 2937, 2871, 1961, 1495, 1421, 1250, 1121, 1079, 1029, 646, 548; 1H NMR 
(400 MHz, CDCl3) : 8.53 (1H, d, J = 5.7 Hz, H1), 7.95 (2H, d, J = 7.6 Hz, H4), 7.50–7.35 (8H, 
m, H5, H6, H7, H8, H9), 7.32 (1H, d, J = 1.7 Hz, H3), 6.85 (1H, dd, J = 5.4, 2.2 Hz, H2), 5.18 (2H, s, 
H10); 
13C NMR (100 MHz, CDCl3) 
                  
   The spectroscopic data is in agreement with a reported synthesis.3 m/z 
LRMS (ESI + APCI) found [M+H]+ 262.1, C18H16NO








 Prepared according to general procedure B (except that CH2Cl2 was used instead of Et2O 
for the extraction stage of the workup) using sodium hydride (60% dispersion in mineral oil, 30 
mg, 0.75 mmol), pyridin-3-ylmethanol (73 L, 0.75 mmol), triphenyl(2-phenylpyridin-4-
yl)phosphonium trifluoromethanesulfonate (283mg, 0.50 mmol) and THF (1.0 mL). Prior to flash 
chromatography the crude reaction product was dissolved in methanol (5.0 mL) and a methanolic 
solution of hydrochloric acid (5.0 mL of 4.2 M solution) was added dropwise. The resulting 
mixture was concentrated in vacuo and dry loaded onto a silica gel column (elution: 2.5% MeOH 
in CH2Cl2, then 30 mL of NEt3, then  EtOAc) afforded the title compound as a pink amorphous 
solid (84 mg, 0.32 mmol, 64% yield). mp 90-91 ºC; IR max/cm-1 (film): 3027, 2984, 1561, 1207, 
1013, 695; 1H NMR (400 MHz, CDCl3) : 8.70 (1H, s, H7), 8.61 (1H, d, J = 4.6 Hz, H10), 8.52 
(1H, d, J = 5.7 Hz, H1), 7.94 (2H, d, J = 7.5 Hz, H4), 7.76 (1H, d, J = 7.7 Hz, H8), 7.48-7.36 (3H, 
m, H5 and H6), 7.33 (1H, dd, J = 7.7, 4.7 Hz, H9), 7.29 (1H, d, J = 2.3 Hz, H3), 6.81 (1H, dd, J = 
5.7, 2.3 Hz, H2), 5.15 (2H, s, H11); 
13C NMR (100 MHz, CDCl3)  165.07, 159.28, 150.95, 149.78, 
148.93, 139.07, 135.23, 131.26, 129.05, 128.62, 126.84, 123.53, 108.52, 107.36, 67.27; m/z LRMS 
(ESI + APCI) found [M+H]+ 263.2, C17H15N2O







 Prepared according to general procedure B using sodium hydride (60% dispersion in 
mineral oil, 30 mg, 0.75 mmol), 2,2,2-trifluoroethan-1-ol (57 L, 0.75 mmol), triphenyl(2-
phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 
mL). Flash column chromatography (silica gel, gradient elution: 10% EtOAc in hexanes to 15% 
EtOAc in hexanes) afforded the title compound as an off white amorphous solid (100 mg, 0.40 
mmol, 79% yield). mp 50-51 ºC; IR max/cm-1 (film): 3095, 2975, 1568, 1271, 1164, 978, 776; 1H 
NMR (400 MHz, CDCl3) : 8.56 (1H, d, J = 5.6 Hz, H1), 7.96 (2H, d, J = 7.4 Hz, H4), 7.49-7.40 
(3H, m, H5 and H6), 7.26 (1H, d, J = 2.4 Hz, H3), 6.77 (1H, dd, J = 5.6, 2.4 Hz, H2), 4.43 (2H, q, J 
= 7.9 Hz, H7); 
13C NMR (100 MHz, CDCl3)  163.99, 159.68, 151.21, 138.79, 129.31, 128.71, 
126.90, 122.9 (q, J = 227.7 Hz), 108.07, 107.15, 64.9 (q, J = 35.9 Hz); 19F NMR (365 MHz, 
CDCl3)  -73.70. The spectroscopic data is in agreement with a reported synthesis.4 m/z LRMS 
(ESI + APCI) found [M+H]+ 254.1, C13H11F3NO






 Prepared according to general procedure B using sodium hydride (60% dispersion in 
mineral oil, 30 mg, 0.75 mmol), prop-2-yn-1-ol (43 L, 0.75 mmol), triphenyl-(2-phenylpyridin-
4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash 
column chromatography (silica gel: 5% EtOAc in hexanes) afforded the title compound as a yellow 
oil (68 mg, 0.33 mmol, 65% yield). IR max/cm-1 (film): 3296, 3055, 2923, 1589, 1474, 1196, 1019; 
1H NMR (400 MHz, CDCl3) : 8.54 (1H, d, J = 5.6 Hz, H1), 7.96 (2H, d, J = 7.4 Hz, H4), 7.50-
7.38 (3H, m, H5 and H6), 7.31 (1H, d, J = 2.4 Hz, H3), 6.84 (1H, dd, J = 5.6, 2.4 Hz, H2), 4.78 (2H, 
d, J = 2.3 Hz, H7), 2.60 (1H, t, J = 2.3 Hz, H8); 
13C NMR (100 MHz, CDCl3)  164.29, 159.27, 
150.88, 139.21, 129.03, 128.65, 126.91, 108.69, 107.45, 77.27, 76.62, 55.49. The spectroscopic 
data is in agreement with a reported synthesis.5 m/z LRMS (ESI + APCI) found [M+H]+ 210.1, 
C14H12NO
+ requires 210.1. 
4-(Cyclohexyloxy)-2-phenylpyridine (3df)  
 
 Prepared according to general procedure B using sodium hydride (60% dispersion in 
mineral oil, 30 mg, 0.75 mmol), cyclohexanol (78 L, 0.75 mmol), triphenyl(2-phenylpyridin-4-
yl)phosphonium trifluoromethanesulfonate (282 mg, 0.50 mmol) and THF (1.0 mL). The reaction 
was stirred for 13 hours after the addition of the phosphonium salt. Flash column chromatography 




(107 mg, 0.42 mmol, 85% yield). mp 49-50 ºC; IR max/cm-1 (film): 3032, 2939, 1559, 1476, 1211, 
1018; 1H NMR (400 MHz, CDCl3) : 8.49 (1H, d, J = 5.7 Hz, H1), 7.95 (2H, d, J = 7.5 Hz, H4), 
7.49-7.37 (3H, m, H5 and H6), 7.21 (1H, d, J = 2.2 Hz, H3), 6.74 (1H, dd, J = 5.7, 2.2 Hz, H2), 4.42 
(1H, m, H7), 2.07-1.96 (2H, m, H8), 1.89-1.77 (2H, m, H9), 1.67-1.53 (3H, m, H8 and H10), 1.48-
1.30 (3H, m, H9 and H10) ; 
13C NMR (100 MHz, CDCl3)  164.70, 159.17, 150.80, 139.56, 128.80, 
128.56, 126.88, 109.18, 108.30, 75.16, 31.40, 25.38, 23.51; m/z LRMS (ESI + APCI) found 
[M+H]+ 254.2, C17H20NO
+ requires 254.2. 
4-((1-Benzylpyrrolidin-3-yl)oxy)-2-phenylpyridine (3dg) 
 
 Prepared according to general procedure B using sodium hydride (60% dispersion in 
mineral oil, 30 mg, 0.75 mmol), 1-benzylpyrrolidin-3-ol (124 L, 0.75 mmol), triphenyl(2-
phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 
mL). Flash column chromatography (basic alumina, gradient elution: 10% EtOAc in hexanes to 
30% EtOAc in hexanes) afforded the title compound as a yellow oil (125 mg, 0.38 mmol, 75% 
yield). IR max/cm-1 (film): 3029, 2920, 2792, 1559,1207, 694; 1H NMR (400 MHz, CDCl3) : 8.49 
(1H, d, J = 5.7 Hz, H1), 7.96 (2H, d, J = 7.5 Hz, H4), 7.52-7.23 (8H, m, H5, H6, H7, H8, and H9), 
7.19 (1H, d, J = 2.1 Hz, H3), 6.68 (1H, dd, J = 5.7, 2.1 Hz, H2), 4.98-4.86 (1H, m, H10), 3.72 (1H, 




(2H, m, H12 and H13), 2.59 (1H, app q, J = 7.6 Hz, H12), 2.42-2.29 (1H, m, H11), 2.09-1.96 (1H, m, 
H11); 
13C NMR (100 MHz, CDCl3)  164.53, 159.07, 150.78, 139.34, 138.31, 128.87, 128.71, 
128.56, 128.23, 127.04, 126.82, 108.99, 108.02, 76.78, 60.06, 59.77, 52.56, 32.05; m/z LRMS (ESI 
+ APCI) found [M+H]+ 331.2, C22H23N2O
+ requires 331.2. 
4-((1-Benzhydrylazetidin-3-yl)oxy)-2-phenylpyridine (3dh) 
 
 Prepared according to general procedure B using sodium hydride (60% dispersion in 
mineral oil, 30 mg, 0.75 mmol), 1-benzhydrylazetidin-3-ol (180 mg, 0.75 mmol), triphenyl(2-
phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 
mL). Flash column chromatography (silica gel, gradient elution: 10% EtOAc in hexanes to 30% 
EtOAc in hexanes) afforded the title compound as a yellow oil (158 mg, 0.40 mmol, 80% yield). 
IR max/cm-1 (film): 3027, 2954, 2838, 1592, 1211, 906, 729; 1H NMR (400 MHz, CDCl3) : 8.47 
(1H, d, J = 5.5 Hz, H1), 7.92 (2H, d, J = 7.4 Hz, H4), 7.48-7.38 (7H, m, H5, H6, and H7), 7.30 (4H, 
app t, J = 7.4 Hz, H8), 7.21 (2H, t, J = 7.4 Hz, H9), 7.10 (1H, d, J = 2.3 Hz, H3), 6.61 (1H, dd, J = 
5.5, 2.3 Hz, H2), 4.93 (1H, app qn, J = 5.6 Hz, H10), 4.45 (1H, s, H12), 3.76 (2H, app t, J = 5.6 Hz, 
H11), 3.18 (2H, app t, J = 5.6 Hz, H11); 




141.67, 139.26, 129.05, 128.68, 128.55, 127.39, 127.34, 126.90, 108.68, 107.31, 78.28, 66.32, 
60.16; m/z LRMS (ESI + APCI) found [M+H]+ 393.2, C27H25N2O
+ requires 393.2. 
4-((1-Ethynylcyclopentyl)oxy)-2-phenylpyridine (3di) 
  
 Prepared according to general procedure B using sodium hydride (60% dispersion in 
mineral oil, 30 mg, 0.75 mmol), 1-ethynylcyclopentan-1-ol (85 L, 0.75 mmol), triphenyl(2-
phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 
mL). Flash column chromatography (silica gel: 10% EtOAc in hexanes) afforded the title 
compound as a yellow oil (93 mg, 0.35 mmol, 71% yield). IR max/cm-1 (film): 3292, 3032, 2960, 
1590, 1472, 1189, 992; 1H NMR (400 MHz, CDCl3) : 8.51 (1H, d, J = 5.6 Hz, H1), 7.96 (2H, d, 
J = 7.8 Hz, H4), 7.55-7.35 (4H, m, H3, H5 and H6), 7.05 (1H, dd, J = 5.6, 2.4 Hz, H2), 2.73 (1H, s, 
H9), 2.43-2.33 (2H, m, H7), 2.25-2.15 (2H, m, H7), 1.86-1.78 (4H, m, H8); 
13C NMR (100 MHz, 
CDCl3)  162.79, 158.76, 150.34, 139.51, 128.80,128.58, 126.85, 111.58, 110.10, 84.05, 80.99, 
75.58, 40.73, 23.79; m/z LRMS (ESI + APCI) found [M+H]+ 264.2, C18H18NO






 Prepared according to general procedure B using sodium hydride (60% dispersion in 
mineral oil, 30 mg, 0.75 mmol), n-hexanol (94 L, 0.75 mmol), (2-chloropyridin-4-
yl)triphenylphosphonium trifluoromethanesulfonate (262 mg, 0.50 mmol) and THF (1.0 mL). 
Flash column chromatography (silica gel, gradient elution: 4% EtOAc in hexanes to 8% EtOAc in 
hexanes) afforded the title compound as a yellow oil (82 mg, 0.34 mmol, 77% yield). IR max/cm-
1 (film): 2930, 1584, 1460, 1304, 1070, 835; 1H NMR (400 MHz, CDCl3) : 8.15 (1H, d, J = 5.7 
Hz, H1), 6.80 (1H, d, J = 2.2 Hz, H3), 6.71 (1H, dd, J = 5.7, 2.2 Hz, H2), 3.98 (2H, t, J = 6.7 Hz, 
H4), 1.77 (2H, qn, J = 6.9 Hz, H5), 1.43 (2H, qn, J = 6.9 Hz, H6), 1.37-1.27 (4H, m, H7 and H8), 
0.89 (3H, t, J = 6.8 Hz, H9); 
13C NMR (100 MHz, CDCl3)  166.76, 152.52, 150.13, 110.03, 
109.78, 68.53, 31.37, 28.66, 25.46, 22.48, 13.92. The spectroscopic data is in agreement with a 
reported synthesis.6 m/z LRMS (ESI + APCI) found [M+H]+ 214.1, C11H17ClNO
+ requires 214.1. 
2-Bromo-4-(hexyloxy)pyridine (3ba) 
 
 Prepared according to general procedure B using sodium hydride (60% dispersion in 
mineral oil, 30 mg, 0.75 mmol), n-hexanol (94 L, 0.75 mmol), (2-bromopyridin-4-
yl)triphenylphosphonium trifluoromethanesulfonate (284 mg, 0.50 mmol) and THF (1.0 mL). 
Flash column chromatography (silica gel, gradient elution: 2.5% EtOAc in hexanes to 10% EtOAc 
in hexanes) afforded the title compound as a pale orange oil (103 mg, 0.40 mmol, 80% yield). IR 




Hz, H1) 6.96 (1H, d, J = 2.2 Hz, H3) 6.74 (1H, dd, J = 5.7, 2.2 Hz, H2), 3.97 (2H, t, J = 6.6 Hz, 
H4), 1.77 (2H, qn, J = 6.8 Hz, H5), 1.43 (2H, qn, J = 6.8 Hz, H6), 1.37-1.28 (4H, m, H7 and H8), 
0.89 (3H, t, J = 6.8 Hz, H9); 
13C NMR (100 MHz, CDCl3)  166.32, 150.51, 142.92, 113.59, 
110.46, 68.52, 31.37, 28.66, 25.46, 22.49, 13.94. The spectroscopic data is in agreement with a 
reported synthesis.7 m/z LRMS (ESI + APCI) found [M+H]+ 258.0, C11H17BrNO
+ requires 258.0. 
2-Fluoro-4-(hexyloxy)pyridine (3ca) 
 
 Prepared according to general procedure B using sodium hydride (60% dispersion in 
mineral oil, 30 mg, 0.75 mmol), n-hexanol (94 L, 0.75 mmol), (2-fluoropyridin-4-
yl)triphenylphosphonium trifluoromethanesulfonate (254 mg, 0.50 mmol) and THF (1.0 mL). 
Flash column chromatography (silica gel, gradient elution: 2.5% EtOAc in hexanes to 10% EtOAc 
in hexanes) afforded the title compound as a yellow oil (67 mg, 0.34 mmol, 68% yield). IR max/cm-
1 (film): 2955, 1609, 1467, 1417, 1159; 1H NMR (400 MHz, CDCl3) : 7.99 (1H, d, J = 5.6 Hz, 
H1) 6.68 (1H, dd, J = 5.7, 2.1 Hz, H2) 6.35 (1H, d, J = 2.1 Hz, H3) 3.99 (2H, t, J = 6.5 Hz, H4) 1.79 
(2H, qn, J =  6.7 Hz, H5), 1.44 (2H, qn, J = 6.7 Hz, H6) 1.38-1.28 (4H, m, H7 and H8), 0.90 (3H, t, 
J = 6.7 Hz, H9); 
13C NMR (100 MHz, CDCl3)  169.00 (d, J = 12.0 Hz), 165.31 (d, J = 235.0 Hz), 
147.90 (d, J = 19.1 Hz), 109.38 (d, J = 3.8 Hz), 94.43 (d, J = 41.6 Hz), 68.69, 31.41, 28.69, 25.50, 
22.51, 13.95; 19F NMR (365 MHz, CDCl3)  -67.03; m/z LRMS (ESI + APCI) found [M+H]+ 
198.2, C11H17FNO






 Prepared according to general procedure B using sodium hydride (60% dispersion in 
mineral oil, 30 mg, 0.75 mmol), n-hexanol (94 L, 0.75 mmol), [2,2'-bipyridin]-4-
yltriphenylphosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash 
column chromatography (basic alumina, gradient elution: 5% EtOAc in hexanes to 20% EtOAc in 
hexanes) afforded the title compound as a pink oil (72 mg, 0.28 mmol, 56% yield). IR max/cm-1 
(film): 3058, 2929, 1582, 1458, 1302, 1209, 793; 1H NMR (400 MHz, CDCl3) : 8.63 (1H, d, J = 
4.7 Hz, H7), 8.43 (1H, d, J = 5.7 Hz, H1), 8.36 (1H, d, J = 7.7 Hz, H4), 7.92 (1H, d, J = 2.4 Hz, 
H3), 7.76 (1H, t, J = 7.7 Hz, H5), 7.25 (1H, dd, J = 7.7, 4.7 Hz, H6), 6.78 (1H, dd, J = 5.7, 2.4 Hz, 
H2), 4.08 (2H, t, J = 6.6 Hz, H8), 1.78 (2H, qn, J = 6.8 Hz, H9), 1.48-1.25 (6H, m, H10, H11, and 
H12), 0.87 (3H, t, J = 6.5 Hz, H13); 
13C NMR (100 MHz, CDCl3)  166.17, 157.86, 156.03, 150.18, 
148.97, 136.79, 123.69, 121.18, 111.09, 106.56, 68.01, 31.44, 28.88, 25.56, 22.52, 13.95; m/z 
LRMS (ESI + APCI) found [M+H]+ 257.2, C16H20N2O






 Prepared according to general procedure B using sodium hydride (60% dispersion in 
mineral oil, 30 mg, 0.75 mmol), n-hexanol (94 L, 0.75 mmol), triphenyl(3-phenylpyridin-4-
yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column 
chromatography (silica gel, gradient elution: 10% EtOAc in hexanes to 40% EtOAc in hexanes) 
afforded the title compound as a yellow oil (92 mg, 0.36 mmol, 72% yield). IR max/cm-1 (film): 
3055, 2930, 1584, 1280, 1007, 697; 1H NMR (400 MHz, CDCl3) : 8.50-8.38 (2H, m, H1 and H3), 
7.53 (2H, d, J = 7.5 Hz, H4), 7.42 (2H, t, J = 7.5 Hz, H5), 7.35 (1H, t, J = 7.5 Hz, H6), 6.86 (1H, d, 
J = 5.5 Hz, H2), 4.03 (2H, t, J = 6.5 Hz, H7), 1.75 (2H, qn, J = 6.5 Hz, H8), 1.41 (2H, qn, J = 6.7 
Hz, H9), 1.35-1.24 (4H, m, H10 and H11), 0.88 (3H, t, J = 6.7, H12); 
13C NMR (100 MHz, CDCl3) 
 161.89, 150.82, 150.28, 134.91, 129.42, 128.04, 127.42, 126.38, 107.07, 68.09, 31.27, 28.61, 
25.52, 22.44, 13.86; m/z LRMS (ESI + APCI) found [M+H]+ 256.2, C17H22NO
+ requires 256.2. 
4-(Hexyloxy)-5,6,7,8-tetrahydroquinoline (3ga) 
 
 Prepared according to general procedure B using sodium hydride (60% dispersion in 
mineral oil, 30 mg, 0.75 mmol), n-hexanol (94 L, 0.75 mmol), triphenyl(5,6,7,8-
tetrahydroquinolin-4-yl)phosphonium trifluoromethanesulfonate (272 mg, 0.50 mmol) and THF 
(1.0 mL). Flash column chromatography (neutralized silica gel: 20% EtOAc in hexanes) afforded 
the title compound as a yellow oil (93 mg, 0.40 mmol, 79% yield). IR max/cm-1 (film): 2929, 2870, 




J = 5.5 Hz, H2), 3.94 (2H, t, J = 6.4 Hz, H7), 2.83 (2H, t, J = 6.1 Hz, H6), 2.60 (2H, t, J = 6.1 Hz, 
H3), 1.88-1.67 (6H, m, H4, H5, and H8), 1.43 (2H, qn, J = 6.7 Hz, H9), 1.37-1.24 (4H, m, H10 and 
H11), 0.88 (3H, t, J = 6.7 Hz, H12); 
13C NMR (100 MHz, CDCl3)  162.82, 157.70, 147.66, 121.04, 
103.70, 67.68, 32.45, 31.40, 28.86, 25.61, 22.73, 22.49, 22.17, 22.14, 13.90; m/z LRMS (ESI + 
APCI) found [M+H]+ 234.2, C15H24NO
+ requires 234.2. 
4-(Hexyloxy)-2-methyl-3-(thiophen-3-yl)pyridine (3ha) 
 
 Prepared according to general procedure B using sodium hydride (60% dispersion in 
mineral oil, 30 mg, 0.75 mmol), n-hexanol (94 L, 0.75 mmol), (2-methyl-3-(thiophen-3-
yl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (293 mg, 0.50 mmol) and THF 
(1.0 mL). Flash column chromatography (basic alumina, gradient elution: 15% EtOAc in hexanes 
to 25% EtOAc in hexanes) afforded the title compound as a yellow oil (100 mg, 0.36 mmol, 73% 
yield). IR max/cm-1 (film): 2928, 1571, 1462, 1292, 1075, 752; 1H NMR (400 MHz, CDCl3) : 
8.32 (1H, d, J = 5.7 Hz, H1), 7.33 (1H, dd, J = 5.0, 2.7 Hz, H4), 7.15 (1H, d, J = 2.7 Hz, H3), 7.02 
(1H, d, J = 5.0 Hz, H5), 6.68 (1H, d, J = 5.7 Hz, H2), 3.92 (2H, t, J = 6.4 Hz, H7), 2.38 (3H, s, H6), 
1.64 (2H, qn, J = 6.5 Hz, H8), 1.34-1.17 (6H, m, H9, H10, and H11), 0.84 (3H, t, J = 6.7 Hz, H12); 
13C NMR (100 MHz, CDCl3)  162.79, 157.75, 149.13, 134.76, 129.34, 124.26, 123.95, 120.93, 
104.79, 68.03, 31.17, 28.53, 25.35, 23.36, 22.40, 13.85; m/z LRMS (ESI + APCI) found [M+H]+ 
276.2, C16H22NOS






 Prepared according to general procedure B using sodium hydride (60% dispersion in 
mineral oil, 30 mg, 0.75 mmol), n-hexanol (94 L, 0.75 mmol), (2-methyl-5-
(phenylethynyl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (302 mg, 0.50 
mmol) and THF (1.0 mL). Flash column chromatography (silica gel: 15% EtOAc in hexanes) 
afforded the title compound as a white solid (91 mg, 0.31 mmol, 62% yield). mp 66–68 ºC; IR 
max/cm-1 (film): 3055, 3035, 3019, 2954, 2930, 2871, 2855, 2731, 2594, 2224, 2161, 2050, 1979, 
1966, 1947, 1893, 1822, 1802, 1667, 1544, 1426, 1325, 1237, 1147, 1126, 1068, 911, 768, 723, 
678; 1H NMR (400 MHz, CDCl3) : 8.48 (1H, s, H1), 7.53 (2H, dd,  J = 4.1, 7.0 Hz, H4), 7.38–
7.31 (3H, m, H3 and H5), 6.66 (1H, s, H2), 4.08 (2H, t, J = 6.4 Hz, H7), 2.55 (3H, s, H6), 1.88 (2H, 
qn, 7.0 Hz, H8), 1.54 (2H, qn, 7.0 Hz, H9), 1.44–1.31 (4H, m, H10 and H11), 0.90 (3H, t, J = 6.9 
Hz); 13C NMR (100 MHz, CDCl3)  165.25, 159.73, 152.67, 131.48, 128.24, 128.20, 123.31, 
107.58, 106.12, 95.08, 82.79, 68.38, 31.43, 28.76, 25.54, 24.91, 22.54, 13.94; m/z LRMS (ESI + 
APCI) found [M+H]+ 294.2, C20H24NO









 Prepared according to general procedure B using sodium hydride (60% dispersion in 
mineral oil, 20 mg, 0.50 mmol), n-hexanol (63 L, 0.50 mmol), (2-fluoro-5-methylpyridin-4-
yl)triphenylphosphonium trifluoromethanesulfonate (261 mg, 0.50 mmol) and THF (1.0 mL). 
Flash column chromatography (silica gel: 2.5% EtOAc in hexanes) afforded the title compound as 
a white amorphous solid (64 mg, 0.30 mmol, 60% yield). mp 30-32 ºC; IR max/cm-1 (film): 3073, 
2944, 1610, 1493, 1332, 1160, 1026, 846; 1H NMR (400 MHz, CDCl3) : 7.78 (1H, s, H1), 6.27 
(1H, s, H2), 3.98 (2H, t, J = 6.5 Hz, H4), 2.10 (3H, s, H3), 1.81 (2H, qn, J = 6.5 Hz, H5), 1.54-1.27 
(6H, m, H6, H7, and H8), 0.90 (3H, t, J = 6.8 Hz, H9); 
13C NMR (100 MHz, CDCl3)  166.82 (d, 
J = 10.7 Hz), 163.77 (d, J = 233.5 Hz), 146.46 (d, J = 17.6 Hz), 120.38 (d, J = 4.6 Hz), 91.45 (d, 
J = 42.7 Hz), 68.47, 31.40, 28.66, 25.57, 22.51, 13.93, 12.59; 19F NMR (365 MHz, CDCl3)  -
69.11; m/z LRMS (ESI + APCI) found [M+H]+ 212.2, C12H19FNO






 Prepared according to general procedure B using sodium hydride (60% dispersion in 
mineral oil, 30 mg, 0.75 mmol), n-hexanol (94 L, 0.75 mmol), a 7:1 mixture of (5-methoxy-2-
methylpyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate and (3-methoxy-6-
methylpyridin-2-yl)triphenylphosphonium trifluoromethanesulfonate (267 mg, 0.50 mmol) and 
THF (1.0 mL). Flash column chromatography (silica gel was packed in hexanes and neutralized 
with NEt3 then gradient elution: 40% EtOAc in hexanes to 50% EtOAc in hexanes) afforded the 
title compound as a tan amorphous solid (51 mg, 0.23 mmol, 46% yield). mp 41-42 ºC; IR max/cm-
1 (film): 3068, 3004, 2938, 1590, 1511, 1231, 1026; 1H NMR (400 MHz, CDCl3) : 7.96 (1H, s, 
H1), 6.61 (1H, s, H2), 4.00 (2H, t, J = 7.2 Hz, H5), 3.86 (3H, s, H3), 2.43 (3H, s, H4), 1.82 (2H, qn, 
J = 7.2 Hz, H6), 1.43 (2H, qn, J = 7.1 Hz, H7), 1.35-1.26 (4H, m, H8 and H9), 0.87 (3H, t, J = 7.0 
Hz, H10); 
13C NMR (100 MHz, CDCl3)  154.99, 152.62 143.98, 133.25, 106.80, 68.47, 56.85, 
31.42, 28.70, 25.48, 24.10, 22.47, 13.92; m/z LRMS (ESI + APCI) found [M+H]+ 224.2, 
C13H22NO2
+ requires 224.2. 
2-Butyl-4-(hexyloxy)-5-(trifluoromethyl)pyridine (3la) 
 
 Prepared according to general procedure B using sodium hydride (60% dispersion in 
mineral oil, 30 mg, 0.75 mmol), n-hexanol (94 L, 0.75 mmol), (2-butyl-5-
(trifluoromethyl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (307 mg, 0.50 




compound as a yellow oil (112 mg, 0.37 mmol, 74% yield). IR max/cm-1 (film): 2957, 2861, 1603, 
1325, 1129, 1043; 1H NMR (400 MHz, CDCl3) : 8.52 (1H, s, H1), 6.71 (1H, s, H2), 4.07 (2H, t, J 
= 6.5 Hz, H7), 2.76 (2H, t, J = 7.6 Hz, H3), 1.81 (2H, qn, J = 6.5 Hz, H8), 1.69 (2H, qn, J = 7.7 Hz, 
H4), 1.50-1.25 (8H, m, H5, H9, H10, and H11), 0.95-0.85 (6H, m, H6 and H12); 
13C NMR (100 MHz, 
CDCl3)  168.62, 163.29, 147.39 (q, J = 5.8 Hz), 123.42 (q, J = 272.4 Hz), 113.06 (q, J = 31.3 
Hz), 106.25, 68.64, 38.59, 31.74, 31.28, 28.57, 25.33, 22.46, 22.44, 13.86, 13.83; 19F NMR (365 




 Prepared according to general procedure B using sodium hydride (60% dispersion in 
mineral oil, 30 mg, 0.75 mmol), n-hexanol (94 L, 0.75 mmol), triphenyl(4-
(trifluoromethyl)pyridin-2-yl)phosphonium trifluoromethanesulfonate (279 mg, 0.50 mmol) and 
THF (1.0 mL). Flash column chromatography (silica gel: 2.5% EtOAc in hexanes) afforded the 
title compound as a yellow oil (79 mg, 0.32 mmol, 64% yield). IR max/cm-1 (film): 2932, 1571, 
1423, 1375, 1335, 1171, 1138; 1H NMR (400 MHz, CDCl3) : 8.28 (1H, d, J = 5.3 Hz, H1), 7.02 
(1H, d, J = 5.3 Hz, H2), 6.94 (1H, s, H3), 4.32 (2H, t, J = 6.6 Hz, H4), 1.77 (2H, qn, J = 6.7 Hz, 
H5), 1.44 (2H, qn, J = 6.7 Hz, H6), 1.38-1.28 (4H, m, H7 and H8), 0.90 (3H, t, J = 6.8 Hz, H9); 
13C 
NMR (100 MHz, CDCl3)  164.48, 148.26, 140.76 (q, J = 33.6 Hz), 122.72 (q, J = 273.1 Hz), 








 Prepared according to general procedure B (except that the reaction was allowed to stir for 
14 hours after the addition of the phosphonium salt and CH2Cl2 was used instead of Et2O for the 
extraction stage of the workup) using sodium hydride (60% dispersion in mineral oil, 11 mg, 0.28 
mmol), hexanol (35 L, 0.28 mmol), (4-bromopyridin-2-yl)triphenylphosphonium 
trifluoromethanesulfonate (142 mg, 0.25 mmol) and THF (0.5 mL). Flash column chromatography 
(silica gel, gradient elution: 10% toluene in hexanes to 20% toluene in hexanes) to afford the title 
compound as a clear oil (33 mg, 0.13 mmol, 52% yield). IR max/cm-1 (film): 2927, 1577, 1553, 
1466, 1410, 1351, 1308, 1221, 1016, 982; 1H NMR (400 MHz, CDCl3) : 7.96 (1H, d, J = 5.7 Hz, 
H1), 6.99 (1H, dd, J = 5.7, 1.5 Hz, H2), 6.93 (1H, d, J = 1.5 Hz, H3), 4.26 (2H, t, J = 6.7 Hz, H4), 
1.75 (2H, qn, J = 7.3 Hz, H5), 1.49-1.28 (6H, m, H6, H7, and H8), 0.90 (3H, m, H9); 
13C NMR (100 
MHz, CDCl3) 164.69, 147.44, 133.69, 119.97, 114.26, 66.61, 31.54, 28.91, 25.67, 22.58, 14.01; 
m/z LRMS (ESI + APCI) found [M+H]+ 258.1, C11H17BrNO









 Prepared according to general procedure B using sodium hydride (60% dispersion in 
mineral oil, 15 mg, 0.38 mmol), n-hexanol (47 L, 0.38 mmol), (6-butyl-5-(methoxymethyl)-4-
(p-tolyl)pyridin-2-yl)triphenylphosphonium trifluoromethanesulfonate (170 mg, 0.25 mmol) and 
THF (0.5 mL). Flash column chromatography (silica gel, gradient elution: 20% hexanes in CH2Cl2 
to CH2Cl2) afforded the title compound as a yellow oil (69 mg, 0.19 mmol, 76 % yield). IR max/cm-
1 (film): 2927, 1594, 1342 1185, 1089, 821; 1H NMR (400 MHz, CDCl3) : 7.32 (2H, d, J = 7.7 
Hz, H2), 7.23 (2H, d, J = 7.7 Hz, H3), 6.47 (1H, s, H1), 4.31 (2H, t, J = 6.7 Hz, H7), 4.20 (2H, s, 
H4), 3.32 (3H, s, H5), 2.85 (2H, t, J = 7.8 Hz, H13), 2.41 (3H, s, H6), 1.84-1.72 (4H, m, H14 and 
H8), 1.52-1.41 (4H, m, H15 and H9), 1.40-1.29 (4H, m, H10 and H11), 0.99 (3H, t, J = 7.4 Hz, H16), 
0.91 (3H, t, J = 7.0 Hz, H12); 
13C NMR (100 MHz, CDCl3)  162.64, 161.30, 154.16, 137.59, 
136.74, 128.80, 128.71, 121.05, 107.82, 68.36, 65.95, 57.86, 34.45, 31.67, 31.64, 29.12, 25.76, 










 Prepared according to general procedure B (except that the reaction was allowed to stir for 
30 hours after the addition of the phosphonium salt) using sodium hydride (60% dispersion in 
mineral oil, 30 mg, 0.75 mmol), n-hexanol (94 L, 0.75 mmol), (5-(4-methoxyphenyl)pyrimidin-
4-yl)triphenylphosphonium trifluoromethanesulfonate (298 mg, 0.50 mmol) and THF (1.0 mL). 
Flash column chromatography (silica gel, gradient elution: 10% EtOAc in hexanes to 20% EtOAc 
in hexanes) afforded the title compound as a yellow oil (85 mg, 0.30 mmol, 60% yield). IR max/cm-
1 (film): 3038, 2930, 1554, 1448, 1306, 1249, 995, 753; 1H NMR (400 MHz, CDCl3) : 8.68 (1H, 
s, H2), 8.45 (1H, br s, H1), 7.52-7.47 (2H, m, H3), 6.99-6.93 (2H, m, H4), 4.41 (2H, t, J = 6.7 Hz, 
H6), 3.84 (3H, s, H5), 1.77 (2H, qn, J = 6.8 Hz, H7), 1.41 (2H, qn, J = 6.8 Hz, H8), 1.36-1.27 (4H, 
m, H9 and H10), 0.87 (3H, t, J = 6.9 Hz, H11); 
13C NMR (100 MHz, CDCl3)  165.87, 159.57, 
156.36, 155.36, 130.06, 125.29, 121.84, 113.87, 66.87, 55.22, 31.35, 28.53, 25.59, 22.46, 13.90; 
m/z LRMS (ESI + APCI) found [M+H]+ 287.2, C17H23N2O2






 Prepared according to general procedure B using sodium hydride (60% dispersion in 
mineral oil, 30 mg, 0.75 mmol), n-hexanol (94 L, 0.75 mmol), triphenyl(pyrazin-2-
yl)phosphonium trifluoromethanesulfonate (245 mg, 0.5 mmol) and THF (1.0 mL). Flash column 
chromatography (silica gel: 10% EtOAc in hexanes) afforded the title compound as a yellow oil 
(70 mg, 0.39 mmol, 78% yield). IR max/cm-1 (film): 3060, 2923, 1532, 1414, 1284, 1005; 1H NMR 
(400 MHz, CDCl3) : 8.19 (1H, br s, H1), 8.10-7.97 (2H, br s, H2 and H3), 4.28 (2H, t, J = 6.7 Hz, 
H4), 1.76 (2H, qn, J = 6.8 Hz, H5), 1.42 (2H, qn, J = 6.8 Hz, H6), 1.37-1.25 (4H, m, H7 and H8), 
0.88 (3H, t, J = 6.8 Hz, H9); 
13C NMR (100 MHz, CDCl3)   140.49, 136.18, 136.02, 66.40, 
31.49, 28.74, 25.60, 22.54, 13.97. The spectroscopic data is in agreement with a reported 
synthesis.8 m/z LRMS (ESI + APCI) found [M+H]+ 181.2, C10H17N2O




 Prepared according to general procedure B (except that CH2Cl2 was used instead of Et2O 
for the extraction stage of the workup) using sodium hydride (60% dispersion in mineral oil, 30 
mg, 0.75 mmol), methanol (30 L, 0.75 mmol), (S)-(3-(1-methylpyrrolidin-2-yl)pyridin-4-
yl)triphenylphosphonium trifluoromethanesulfonate (286 mg, 0.50 mmol) and THF (1.0 mL). 
Flash column chromatography (silica gel was packed in hexanes and neutralized with NEt3 then 




column (basic alumina: 2% MeOH in CH2Cl2) afforded the title compound as a tan amorphous 
solid (76 mg, 0.40 mmol, 79% yield). mp 73-75 ºC; IR max/cm-1 (film): 3031, 2969, 2780, 1589, 
1455, 1274, 1023, 805; 1H NMR (400 MHz, CDCl3) : 8.51 (1H, br s, H3), 8.34 (1H, br s, H1), 
6.70 (1H, d, J = 5.7 Hz, H2), 3.81 (3H, s, H9), 3.44 (1H, app t, J = 8.3 Hz, H4), 3.19 (1H, app t, J 
= 8.5 Hz, H7), 2.30-2.14 (5H, m, H5, H7, and H8), 1.93-1.80 (1H, m, H6), 1.80-1.69 (1H, m, H6), 
1.64-1.52 (1H, m, H5); 
13C NMR (100 MHz, CDCl3)  163.51, 149.64, 148.92, 126.87, 105.58, 
62.64, 56.96, 55.14, 40.73, 33.02, 22.66. The spectroscopic data is in agreement with a reported 
synthesis.9 m/z LRMS (ESI + APCI) found [M+H]+ 193.1, C11H17N2O




 Prepared according to general procedure B (except that the reaction was allowed to stir for 
15 hours after the addition of the phosphonium salt and CH2Cl2 was used instead of Et2O for the 
extraction stage of the workup) using sodium hydride (60% dispersion in mineral oil, 15 mg, 0.38 





trifluoromethanesulfonate (198 mg, 0.25 mmol) and THF (0.5 mL). Flash column chromatography 
(silica gel was packed in hexanes and neutralized with NEt3 then: 1% NEt3, 50% CH2Cl2 in 
hexanes) followed by a second flash column (basic alumina, gradient elution: 30% EtOAc in 
hexanes to 50% EtOAc in hexanes)8   afforded the title compound as a yellow oil (64 mg, 0.13 
mmol, 53% yield). IR max/cm-1 (film): 3010, 2929, 1688, 1567, 1435, 1230, 748 1H NMR (400 
MHz, CDCl3) : 8.27 (1H, d, J = 5.6 Hz, H1), 7.18 (1H, s, H5), 7.14-7.07 (2H, m, H3 and H4), 6.61 
(1H, d, J = 5.6 Hz, H2), 4.12 (2H, q, J = 7.1 Hz, H12), 4.01-3.69 (4H, m, H10 or H11 and H12), 3.40-
3.28 (1H, m, H6), 3.17-2.98 (3H, m, H7 and H10 or H11), 2.92-2.71 (2H, m, H6 and H7), 2.58-2.45 
(1H, m, H8 or H9), 2.43-2.18 (3H, m, H8 or H9), 1.77 (2H, qn, J = 6.9 Hz, H15), 1.50-1.28 (6H, m, 
H16, H17, and H18), 1.27-1.17 (3H, m, H12), 0.89 (3H, t, J = 6.9 Hz, H19); 
13C NMR (100 MHz, 
CDCl3)  163.41, 156.51, 155.43, 147.69, 140.30, 138.79, 137.37, 133.98, 132.73, 129.73, 
128.28, 126.05, 122.03, 104.98, 68.08, 61.22, 44.78, 44.70, 31.40, 30.70, 30.56, 29.64, 28.86, 







                                                             
8  To remove an impurity the product was dissolved in Et2O (10 mL) and trifluoroacetic acid (0.5 mL) was added 
dropwise at 0 ºC and then concentrated in vacuo. The residue was dissolved in CH2Cl2 and washed with a saturated 
aqueous solution of sodium bicarbonate (10 mL). The organic layer was washed with a saturated aqueous solution of 






 Prepared according to general procedure B (except that the reaction was allowed to stir for 
18 hours after the addition of the phosphonium salt and CH2Cl2 was used instead of Et2O for the 
extraction stage of the workup) using sodium hydride (60% dispersion in mineral oil, 15 mg, 0.38 
mmol), methanol (15 L, 0.38 mmol), (2-(1-(4-chlorophenyl)-3-(dimethylamino)propyl)pyridin-
4-yl)triphenylphosphonium trifluoromethanesulfonate (171 mg, 0.25 mmol) and THF (0.5 mL). 
Flash column chromatography (silica gel was packed in hexanes and neutralized with NEt3 then: 
1% MeOH, 1% NEt3 in CH2Cl2) followed by a second flash column (basic alumina: 2% MeOH in 
CH2Cl2) afforded the title compound as a tan oil (35 mg, 0.12 mmol, 46% yield). IR max/cm-1 
(film): 3011, 2940, 2768, 1593, 1567, 1488, 1304, 1037, 749; 1H NMR (400 MHz, CDCl3) : 8.35 
(1H, d, J = 5.6 Hz, H1), 7.28-7.18 (4H, m, H4 and H5), 6.64 (1H, d, J = 2.4 Hz, H3), 6.60 (1H, dd, 
J = 5.6, 2.4 Hz, H2), 4.05-4.00 (1H, m, H6), 3.75 (3H, s, H10), 2.44-2.30 (1H, m, H7), 2.21-2.06 
(9H, m, H7, H8, and H9); 
13C NMR (100 MHz, CDCl3)  166.01, 164.65, 150.60, 142.03, 132.15, 
129.33, 128.54, 108.86, 107.51, 57.59, 54.98, 50.60, 45.36, 32.69; m/z LRMS (ESI + APCI) found 
[M+H]+ 305.2, C17H22ClN2O







 Prepared according to general procedure B using sodium hydride (60% dispersion in 
mineral oil, 11 mg, 0.28 mmol), n-hexanol (35 L, 0.28 mmol), triphenyl((rac)-7,8,9,10-
tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxalin-2-yl)phosphonium 
trifluoromethanesulfonate (130 mg, 0.18 mmol) and THF (0.4 mL). Flash column chromatography 
(silica gel: 20% EtOAc in hexanes) afforded the title compound as a tan oil (18 mg, 0.045 mmol, 
25% yield).; IR max/cm-1 (film): 3026, 2950, 1570, 1473, 1345, 1300, 1204; 1H NMR (400 MHz, 
CDCl3) : 8.40 (1H, s, H1), 7.69 (1H, s, H2) 7.56 (1H,s, H3), 7.15-7.09 (3H, m, H5 and H6), 6.90-
6.82 (2H, m, H4), 4.47 (2H, t, J = 6.8 Hz, H13), 3.48 (2H, s, H12) 3.32-3.25 (2H, br s, H7 and H8), 
2.95 (2H, m, H10 or H11), 2.53 (2H, m, H10 or H11), 2.37-2.27 (1H, m, H9), 1.91-1.78 (3H, m, H9 
and H14), 1.57-1.45 (2H, m, H15), 1.44-1.32 (4H, m, H16 and H17), 0.93 (3H, t, J = 7.0 Hz, H18); 
13C 
NMR (100 MHz, CDCl3)  157.19, 150.56, 146.56, 140.35, 138.59, 138.38, 137.42, 128.34, 
127.99, 126.58, 120.32, 118.83, 66.29, 61.59, 57.31, 57.12, 43.51, 41.38, 40.98, 31.58, 28.83, 
25.75, 22.61, 14.06; m/z LRMS (ESI + APCI) found [M+H]+ 402.2, C26H32N3O










 Prepared according to general procedure B using sodium hydride (60% dispersion in 
mineral oil, 15 mg, 0.38 mmol), n-hexanol (47 L, 0.38 mmol), (3-((8R,9S,10R,13S,14S)-3-((tert-
butyldimethylsilyl)oxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-
cyclopenta[a]phenanthren-17-yl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate 
(219 mg, 0.25 mmol) and THF (0.5 mL). Flash column chromatography (silica gel, gradient 
elution: 30% EtOAc in hexanes to 40% EtOAc in hexanes) afforded the title compound as a white 
solid (82 mg, 0.15 mmol, 60% yield). mp 59-64 ºC; IR max/cm-1 (film): 2928, 1577, 1496, 1382, 
1279, 1250, 1077, 1022, 888; 1H NMR (400 MHz, CDCl3) : 8.40-8.15 (2H, m), 6.76 ( 1H, d, J = 
5.6 Hz), 5.89-5.84 (1H, dd, J = 3.0, 1.5 Hz), 5.38-5.32 (1H, m), 3.98 (2H, t, J = 6.6 Hz), 3.49 (1H, 
m), 2.34-2.14 (3H, m), 2.12-1.99 (2H, m), 1.85-1.27 (18H, m), 1.12-0.81 (20H, m), 0.05 (6H, s); 
13C NMR (100 MHz, CDCl3)  163.00, 150.04, 149.49, 148.60, 141.88, 130.91, 123.01, 120.90, 
106.78, 72.57, 68.01, 57.21, 50.59, 48.61, 42.83, 37.29, 36.79, 34.99, 32.14, 32.05, 31.63, 31.38, 
30.71, 28.74, 25.92, 25.66, 22.56, 20.84, 19.35, 18.24, 16.12, 13.98, -4.60; m/z LRMS (ESI + 
APCI) found [M+H]+ 564.4, C36H58NO2Si







 Prepared according to general procedure B (except that the reaction was allowed to stir for 
11 hours after the addition of the phosphonium salt and CH2Cl2 was used instead of Et2O for the 
extraction stage of the workup) using sodium hydride (60% dispersion in mineral oil, 15 mg, 0.38 
mmol), methanol (15 L, 0.38 mmol), (4-((R)-(benzyloxy)((1S,2S,4S,5R)-5-vinylquinuclidin-2-
yl)methyl)quinolin-2-yl)triphenylphosphonium trifluoromethanesulfonate (199 mg, 0.25 mmol) 
and THF (0.5 mL). Flash column chromatography (silica gel was packed in hexanes and 
neutralized with NEt3 then: 1% NEt3, 50% CH2Cl2 in hexanes) afforded the title compound as a 
pale yellow oil (60 mg, 0.14 mmol, 58% yield). IR max/cm-1 (film): 3065, 2938, 1609, 1382, 1338, 
1236, 1045, 754; 1H NMR (400 MHz, CDCl3) : 8.00 (1H, d, J = 8.0 Hz, H2), 7.91 (1H, d, J = 8.2 
Hz, H5), 7.64 (1H, t, J = 7.5 Hz, H4), 7.45-7.27 (6H, m , H6, H7, H8 and H3), 7.06 (1H s, H1), 5.83-
5.64 (1H, m, H9), 5.31-5.15 (1H, br s, H12), 5.00-4.85 (2H, m, H10), 4.50 (1H, d, J = 11.3 Hz, H13), 
4.40 (1H, d, J = 11.3 Hz, H13), 4.07 (3H, s, H11), 3.45-3.31 (1H, m , H18), 3.18-3.03 (2H, m, H20 
and H14), 2.72-2.55 (2H, m, H18 and H20), 2.30-2.18 (1H, m, H19), 1.89-1.40 (5H, m, H15, H16, and 
H17); 
13C NMR (100 MHz, CDCl3)  162.30, 148.70, 147.35, 141.69, 137.83, 129.26, 128.38, 




43.17, 39.89, 27.89, 27.55, 22.07; m/z LRMS (ESI + APCI) found [M+H]+ 415.3, C27H31N2O2
+ 
requires 415.2. 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Bis-Heterobiaryl Formation using Phosphorus Ligand-Coupling: Experimental  
(Combined Work of Xuan Zhang, Ben Boyle and Michael Hilton) 
 
A 2.1 General Methods and Materials 
 Tf2O (99%) was purchased from Oakwood Chemical and used without further purification 
but was routinely stored in a –20 ºC fridge. DBU was distilled before use. (2,2,2)-Trifluoroethanol 
(TFE) was purchased from Oakwood Chemicals and used without further purification. 200 proof 
ethanol was purchased from PHARMCO-AAPER and used without further purification. HCl (4.0 
M in dioxanes) and trifluoromethanesulfonic acid (98%) were purchased from Sigma Aldrich 
chemical company and used without further purification but were routinely stored in a –20 ºC 
fridge. All reactions were run under a nitrogen atmosphere unless otherwise noted.  
A 2.2 Instrumentation 
 1H NMR spectra were recorded using a Varian 400 MR spectrometer, an Agilent Inova 
400 spectrometer, an Agilent Inova 500 spectrometer, or a Bruker AV-111 400 spectrometer. The 
chemical shifts (δ) were reported in ppm and referenced to the corresponding NMR solvent: CDCl3 
(7.26 ppm), (CD3)2SO (2.50 ppm), or CD3OD (3.31 ppm). Coupling constants (J) were reported 
in Hertz (Hz) and the multiplicity was reported as follows: s = singlet, d = doublet, t = triplet, q = 
quartet, qn = quintet, sext = sextet, sp = septet, m = multiplet, br = broad. 13C NMR spectra were 
recorded using a Bruker Ultrashield–400, a Varian 400 MR or an Agilent Inova 400 spectrometer. 
257 
 
The chemical shifts (δ) were reported in ppm and referenced to the corresponding NMR solvent: 
CDCl3 (77.00 ppm), (CD3)2SO (39.51 ppm), or CD3OD (49.00 ppm). Low–resolution mass spectra 
were recorded on an Agilent 6310 Quadrupole Mass Spectrometer. Infrared spectra were recorded 
on a Bruker Tensor 27 FT–IR spectrometer with absorptions reported in wavenumbers (cm–1). 
Melting points were recorded using a Büchi B–450 melting point apparatus.  
A 2.3. General Procedures 
A 2.3.1 Synthesis of the Fragmentable Phosphine  
Methyl 3-(diphenylphosphaneyl)propanoate (1) 
 
An oven-dried round bottomed flask was charged with diphenylphosphane (17.4 mL, 100 
mmol) under a nitrogen atmosphere. Methyl acrylate (9.0 mL, 100 mmol), previously degassed 
via N2 sparging, was added dropwise at room temperature over 15 minutes. The reaction was 
stirred for 16 hours at room temperature before concentrating in vacuo. The crude material was 
purified by flash chromatography (silica gel: 9% EtOAc in hexanes) afforded the title compound 
as a colorless oil (24.26 g, 89.10 mmol, 89% yield). IR max/cm-1 (film): 3053, 2949, 1735, 1481, 
1433, 1353, 1221, 1164, 736, 695; 1H NMR (400 MHz, CDCl3) : 7.47-7.39 (4H, m), 7.38-7.30 
(6H, m), 3.65 (3H, s), 2.46-2.31 (4H, m); 13C NMR (100 MHz, CDCl3)  173.05 (d, J = 15.3 Hz), 
137.52 (d, J = 13.0 Hz), 132.39 (d, J = 19.2 Hz), 128.47, 128.22 (d, J = 6.6 Hz), 51.33, 30.21 (d, 
J = 19.8 Hz), 22.69 (d, J =12.2 Hz); P (162 MHz, CDCl3)  −15.76; m/z HRMS (DART) found 




A 2.3.2 General Procedure A (Preparation of Heteroaryl Phosphines) 
 
An oven dried 8 mL vial (≤ 0.5 mmol scale) or a round bottom flask (> 0.5 mmol scale) 
equipped with a stir bar was charged with the heterocycle (1.0 equiv) and placed under a nitrogen 
atmosphere. CH2Cl2 (0.1 M) was added, the reaction vessel cooled to –78 ºC and Tf2O (1.0 equiv) 
was added dropwise over 5 minutes. The reaction was stirred for 30 minutes before the mixture 
was warmed to –50 ºC and then methyl 3-(diphenylphosphaneyl)propanoate (1.1 equiv) was added 
dropwise as a solution (2.0 M in CH2Cl2). The reaction was subjected to three rapid cycles of 
vacuum / nitrogen backfill and was stirred for a further 30 minutes at –50 ºC. The reaction was 
cooled to –78 ºC and DBU (3.0 equiv) was added dropwise via syringe, the cooling bath was 
removed and the reaction was allowed to warm to room temperature while stirring for 
approximately 2 hours. The reaction was diluted with H2O and then extracted with CH2Cl2 (3x). 
The combined organic extracts were dried (MgSO4), filtered and concentrated in vacuo. The 
residue was purified by flash column chromatography under the stated conditions to provide the 





Prepared according to general procedure A using 2-phenylpyridine (2.13 mL, 14.90 mmol), 
Tf2O (2.50 mL, 14.90 mmol), methyl 3-(diphenylphosphaneyl)propanoate (4.44 g, 16.30 mmol), 
DBU (6.67 mL, 44.70 mmol) and CH2Cl2 (149 mL). Crude (to determine the inherent 
regioselectivity a separate reaction was ran with 1eq DBU instead of 3eq resulting in a pre-
fragmented phosphonium salt. See crude 31P NMR for structure) regiomeric ratio 13.3:1.0 (4-
position:2-position). Flash column chromatography (silica gel, gradient elution: 1% Et2O in 
toluene to 2.5% Et2O in toluene) afforded the title compound as a white solid (3.59 g, 10.57 mmol, 
71% yield). mp 73-74 ºC; IR max/cm-1 (film): 3053, 1570, 1434, 1373, 1026, 907, 837, 733, 693; 
1H NMR (400 MHz, CDCl3) : 8.63 (1H, dd, J = 5.1, 2.4 Hz), 7.92 (2H, d, J = 7.5 Hz), 7.65 (1H, 
d, J = 7.5 Hz) 7.50-7.35 (13H, m), 7.06 (1H, dd, J = 6.2, 5.1 Hz); 13C NMR (100 MHz, CDCl3) 
 156.79 (d, J = 5.1 Hz), 149.48 (d, J = 17.5 Hz), 149.12 (d, J = 4.2 Hz), 139.04, 134.93 (d, J = 
10.1 Hz), 134.09 (d, J = 20.4 Hz), 129.44, 128.94, 128.76 (d, J = 7.5 Hz), 128.62, 126.86, 125.48 
(d, J = 13.5 Hz), 124.13 (d, J = 18.0 Hz); P (162 MHz, CDCl3)  -6.38; m/z HRMS (DART) 
found [M+H]+ 340.1271, C23H19NP+ requires  340.1250. 
2-(4-Bromophenyl)-4-(diphenylphosphaneyl)pyridine (2b) 
 
Prepared according to general procedure A using 2-(4-bromophenyl)pyridine (2.20 g, 9.40 
mmol), Tf2O (1.58 mL, 9.40 mmol), methyl 3-(diphenylphosphaneyl)propanoate (2.82 g, 10.34 
mmol), DBU (4.21 mL, 28.20 mmol) and CH2Cl2 (94 mL). Crude (to determine the inherent 
regioselectivity a separate reaction was ran with 1eq DBU instead of 3eq resulting in a pre-
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fragmented phosphonium salt. See crude 31P NMR for structure.) regiomeric ratio 13.9:1.0 (4-
position:2-position). Flash column chromatography (silica gel: 1% ether in toluene) afforded the 
title compound as a white solid (2.40 g, 5.75 mmol, 61% yield).  mp 120-123 ºC; IR max/cm-1 
(film): 3056, 1580, 1462, 1431, 1403, 1366, 1070, 826, 741, 694; 1H NMR (400 MHz, CDCl3) : 
8.61 (1H, dd, J = 5.0, 2.4 Hz), 7.79 (2H, d, J = 8.6 Hz), 7.61 (1H, d, J = 7.3 Hz), 7.55 (2H, d, J = 
8.6 Hz), 7.48-7.36 (10H, m), 7.06 (1H, t, J = 5.4 Hz); 13C NMR (100 MHz, CDCl3)  155.52 (d, 
J = 5.3 Hz), 149.85 (d, J = 18.3 Hz), 149.12 (d, J = 4.1 Hz), 137.81, 134.77 (d, J = 9.9 Hz), 134.07 
(d, J = 20.6 Hz), 131.70, 129.49, 128.78 (d, J = 7.6 Hz), 128.37, 125.73 (d, J = 13.0 Hz), 123.77 
(d, J = 18.4 Hz), 123.45; P (162 MHz, CDCl3)  -6.35; m/z HRMS (DART) found [M+H]+ 
418.1046, C23H18BrNP+ requires  418.1036. 
5-Chloro-4-(diphenylphosphino)-2-methylpyridine (2c) 
 
Prepared according to general procedure A using 5-chloro-2-methylpyridine (333 mg, 2.60 
mmol), Tf2O (437 μL, 2.60 mmol), methyl 3-(diphenylphosphino)propanoate  (779 mg, 2.86 
mmol), DBU (1.17 mL, 7.80 mmol) and CH2Cl2 (26 mL). Flash chromatography (silica gel: 9% 
EtOAc in hexanes to 16% EtOAc in hexanes) afforded the title compound as a white amorphous 
powder (524 mg, 1.69 mmol, 65% yield). mp 112‒114 °C; IR υmax/cm-1 (film): 3052, 2990, 2921, 
1563, 1477, 1441, 1434, 1323, 1127, 749, 744; 1H NMR (400 MHz, CDCl3) δ: 8.42 (1H, d, J = 
4.5 Hz), 7.44‒7.37 (6H, m), 7.32‒7.28 (4H, m), 6.48 (1H, d, J = 3.0 Hz), 2.38 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ: 156.39, 148.01, 147.45 (d, J = 19.8 Hz), 134.15 (d, J = 20.7 Hz), 133.52 (d, 
J = 8.9 Hz), 133.28 (d, J = 22.2 Hz), 129.58, 128.87 (d, J = 7.6 Hz), 126.91, 23.93; 31P NMR (162 
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Prepared according to general procedure A using 3-chloropyridine (380 L, 4.00 mmol), 
Tf2O (672 μL, 4.00 mmol), methyl 3-(diphenylphosphino)propanoate  (1.20 g, 4.40 mmol), DBU 
(1.80 mL, 12.00 mmol) and CH2Cl2 (40 mL). Flash chromatography (silica gel: CH2Cl2 to 5% 
EtOAc in CH2Cl2 afforded the title compound as a white powder (1.08 g, 3.64 mmol, 91% yield). 
mp 66-68 °C; IR υmax/cm-1 (film): 3047, 1568, 1478, 1447, 1433, 1392, 1265, 1181, 1119, 1095, 
1077, 1029, 836, 744; 1H NMR (400 MHz, CDCl3) δ: 8.54 (1H, d, J = 4.4 Hz), 8.32 (1H, dd, J = 
4.9, 0.8 Hz),  7.46‒7.36 (6H, m), 7.34‒7.27 (4H, m), 6.64 (1H, ddd, J = 5.0, 2.8, 0.5 Hz); 13C NMR 
(100 MHz, CDCl3) δ: 148.85, 147.70 (d, J = 20.5 Hz), 147.34, 136.20 (d, J = 22.2 Hz), 134.14 (d, 
J = 20.9 Hz), 133.29 (d, J = 9.1 Hz), 129.66, 128.91 (d, J = 7.8 Hz), 127.35; 31P NMR (162 MHz, 
CDCl3) δ: −11.94; m/z LRMS (ESI + APCI) found [M+H]+ 298.1, C17H14ClNP+ requires 298.1. 
2-((4-Bromo-3-fluorophenoxy)methyl)-4-(diphenylphosphino)pyridine (2e) 
 
Prepared according to general procedure A using 2-((4-bromo-3-
fluorophenoxy)methyl)pyridine (1.41 g, 5.00 mmol), Tf2O (840 μL, 5.00 mmol), methyl 3-
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(diphenylphosphino)propanoate (1.50 g, 5.50 mmol), DBU (2.25 mL, 15.00 mmol) and CH2Cl2 
(50 mL). Flash chromatography (silica gel: 16% EtOAc in hexanes) afforded the title compound 
as a white amorphous powder (1.96 g, 4.20 mmol, 84% yield). mp 125‒127 °C; IR υmax/cm-1 (film): 
3091, 3068, 2915, 1603, 1580, 1540, 1490, 1476, 1470, 1447, 1435, 1431, 1375, 1294, 1242, 1168, 
1149, 1094, 1062, 1027, 991, 949, 887, 853, 831, 804, 747, 731; 1H NMR (400 MHz, CDCl3) δ: 
8.50‒8.48 (1H, m), 7.42‒7.27 (11H, m), 7.22‒7.20 (1H, m), 7.05‒7.02 (1H, m), 6.64 (1H, dd, J = 
10.2, 2.8 Hz), 6.56 (1H, ddd, J = 8.9, 2.8, 1.0 Hz), 5.13 (2H, s); 13C NMR (100 MHz, CDCl3) δ: 
159.36 (d, J = 245.5 Hz), 158.60 (d, J = 9.7 Hz), 155.60 (d, J = 4.2 Hz), 150.34 (d, J = 18.4 Hz), 
148.87 (d, J = 4.3 Hz), 134.60 (d, J = 9.8 Hz), 134.12 (d, J = 20.4 Hz), 133.32 (d, J = 1.9 Hz), 
129.58, 128.83 (d, J = 7.5 Hz), 126.30 (d, J = 14.9 Hz), 124.69 (d, J = 15.9 Hz), 112.01 (d, J = 3.2 
Hz), 104.02 (d, J = 25.4 Hz), 99.87 (d, J = 21.2 Hz), 70.83; 19F NMR (365 MHz, CDCl3) δ: -
105.03 (t, J = 8.2 Hz); 31P NMR (162 MHz, CDCl3) δ: −6.50; m/z HRMS (DART) found [M+H]+ 
466.0399, C24H19BrFNOP+ requires 466.0372. 
2-(Diphenylphosphino)-4-methylquinoline (2f) 
 
Prepared according to general procedure A using 4-methylquinoline (793 μL, 6.00 mmol), 
Tf2O (1.01 mL, 6.00 mmol), methyl 3-(diphenylphosphino)propanoate  (1.80 g, 6.60 mmol), DBU 
(2.70 mL, 18.00 mmol) and CH2Cl2 (60 mL). Flash chromatography (silica gel: 16% EtOAc in 
hexanes) afforded the title compound as a white amorphous powder (1.63 g, 4.98 mmol, 83% 
yield). mp 99‒102 °C; IR υmax/cm-1 (film): 3058, 2953, 2926, 2858, 1727, 1576, 1541, 1497, 1479, 
1444, 1435, 1431, 761, 751, 739; 1H NMR (400 MHz, CDCl3) δ: 8.17 (1H, d, J = 8.4 Hz), 7.96 
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(1H, d, J = 8.3 Hz), 7.72‒7.68 (1H, m), 7.58‒7.54 (1H, m), 7.50‒7.46 (4H, m), 7.40‒7.37 (6H, m), 
7.06 (1H, s), 2.58 (3H, d, J = 0.6 Hz); 13C NMR (100 MHz, CDCl3) δ: 164.19 (d, J = 3.8 Hz), 
148.32 (d, J = 15.3 Hz), 143.42 (d, J = 2.8 Hz), 136.40 (d, J = 11.4 Hz), 134.11 (d, J = 19.4 Hz), 
130.24, 129.17, 128.86, 128.48 (d, J = 7.0 Hz), 126.88, 126.53, 124.88 (d, J = 14.6 Hz), 123.60, 
18.71; 31P NMR (162 MHz, CDCl3) δ: −2.45; m/z HRMS (DART) found [M+H]+ 328.1254, 
C22H19NP+ requires 328.1255. 
2-(Diphenylphosphaneyl)-4-ethoxyquinoline (2g)  
 
Prepared according to general procedure A, using 4-ethoxyquinoline (500 mg, 3.00 mmol), 
Tf2O (500 L, 3.00 mmol), methyl-3-(diphenylphosphaneyl)propanoate (900 mg, 3.30 mmol), 
DBU (1.35 mL, 9.00 mmol), and CH2Cl2 (60 mL). The crude material was purified by flash 
chromatography (silica gel: 15% EtOAc in hexanes) to provide the title compound as a white 
crystalline solid (880 mg, 2.46 mmol, 82% yield). mp 114-118 oC; IR max/cm-1 (film): 3058, 2975, 
1482, 1231, 1115, 1018, 696; 1H NMR (400 MHz, CDCl3) : 8.18 (1H, dd, J = 8.8, 1.2 Hz), 8.05 
(1H, d, J = 8.2 Hz), 7.70-7.64 (1H, m), 7.51-7.39 (5H, m); 7.38-7.31 (6H, m), 6.49 (1H, d, J = 0.6 
Hz), 3.94 (2H, q, J = 7.0 Hz), 1.41 (3H, t, J = 7.0 Hz); 13C NMR (100 MHz, CDCl3)   165.60 (d, 
J = 4.7 Hz), 160.96 (d, J = 3.5 Hz), 149.60 (d, J = 16.9 Hz), 136.56 (d, J = 11.9 Hz), 134.10 (d, J 
= 19.4 Hz), 129.73, 129.15, 128.92, 128.49 (d, J = 7.0 Hz), 125.72, 121,72, 120.23, 104.02, 63.69, 
14.22  31P NMR (162 MHz, CDCl3)   −1.06; m/z HRMS (DART) found [M+H]+ 358.1349 







Prepared according to general procedure A using ethyl (S)-4-((4-chlorophenyl)(pyridin-2-
yl)methoxy)piperidine-1-carboxylate (1.026 g, 2.74 mmol), Tf2O (0.46 mL, 2.74 mmol), methyl 
3-(diphenylphosphaneyl)propanoate (820 mg, 3.01 mmol), DBU (1.22 mL, 8.21 mmol) and 
CH2Cl2 (27.5 mL). Flash column chromatography (silica gel, gradient elution: 45% EtOAc in 
hexanes to 50% EtOAc in hexanes) afforded the title compound as a tan oil (1.19 g, 2.13 mmol, 
78% yield). IR max/cm-1 (film): 3052, 2981, 2928, 1692, 1577, 1489, 1434, 1381, 1272, 1227, 
1087, 742; 1H NMR (400 MHz, CDCl3) : 8.37 (1H, ddd, J = 5.1, 2.3, 0.8 Hz), 7.41-7.19 (15H, 
m), 6.95 (1H, m), 5.52 (1H, s), 4.10 (2H, q, J = 7.2 Hz), 3.61-3.45 (3H, m), 3.25-3.06 (2H, m), 
1.80-1.67 (1H, m), 1.63-1.38 (3H, m), 1.23 (3H, t, J = 7.2 Hz); 13C NMR (100 MHz, CDCl3) 
 161.03 (d, J = 4.2 Hz), 155.36, 150.31 (d, J = 18.2 Hz), 148.31 (d, J = 4.2 Hz), 139.82, 134.79 
(d, J = 10.1 Hz), 134.76 (d, J = 10.1 Hz), 134.12 (d, J = 20.7 Hz), 134.01 (d, J = 20.7 Hz), 133.31, 
129.51 (d, J = 2.8 Hz), 128.72 (d, J = 7.6 Hz), 128.45, 128.14, 125.75 (d, J = 15.0 Hz), 123.83 (d, 
J = 15.6 Hz), 80.72, 72.23, 61.13, 40.69, 30.80, 30.66, 14.64; 31P NMR (162 MHz, 





(2R, 6S)-4-((2-(Diphenylphosphaneyl)quinolin-4-yl)methyl)-2,6-dimethylmorpholine (2i)  
 
Prepared according to general procedure A, using (2R, 6S)-2,6-dimethyl-4-(quinolin-4-
ylmethyl)morpholine (1.28 g, 5.00 mmol), Tf2O (840 L, 5.00 mmol), methyl-3-
(diphenylphosphaneyl)propanoate (1.50 g, 5.50 mmol), DBU (2.25 mL, 15.00 mmol), and CH2Cl2 
(50 mL). Crude material was purified by flash chromatography (silica gel: 15% EtOAc in hexanes) 
to provide the title compound as a white amorphous solid (1.42 g, 3.25 mmol, 65% yield). IR 
max/cm-1 (film): 3054, 2971, 2932, 2868, 2811, 2236, 570, 566, 542, 537, 529; 1H NMR (400 
MHz, CDCl3) : 7.95 (1H, d, J = 8.5 Hz), 7.88 (1H, d, J = 8.0 Hz), 7.48 (1H, m), 7.33 (1H, m), 
7.30-7.24 (4H, m), 7.20-7.12 (6H, m), 7.07 (1H, s), 3.59 (2H, s), 3.35-3.24 (2H, m), 2.37 (2H, d, 
J = 10.4 Hz), 1.57 (2H, t, J = 10.7 Hz), 0.90 (6H, d, J = 6.3 Hz); 13C NMR (100 MHz, CDCl3) 
 164. 39 (d, J = 3.7 Hz), 148.59 (d, J = 15.1 Hz), 142.58 (d, J = 2.7 Hz), 136.39 (d, J = 11.3 Hz), 
134.05 (d, J = 19.5 Hz) 130.26, 129.12, 128.90, 128.45 (d, J = 6.9 Hz), 126.5, 125.96, 123.94 (d, 
J = 14.5 Hz), 123.45, 71.46, 59.42, 58.82, 18.94; 31P NMR (162 MHz, CDCl3)  −2.22; m/z HRMS 







A 2.3.3 General Procedure B (Preparation of Heteroaryl Phosphonium Salts) 
 
 An oven dried 8 mL vial (≤ 0.5 mmol scale) or a round bottom flask (> 0.5 mmol scale) 
equipped with a stir bar was charged with the heterocycle (1.0 equiv) and placed under a 
nitrogen atmosphere. CH2Cl2 (0.1 M) was added, the reaction vessel cooled to –78 ºC and Tf2O 
(1.0 equiv) was added dropwise over 5 minutes. The reaction was stirred for 30 minutes before 
the mixture was warmed to –50 ºC and then the heteroaryl phosphine (1.1 equiv) was added in 
one portion as a solid or dropwise as a solution (2.0 M in CH2Cl2). The reaction was subjected to 
three rapid cycles of vacuum / nitrogen backfill and was stirred for a further 30 minutes at –50 
ºC. The reaction was cooled to –78 ºC and DBU (1.0 equiv) was added dropwise via syringe, the 
cooling bath was removed, and the reaction was allowed to warm to room temperature while 
stirring (approximately 15-30 minutes). The reaction mixture was diluted with CH2Cl2 and 
washed with H2O (3x). The organic layer was dried (MgSO4), filtered and concentrated in vacuo 
to approximately 2-10 mL (depending on the scale of the reaction). The concentrated reaction 
mixture was added dropwise to an excess of chilled Et2O (0 ºC) that was then placed in a –20 ºC 
refrigerator for approximately 2-12 hours. The suspension was filtered on a frit, the solid washed 




Diphenyl(2-phenylpyridin-4-yl)(pyridin-4-yl)phosphonium trifluoromethanesulfonate (3a) 
 
Prepared according to general procedure B using pyridine (119 L, 1.50 mmol), Tf2O (250 
L, 1.50 mmol), 4-(diphenylphosphaneyl)-2-phenylpyridine (560 mg, 1.65 mmol), DBU (224 L, 
1.50 mmol) and CH2Cl2 (15 mL). After the purification procedure
(solid was dissolved in approximately 2-10 mL of CH2Cl2 and the solution was again added 
dropwise to an excess of chilled Et2O (0 °C). The mixture was then placed in −20 °C refrigerator 
for 5 hour. The resulting suspension was filtered on a frit and the solid was washed with chilled 
Et2O (0 °C) and dried in vacuo to provide the pure phosphonium salt), the title compound was 
isolated as a white solid (702 mg, 1.24 mmol, 83% yield). mp 73 ºC; IR max/cm-1 (film): 3059, 
1573, 1440, 1262, 1223, 1150, 1109, 1030; 1H NMR (400 MHz, CDCl3) : 9.09 (1H, app t, J = 
5.1 Hz), 9.03 (2H, app t, J = 5.1 Hz), 7.99-7.87 (4H, m) 7.87-7.78 (5H, m), 7.77-7.63 (6H, m), 
7.57 (1H, dd, J = 13.1, 5.1 Hz), 7.48-7.41 (3H, m); 13C NMR (100 MHz, CDCl3)  158.99 (d, J = 
10.4 Hz), 151.60 (d, J = 11.8 Hz), 151.49 (d, J = 10.3 Hz), 136.49 (d, J = 1.6 Hz), 136.35 (d, J = 
3.0 Hz), 134.29 (d, J = 10.7 Hz), 130.93 (d, J = 13.3 Hz), 130.14, 128.75, 127.40 (d, J = 84.4 Hz), 
126.98 (d, J = 8.2 Hz), 126.89, 126.39 (d, J = 84.3 Hz), 125.18 (d, J = 8.3 Hz), 122.96 (d, J = 8.9 
Hz), 120.38 (q, J = 321.4 Hz), 113.59 (d, J = 89.4 Hz); 19F NMR (365 MHz, CDCl3)  − P 
NMR (162 MHz, CDCl3)   m/z HRMS (ESI + APCI) found [M-OTf]+ 417.1537, 





Prepared according to general procedure B using 3-chloropyridine (95 L, 1.00 mmol), Tf2O 
(168 L, 1.00 mmol), 2-(4-Bromophenyl)-4-(diphenylphosphaneyl)pyridine (460 mg, 1.10 
mmol), DBU (149 L, 1.00 mmol) and CH2Cl2 (10 mL). After the purification procedure, the title 
compound was isolated as a white solid (556 mg, 0.82 mmol, 82% yield).  mp 94-96 ºC; IR 
max/cm-1 (film): 3062, 1579, 1439, 1258, 1223, 1149, 1107, 1029, 724; 1H NMR (400 MHz, 
CDCl3) : 9.04 (1H, app t, J = 5.4 Hz), 8.97-8.82 (2H, m), 8.02 (1H, d, J = 14.5 Hz), 7.96-7.85 
(4H, m), 7.84-7.72 (8H, m), 7.64-7.52 (3H, m), 7.41 (1H, dd, J = 15.1, 5.0 Hz); 13C NMR (100 
MHz, CDCl3)  158.30 (d, J = 10.8 Hz), 151.78 (d, J = 11.1 Hz), 151.59 (d, J = 5.1 Hz), 150.33 
(d, J = 10.1 Hz), 136.46 (d, J = 3.0 Hz), 135.67 (d, J = 1.7 Hz), 134.51, 134.27, 132.14, 131.17 (d, 
J = 13.6 Hz), 130.91 (d, J = 8.4 Hz), 128.93, 127.66 (d, J = 85.7 Hz), 125.57 (d, J = 88.3 Hz), 
125.33 (d, J = 8.5 Hz), 125.13, 123.02 (d, J = 9.1 Hz), 120.57 (q, J = 321.2 Hz), 113.39 (d, J = 
90.4 Hz); 19F NMR (365 MHz, CDCl3)  -78.18 P (162 MHz, CDCl3)  22.17; m/z HRMS 




yl)diphenylphosphonium trifluoromethanesulfonate (3c) 
 
Prepared according to general procedure B (except that after 2-(4-bromophenyl)-4-
(diphenylphosphino)pyridine was added, the reaction mixture was stirred for 30 min at -30 °C) 
using ethyl 2-butylnicotinate (300.4 mg, 1.45 mmol), Tf2O (244 μL, 1.45 mmol), 2-(4-
bromophenyl)-4-(diphenylphosphino)pyridine (667 mg, 1.60 mmol), DBU (218 μL, 1.45 mmol) 
and CH2Cl2 (14.5 mL). After the purification procedure, the title compound was isolated as a white 
amorphous powder (831 mg, 1.07 mmol, 74% yield). mp 212-214 °C; IR υmax/cm-1 (film): 3045, 
2950, 2927, 2870, 1706, 1787, 1578, 1547, 1538, 1463, 1440, 1435, 1404, 1369, 1291, 1275, 1258, 
1223, 1177, 1152, 1136, 1105, 1069, 1030, 1013, 1004, 816, 751, 727, 721, 697, 685; 1H NMR 
(400 MHz, CDCl3) δ: 9.04-9.00 (2H, m), 7.94-7.84 (5H, m), 7.80-7.69 (8H, m), 7.60-7.54 (3H, 
m), 7.33 (1H, dd, J = 15.7, 5.0 Hz), 3.51 (2H, q, J = 7.2 Hz), 3.07 (2H, t, J = 7.8 Hz), 1.82-1.74 
(2H, m), 1.41 (2H, sext, J = 7.4 Hz), 0.99-0.93 (6H, m); 13C NMR (100 MHz, CDCl3) δ: 166.34 
(d, J = 3.7 Hz), 164.12 (d, J = 6.3 Hz), 157.79 (d, J = 10.6 Hz), 153.20 (d, J = 11.6 Hz), 151.37 (d, 
J = 11.0 Hz), 135.91 (d, J = 2.9 Hz), 135.84 (d, J = 1.7 Hz), 134.53 (d, J = 10.5 Hz), 132.17, 130.65 
(d, J = 13.3 Hz), 129.71 (d, J = 86.4 Hz), 128.79, 128.50 (d, J = 4.9 Hz), 127.95 (d, J = 9.5 Hz), 
126.79 (d, J = 83.3 Hz), 125.40 (d, J = 8.1 Hz), 125.07, 123.09 (d, J = 8.8 Hz), 120.66 (q, J = 
319.6 Hz), 115.84 (d, J = 90.5 Hz), 63.18, 37.27 (d, J = 1.5 Hz), 31.87, 22.62, 13.75, 13.26; 19F 
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NMR (365 MHz, CDCl3) δ: −78.19; 31P NMR (162 MHz, CDCl3) δ: 27.28; m/z HRMS (ESI + 




Prepared according to general procedure B (except that after 5-chloro-4-
(diphenylphosphino)-2-methylpyridine was added, the reaction mixture was stirred for 30 min at 
−30 °C) using 3-methoxypyridine (202 μL, 2.00 mmol), Tf2O (336 μL, 2.00 mmol), 5-chloro-4-
(diphenylphosphino)-2-methylpyridine (686 mg, 2.20 mmol), DBU (300 μL, 2.00 mmol) and 
CH2Cl2 (20 mL). After the purification procedure, the title compound was isolated as an 
amorphous white powder (842 mg, 1.48 mmol, 74% yield). mp 182-186 °C; IR υmax/cm-1 (film): 
3060, 2951, 1570, 1544, 1483, 1460, 1439, 1411, 1380, 1326, 1300, 1258, 1222, 1140, 1103, 1087, 
1072, 1043, 1029, 998, 914, 823, 808, 753, 722, 688, 646; 1H NMR (400 MHz, CDCl3) δ: 8.74 
(1H, d, J = 6.6 Hz), 8.70 (1H, d, J = 6.7 Hz), 8.62 (1H, t, J = 4.6 Hz), 7.91-7.87 (2H, m), 7.81-7.76 
(4H, m), 7.72-7.67 (4H, m), 7.39 (1H, dd, J = 15.2, 5.0 Hz), 7.26 (1H, d, J = 15.6 Hz), 3.72 (3H, 
s), 2.65 (3H, s); 13C NMR (100 MHz, CDCl3) δ: 160.05 (d, J = 10.2 Hz), 155.60, 150.83 (d, J = 
5.7 Hz), 144.17 (d, J = 11.3 Hz), 136.64 (d, J = 4.5 Hz), 135.91 (d, J = 3.1 Hz), 134.11 (d, J = 11.2 
Hz), 130.81 (d, J = 13.7 Hz), 130.79 (d, J = 2.2 Hz), 129.12 (d, J = 8.1 Hz), 127.68 (d, J = 6.8 Hz), 
126.35 (d, J = 90.1 Hz), 120.68 (q, J = 319.6 Hz), 114.06 (d, J = 92.0 Hz), 113.45 (d, J = 88.4 Hz), 
57.39 (dd, J = 4.6, 5.9 Hz), 24.19; 19F NMR (365 MHz, CDCl3) δ: −78.26; 31P NMR (162 MHz, 
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Prepared according to general procedure B (except that after the initial extraction the aqueous 
layer was extracted an additional 3 times with CH2Cl2 and then the combined organic was washed 
once with water prior to concentration) using 3-fluoropyridine (43 L, 0.50 mmol), Tf2O (84 μL, 
0.50 mmol), 3-chloro-4-(diphenylphosphino)pyridine (164 mg, 0.55 mmol), DBU (75 μL, 0.50 
mmol) and CH2Cl2 (5.0 mL). After the purification procedure (concentrated CH2Cl2 solution of 
crude product was added dropwise to an excess of 50% Et2O in hexanes instead of Et2O), the title 
compound was isolated as a pale yellow solid (148 mg, 0.27 mmol, 54% yield). mp 59-62 °C; IR 
υmax/cm-1 (film): 3085, 3024, 1586, 1546, 1472, 1440, 1403, 1282, 1247, 1225, 1201, 1184, 1154, 
1132, 1106, 1030, 996, 749; 1H NMR (400 MHz, CDCl3) δ: 8.99-8.71 (4H, m), 8.02-7.68 (2H, m), 
7.83-7.57 (9H, m), 7.45 (1H, dd, J = 15.4, 4.8 Hz); 13C NMR (100 MHz, CD3OD) δ: 160.39 (d, J 
= 264.3Hz), 153.28 (d, J = 5.2 Hz), 151.07 (d, J = 10.4 Hz), 149.09 (dd, J = 10.7, 5.3 Hz), 141.83 
(dd, J = 24.0, 4.1 Hz), 137.73 (d, J = 3.2 Hz), 136.19 (d, J = 2.0 Hz), 135.86 (d, J = 11.7 Hz), 
132.22 (d, J = 14.1 Hz), 131.34 (d, J = 8.7 Hz), 129.60 (d, J = 3.8 Hz), 127.07 (d, J = 91.3 Hz), 
121.73 (d, J = 319.0 Hz), 116.20 (dd, J = 87.5, 13.3 Hz), 115.76 (d, J = 13.3 Hz); 19F NMR (365 
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MHz, CD3OD) δ: −, −111.00; 31P NMR (162 MHz, CDCl3) δ: 19.61 (d, J = 4.0 Hz); m/z 
LRMS (ESI + APCI) found [M-OTf]+ 393.1, C22H16ClFN2OP+ requires 393.1. 
(2-((4-Bromo-3-fluorophenoxy)methyl)pyridin-4-yl)(2-butyl-5-(trifluoromethyl)pyridin-4-




Prepared according to general procedure B using 2-butyl-5-(trifluoromethyl)pyridine (93 mg, 
0.46 mmol), Tf2O (77 μL, 0.46 mmol), 2-((4-bromo-3-fluorophenoxy)methyl)-4-
(diphenylphosphino)pyridine (234 mg, 0.50 mmol), DBU (68 μL, 0.46 mmol) and CH2Cl2 (4.6 
mL). After the purification procedure, the title compounds were isolated as a mixture (crude: 3.7:1; 
pure: 5.6:1) as a white amorphous powder (204 mg). The mixture was carried forward through the 
ligand coupling step. IR υmax/cm-1 (film): 3063, 2959, 2932, 2872, 1603, 1578, 1532, 1486, 1439, 
1384, 1320, 1259, 1223, 1143, 1120, 1106, 1029, 997, 968, 945, 909, 848, 834, 727; Major, 1H 
NMR (400 MHz, CDCl3) δ: 9.16 (1H, d, J = 7.3 Hz), 9.03 (1H, t, J = 5.2 Hz), 7.93-7.90 (2H, m), 
7.80-7.62 (10H, m), 7.36 (1H, t, J = 8.4 Hz), 7.21 (1H, d, J = 17.4 Hz), 6.63 (1H, dd, J = 10.0, 2.7 
Hz), 6.58 (1H, dd, J = 8.7, 2.4 Hz), 5.33 (2H, s), 2.94 (2H, t, J = 7.7 Hz), 1.66 (2H, qn, J = 7.6 
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Hz), 1.31 (2H, sext, J = 7.5 Hz), 0.87 (3H, t, J = 7.3 Hz); Major, 13C NMR (100 MHz, CDCl3) δ: 
170.37 (d, J = 9.8 Hz), 159.21 (d, J = 245.9 Hz), 158.88 (d, J = 10.3 Hz), 157.97 (d, J = 9.8 Hz), 
151.53 (d, J = 10.7 Hz), 150.06 (m), 136.40 (d, J = 3.0 Hz), 134.56 (d, J = 7.7 Hz), 133.52, 130.93 
(d, J = 13.4 Hz), 130.24 (d, J = 8.5 Hz), 128.43 (d, J = 84.9 Hz), 126.52 (d, J = 8.5 Hz), 124.46 (d, 
J = 8.8 Hz), 124.17 (d, J = 4.1 Hz), 123.82 (d, J = 79.6 Hz), 122.48 (qd, J = 273.8, 2.3 Hz), 120.56 
(q, J = 319.5 Hz), 114.65 (d, J = 89.3 Hz), 111.81 (d, J = 3.0 Hz), 103.90 (d, J = 25.5 Hz), 100.22 
(d, J = 21.1 Hz), 70.00 (d, J = 1.5 Hz), 37.94, 30.25, 22.14, 13.63; Major, 19F NMR (365 MHz, 
CDCl3) δ: −53.41 (d, J = 1.7 Hz), −78.35, −104.68 (t, J = 8.4 Hz); Major, 31P NMR (162 MHz, 
CDCl3) δ: 26.97 (d, J = 2.4 Hz); m/z HRMS (ESI + APCI) found [M-OTf]+ 667.1166, 




Prepared according to general procedure B, using 3-fluoropyridine (171 L, 2.00 mmol), 
Tf2O (336 L, 2.00 mmol), 2-(diphenylphosphaneyl)-4-methylquinoline (720 mg, 2.20 mmol), 
DBU (300 L, 2.00 mmol), and CH2Cl2 (20 mL). After purification procedure, the title compound 
was provided as a light brown crystalline solid (660 mg, 1.16 mmol, 58% yield). mp 65-66 oC IR 
max/cm-1 (film): 3064, 1545, 1505, 997, 857, 688; 1H NMR (400 MHz, CDCl3) : 8.88-8.83 (2H, 
m), 8.19 (1H, d, J = 8.2 Hz), 8.14 (1H, d, J = 8.2 Hz), 7.95-7.78 (13H, m), 7.41 (1H, dt, J = 14.2, 
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5.1 Hz), 2.88 (3H, s); 13C NMR (100 MHz, CDCl3)   158.98 (d, J = 265.8 Hz), 149.37 (d, J = 
11.4 Hz), 148.49 (d, J = 23.9 Hz), 148.15 (dd, J = 9.9, 6.4 Hz), 142.67 (d, J = 120.2 Hz), 139.85 
(dd, J = 22.9, 3.8 Hz), 136.27 (d, J = 31.1 Hz), 134.67 (d, J = 10.6 Hz), 131.68, 130.92 (d, J = 13.4 
Hz), 130.65 (d, J = 1.2 Hz), 130.54, 129.45 (d, J = 3.1 Hz), 128.86 (dd, J = 7.0, 1.7 Hz), 125.22 
(d, J = 27.1 Hz), 124.61 (d, J = 1.4 Hz), 120.79 (q, J = 321.1 Hz), 116.43 (dd, J = 84.7, 13.9 Hz), 
114.84 (d, J = 88.9 Hz), 19.19 (d, J = 1.6 Hz); 19F NMR (365 MHz, CDCl3)  −78.25, −109.74 
(d, J = 6.6 Hz); 31P NMR (162 MHz, CDCl3)  11.79; m/z HRMS (ESI + APCI) found [M-OTf]+ 
423.1454, C27H21FN2P+ requires  423.1426. 
(4-(Ethoxycarbonyl)pyridin-2-yl)(4-ethoxyquinolin-2-yl)diphenylphosphonium 
trifluoromethanesulfonate (3h)  
 
Prepared according to general procedure B, using 4- picolyl acid ethyl ester (150 L, 1.00 
mmol), Tf2O (168 L, 1.00 mmol), 2-(diphenylphosphaneyl)-4-ethoxyquinoline (392 mg, 1.10 
mmol), DBU (150 L, 1.00 mmol), and CH2Cl2 (10 mL). After purification procedure,
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(concentrated CH2Cl2 solution of crude product was added dropwise to an excess of 50% Et2O in 
hexanes instead of Et2O) the title compound was provided as a light brown amorphous solid (400 
mg, 0.61 mmol, 61% yield). IR max/cm-1 (film): 3064, 2986, 1729, 1476, 942, 851, 557, 537; 1H 
NMR (400 MHz, CDCl3) : 9.19 (1H, d, J = 4.8 Hz), 8.48 (1H, d, J = 5.8 Hz), 8.35 (1H, d, J = 8.3 
Hz), 8.31-8.25 (1H, m), 8.05 (1H, d, J = 8.5 Hz), 7.93-7.66 (12H, m), 7.18 (1H, d, J = 6.2 Hz), 
4.40 (2H, q, J = 7.1 Hz), 4.22 (2H, q, J = 7.0 Hz), 1.51 (3H, t, J = 7.0 Hz), 1.35 (3H, t, J = 7.1 Hz); 
13C NMR (100 MHz, CDCl3)   163.46 (d, J = 14.2 Hz), 163.15 (d, J = 2.7 Hz), 153.32 (d, J = 
20.0 Hz), 149.59 (d, J = 25.9 Hz), 145.87 (d, J = 120.4 Hz), 145.13 (d, J = 119.0 Hz), 139.52 (d, 
J = 10.4 Hz), 135.75 (d, J = 3.1 Hz), 134.91 (d, J =  9.9 Hz), 131.83, 131.26 (d, J = 24.2 Hz), 
130.45 (d, J = 13.0 Hz), 129.31 (d, J = 18.0 Hz), 127.48 (d, J = 3.5 Hz), 122.66, 121.93 (d, J = 2.5 
Hz), 120.78 (q, J = 321.0 Hz), 116.87 (d, J = 87.9 Hz), 106.06, 105.78, 65.83, 62.74, 14.04, 13.92; 
19F NMR (365 MHz, CDCl3)  −78.25; 31P NMR (162 MHz, CDCl3)  9.58; m/z HRMS (ESI + 




Prepared according to general procedure B, using 7-chloro-4-(3-fluorophenoxy)quinoline 
(244 mg, 0.89 mmol), Tf2O (151 L, 0.89 mmol), 2-(diphenylphosphaneyl)-4-methylquinoline 
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(320 mg, 0.99 mmol), DBU (133 L, 0.89 mmol), and CH2Cl2 (9 mL). After purification 
procedure, the title compound was provided as a brown amorphous solid (330 mg, 0.47 mmol, 
53% yield). IR max/cm-1 (film): 3067, 1607, 666, 605, 579, 544, 532; 1H NMR (400 MHz, CDCl3) 
: 8.41 (1H, d, J = 9.0 Hz), 8.16-8.14 (2H, m), 7.92-7.67 (15H, m), 7.54 (1H, d, J = 4.6 Hz), 7.31 
(1H, q, J = 5.8 Hz), 7.10 (1H, d, J = 5.6 Hz), 6.98 (1H, dd, J = 8.2, 1.8 Hz), 6.92-6.84 (2H, m), 
2.78 (3H, s); 13C NMR (100 MHz, CDCl3)   163.16 (d, J = 249.9 Hz), 162.90 (d, J = 13.9 Hz), 
153.49 (d, J = 10.4 Hz), 150.56 (d, J = 25.7 Hz), 148.76 (d, J = 10.6 Hz), 148.15 (d, J = 8.6 Hz), 
147.67 (d, J = 132.3 Hz), 143.40 (d, J = 114.9 Hz), 138.65, 135.63 (d, J = 3.1 Hz), 134.76 (d, J = 
9.8 Hz), 131.75 (d, J = 9.4 Hz), 131.56, 130.77, 130.66, 130.35 (d, J = 12.9 Hz), 128.87 (d, J = 
3.0 Hz), 128.57 (d, J = 1.0 Hz), 128.56, 126.04 (d, J = 25.7 Hz), 124.47 (d, J = 1.3 Hz), 123.78, 
120.77 (q, J = 321.2 Hz), 119.87 (d, J = 2.5 Hz), 116.91 (d, J = 87.7 Hz), 117.03 (d, J = 3.5 Hz), 
113.69 (d, J = 20.9 Hz), 109.23 (d, J = 27.4 Hz), 108.87 (d, J = 24.2 Hz), 19.14 (d, J = 1.5 Hz) ; 
19F NMR (365 MHz, CDCl3)  −78.19, −108.64 (q, J = 8.3 Hz); 31P NMR (162 MHz, 






Prepared according to general procedure B (except the stirring time after the addition of the 
heteroaryl phosphine was 45 minutes instead of 30 minutes) using 2-(propylthio)pyrimidine (154 
mg, 1.00 mmol), Tf2O (168 L, 1.00 mmol), 2-(diphenylphosphaneyl)-4-methylquinoline (360 
mg, 1.10 mmol), DBU (149, 1.00 mmol) and EtOAc (5 mL). After the purification procedure, the 
title compound was isolated as a brown solid (433 mg, 0.72 mmol, 72% yield). mp 52-54 ºC; IR 
max/cm-1 (film): 3064, 2963, 1576, 1544, 1526, 1439, 1259, 1143, 1029, 727; 1H NMR (400 MHz, 
CDCl3) : 8.91 (1H, dd, J = 7.6, 4.8 Hz), 8.21-8.12 (2H, m), 7.95-7.87 (3H, m), 7.87-7.80 (5H, 
m), 7.80-7.73 (4H, m), 7.70 (1H, dd, J = 6.0, 4.8 Hz), 7.65 (1H, d, J = 4.8 Hz), 2.93 (2H, t, J = 7.3 
Hz), 2.83 (3H, s), 1.53 (2H, sext, J = 7.3 Hz), 0.84 (3H, t, J = 7.3 Hz); 13C NMR (100 MHz, CDCl3) 
 174.98 (d, J = 18.0 Hz), 159.91 (d, J = 7.3 Hz), 154.41 (d, J = 111.9 Hz), 148.87 (d, J = 10.7 
Hz), 148.51 (d, J = 23.4 Hz), 142.36 (d, J = 117.1 Hz), 136.04 (d, J = 3.0 Hz), 134.99 (d, J = 9.9 
Hz), 131.72, 130.77-130.43 (3C, m), 129.12 (d, J = 3.0 Hz), 125.98 (d, J = 26.5 Hz), 124.51 (d, J 
= 1.2 Hz), 123.11 (d, J = 19.6 Hz), 120.74 (q, J = 321.1 Hz), 115.21 (d, J = 87.3 Hz), 33.05, 22.02, 
19.18 (d, J = 1.5 Hz), 13.23; 19F NMR (365 MHz, CDCl3)  −78.21 P (162 MHz, CDCl3) 





Prepared according to general procedure B using 2,3-dimethylpyrazine (128 μL, 1.20 mmol), 
Tf2O (336 μL, 1.20 mmol), 2-(diphenylphosphino)-4-ethoxyquinoline (472 mg, 1.32 mmol), DBU 
(180 μL, 1.20 mmol) and CH2Cl2 (12 mL). After the purification procedure (concentrated CH2Cl2 
solution of crude product was added dropwise to an excess of hexanes instead of Et2O and placed 
at room temperature overnight), the title compound was isolated as a light brown amorphous 
powder (663 mg, 1.08 mmol, 90% yield). mp 145-148 °C; IR υmax/cm-1 (film): 3066, 2989, 1571, 
1551, 1507, 1438, 1410, 1385, 1354, 1316, 1260, 1222, 1192, 1145, 1108, 1029, 997, 771, 751, 
728, 707; 1H NMR (400 MHz, CDCl3) δ: 8.67 (1H, s), 8.35 (1H, d, J = 8.4 Hz), 8.04 (1H, d, J = 
8.5 Hz), 7.90-7.81 (7H, m), 7.77-7.70 (5H, m), 7.26 (1H, d, J = 6.1 Hz), 4.25 (2H, q, J = 7.0 Hz), 
2.73 (3H, s), 2.69 (3H, s), 1.52 (3H, t, J = 7.0 Hz); 13C NMR (100 MHz, CDCl3) δ: 163.27 (d, J = 
14.0 Hz), 159.36 (d, J = 3.4 Hz), 156.13 (d, J = 15.5 Hz), 149.50 (d, J = 25.9 Hz), 147.83 (d, J = 
23.3 Hz), 144.83 (d, J = 118.6 Hz), 136.09 (d, J = 83.7 Hz), 135.67 (d, J = 3.0 Hz), 134.74 (d, J = 
9.9 Hz), 131.76, 130.37 (d, J = 12.9 Hz), 129.38, 129.16, 122.50, 121.80 (d, J = 2.4 Hz), 120.73 
(q, J = 319.6 Hz), 116.49 (d, J = 87.7 Hz), 105.64 (d, J = 29.0 Hz), 65.66, 22.76, 22.42, 14.01; 19F 
NMR (365 MHz, CDCl3) δ: −78.26; 31P NMR (162 MHz, CDCl3) δ: 7.50; m/z HRMS (ESI + 
APCI) found [M-OTf]+ 464.1931, C29H27N3OP+ requires 464.1892. 
(2-((S)-(4-Chlorophenyl)((1-(ethoxycarbonyl)piperidin-4-yl)oxy)methyl)pyridin-4-yl)(3-
(((R)-1-(3-fluoro-4-(trifluoromethyl)benzyl)pyrrolidin-2-yl)methoxy)pyridin-4-
yl)diphenylphosphonium trifluoromethanesulfonate (3l)  
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Prepared according to general procedure B, using (R)-3-((1-(3-fluoro-4-
(trifluoromethyl)benzyl)pyrrolidin-2-yl)methoxy)pyridine (177 mg, 0.50 mmol), Tf2O (85 L, 
0.50 mmol), ethyl (S)-4-((4-chlorophenyl)(4-(diphenylphosphaneyl)pyridin-2-
yl)methoxy)piperidine-1-carboxylate (307 mg, 0.55 mmol), DBU (75 L, 0.89 mmol), and CH2Cl2 
(5 mL). After the purification procedure (concentrated CH2Cl2 solution of crude product was added 
dropwise to an excess of 50% Et2O in hexanes instead of Et2O), the title compound was provided 
as a brown amorphous solid (370 mg, 0.35 mmol, 70% yield). IR max/cm-1 (film): 3061, 2950, 
2873, 825, 560, 557, 535, 528; 1H NMR (500 MHz, CDCl3) : 8.90 (1H, t, J = 5.1 Hz), 8.74 (1H, 
d, J = 6.4 Hz), 8.57 (1H, t, J = 4.4 Hz), 7.92-7.45 (13H, m), 7.36-7.27 (4H, m), 7.14-6.96 (3H, m), 
5.72 (1H, s), 4.21-4.04 (3H, m), 3.89-3.78 (1H, m), 3.69-3.44 (4H, m), 3.32-3.05 (3H, m), 2.85-
2.65 (1H, m), 2.24-1.94 (2H, br), 1.83-1.63 (3H, m), 1.48-1.35 (4H, m), 1.34-1.16 (4H, m); 13C 
NMR (125 MHz, CDCl3)   164.41 (d, J = 9.9 Hz), 159.67 (dq, J = 256.0, 2.4 Hz), 155.43, 155.18, 
151.30 (d, J = 10.5 Hz), 144.50 (d, J = 11.4 Hz), 138.69, 136.28-136.10 (m), 134.25-134.02 (m, 
2C), 132.57, 131.94 (dd, J = 14.6, 4.6 Hz), 131.03 (dd, J = 13.4, 7.7 Hz), 128.89, 128.86 (d, J = 
15.3 Hz), 128.69 (d, J = 4.8 Hz), 128.59 (d, J = 85.2 Hz), 128.52 (d, J = 70.8 Hz), 128.32, 127.31-
127.08 (m), 125.56 (d, J = 8.6 Hz), 123.15 (d, J = 9.4 Hz), 122.51 (dq, J = 271.8, 1.9 Hz), 120.63 
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(q, J = 320.7 Hz), 114.79 (dd, J = 81.0, 28.2 Hz), 113.05 (d, J = 88.0 Hz), 72.56, 61.37, 57.85, 
54.02, 53.99, 40.82, 40.76, 31.46, 30.43, 29.67, 27.89, 22.63, 14.66; 19F NMR (365 MHz, CDCl3) 
 − (d, J = 13.2 Hz), −78.25, −113.33-115.80 (m); 31P NMR (162 MHz, CDCl3)  21.01; 





Prepared according to general procedure B using 2-(3-fluoro-5-(pyridin-3-yl)phenyl)-6-
methylpyridine (132 mg, 0.50 mmol), Tf2O (84 L, 0.50 mmol), ethyl (S)-4-((4-chlorophenyl)(4-
(diphenylphosphaneyl)pyridin-2-yl)methoxy)piperidine-1-carboxylate (308 mg, 0.55 mmol), 
DBU (75 L, 0.50 mmol) and CH2Cl2 (5 mL). After the purification procedure, the title compound 
was isolated as a white solid (305 mg, 0.31 mmol, 63% yield). mp 103-109 ºC; IR max/cm-1 (film): 
3063, 2928, 1687, 1438, 1261, 1224, 1149, 1030, 796; 1H NMR (400 MHz, CDCl3) : 9.00 (1H, 
app t, J = 4.7 Hz), 8.82 (1H, d, J = 7.0 Hz), 8.74 (1H, app t, J = 5.3 Hz), 7.81-7.72 (2H, m), 7.71-
7.60 (9H, m), 7.58-7.47 (3H, m), 7.44 (1H, d, J = 9.8 Hz), 7.28 (1H, s), 7.29-7.19 (6H, m), 7.07 
(1H, d, J = 7.6 Hz), 7.02 (1H, d, J = 7.7 Hz), 6.46 (1H, d, J = 8.3 Hz) 5.62 (1H, s), 4.09 (2H, q, J 
= 7.2 Hz), 3.62-3.44 (3H, m), 3.17-3.02 (2H, m), 2.44 (3H, s), 1.73-1.59 (2H, m), 1.48-1.33 (2H, 
m), 1.23 (3H, t, J = 7.2 Hz); 13C NMR (100 MHz, CDCl3)  163.84 (d, J = 9.9 Hz), 162.21 (d, J 
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= 249.4 Hz), 158.45, 155.36, 153.28 (d, J = 7.8 Hz), 152.76 (d, J = 2.2 Hz), 150.98-150.64 (2C, 
m), 141.63 (d, J = 7.8 Hz), 140.06 (d, J = 7.2 Hz), 138.47, 137.34, 136.68-136.51 (m), 136.01-
135.82 (m), 134.63-134.36 (m), 133.90, 130.80 (d, J =13.3 Hz), 128.74 (d, J = 83.4 Hz), 128.72, 
128.62 (d, J = 9.0 Hz), 128.43, 125.91 (d, J = 8.1 Hz), 124.96 (d, J = 83.9 Hz), 124.06, 123.52 (d, 
J = 9.0 Hz), 122.95, 120.73 (q, J = 321.2 Hz), 117.38, 116.4 (d, J = 23.3 Hz), 115.36 (d, J = 88.8 
Hz), 115.12 (d, J = 88.8 Hz), 114.44 (d, J = 22.2 Hz), 79.76, 72.91, 61.24, 40.78, 40.70, 31.32, 
30.27, 24.50, 14.63 ; 19F NMR (365 MHz, CDCl3)  -110.66 (t, J = 9.4 Hz), -78.16 P (162 MHz, 






Prepared according to general procedure B using 2-(3-fluoro-5-(pyridin-3-yl)phenyl)-6-
methylpyridine (132 mg, 0.50 mmol), Tf2O (84 L, 0.50 mmol), (2R, 6S)-4-((2-
(diphenylphosphaneyl)quinolin-4-yl)methyl)-2,6-dimethylmorpholine (242 mg, 0.55 mmol), 
DBU (75 L, 0.50 mmol) and CH2Cl2 (5 mL). After the purification procedure, the title compound 
was isolated as an off white solid (317 mg, 0.37 mmol, 74% yield). mp 106-111 ºC; IR max/cm-1 
(film): 3063, 2971, 2930, 2856, 1575, 1439, 1263, 1223, 1143, 1030, 728; 1H NMR (400 MHz, 
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CDCl3) : 9.03 (1H, app t, J = 4.7 Hz), 8.75 (1H, d, J = 6.8 Hz), 8.12 (1H, d, J = 8.4 Hz), 8.02-
7.89 (6H, m), 7.88-7.75 (6H, m), 7.59 (1H, t, J = 7.7 Hz), 7.55-7.36 (4H, m), 7.05 (1H, d, J = 7.7 
Hz), 6.93 (1H, s), 6.64 (1H, d, J = 7.8 Hz), 6.31 (1H, d, J = 8.2 Hz), 3.75 (2H, s), 3.43-3.21 (2H, 
m), 2.52-2.38 (5H, m), 1.83 (2H, t, J = 10.2 Hz) , 1.07 (6H, d, J = 6.3 Hz); 13C NMR (100 MHz, 
CDCl3)  162.04 (d, J = 249.4 Hz), 158.29, 152.53 (d, J = 7.4 Hz), 152.27 (d, J = 2.5 Hz), 150.80 
(d, J = 10.5 Hz), 148.33 (d, J = 23.0), 147.71 (br), 144.34 (d, J = 118.4 Hz), 141.49 (d, J = 8.0 
Hz), 139.73 (d, J = 7.3 Hz), 137.38-137.20 (m), 137.12, 136.08 (d, J = 3.1 Hz), 135.06 (d, J = 9.8 
Hz), 131.61, 130.76 (d, J = 12.9 Hz), 130.22 (2C, m), 128.95 (d, J = 9.7 Hz), 128.39 (d, J = 85.0 
Hz), 127.11 (d, J = 3.4 Hz), 123.26, 123.04 (d, J = 2.5 Hz), 122.91, 122.44 (d, J = 28.4 Hz) 120.85 
(q, J = 321.3 Hz), 116.58 (d, J = 86.4 Hz), 116.55, 116.00 (d, J = 23.4 Hz), 113.76 (d, J = 22.6 
Hz), 71.62, 59.29, 57.36, 24.58, 18.86; 19F NMR (365 MHz, CDCl3)  −78.07, −111.47 (t, J = 
10.2 Hz) P (162 MHz, CDCl3)  11.94; m/z HRMS (ESI + APCI) found [M-OTf]+ 703.2979, 
C45H41FN4OP+ requires  703.3002. 
 (4-(((2S, 6R)-2,6-Dimethylmorpholino)methyl)quinolin-2-yl)(3-(((R)-1-(3-fluoro-4-
(trifluoromethyl)benzyl)pyrrolidin-2-yl)methoxy)pyridin-4-yl)diphenylphosphonium 
trifluoromethanesulfonate (3o)  
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Prepared according to general procedure B, using (R)-3-((1-(3-fluoro-4-
(trifluoromethyl)benzyl)pyrrolidin-2-yl)methoxy)pyridine (177 mg, 0.50 mmol), Tf2O (85 L, 
0.50 mmol), (2R, 6S)-4-((2-(diphenylphosphaneyl)quinolin-4-yl)methyl)-2,6-dimethylmorpholine 
(242 mg, 0.55 mmol), DBU (75 L, 0.89 mmol), and CH2Cl2 (5 mL). After the purification 
procedure (concentrated CH2Cl2 solution of crude product was added dropwise to an excess of 
50% Et2O in hexanes instead of Et2O), the title compound was provided as a brown amorphous 
solid (310 mg, 0.33 mmol, 66% yield). IR max/cm-1 (film): 3061, 3012, 2974, 2935, 2875, 2818, 
1630, 1440, 909, 689, 665, 636, 603; 1H NMR (400 MHz, CDCl3) : 8.75 (1H, d, J = 6.6 Hz), 
8.65-8.60 (1H, m), 8.23 (1H, dd, J = 7.9, 0.7 Hz), 8.15 (1H, d, J = 8.4 Hz), 7.98-7.69 (13H, m), 
7.34 (1H, t, J = 7.7 Hz), 7.12 (1H, dd, J = 19.6, 9.8 Hz), 6.85-6.69 (2H, m), 4.10-3.91 (4H, m), 
3.53-3.40 (2H, m), 3.34 (1H, d, J = 14.2 Hz), 2.80 (1H, d, J = 13.8 Hz), 2.65-2.51 (3H, m), 2.07-
1.87 (3H, m), 1.87-1.74 (1H, m), 1.69-1.54 (1H, m), 1.47-1.25 (3H, m), 1.11 (6H, app t, J = 5.9 
Hz); 13C NMR (100 MHz, CDCl3)   159.46 (dq, J = 257.36 257.4, 2.3 Hz), 155.69, 148.76 (d, J 
= 23.1 Hz), 148.24, (d, J =  11.2 Hz), 144.40 (d, J = 10.2 Hz), 143.96 (d, J = 120.6 Hz), 136.87 
(m), 135.79 (m), 134.55-134.19 (m), 131.76, 130.66 (d, J = 13.2 Hz), 130.63, 129.17, 128.57, 
128.27 (d, J = 73.9 Hz), 127.00-126.76 (m, 2C), 124.03, 123.86, 123.63 (d, J = 3.6 Hz), 122.37, 
122.50 (dq, J = 273.6 Hz), 120.76 (q, J = 318.4 Hz), 116.78 (dd, J = 89.6, 3.1 Hz), 116.11 (dd, J 
= 91.4, 1.4 Hz), 114.57 (d, J = 86.2 Hz), 73.54, 71.64, 62.21, 59.64, 59.39 (d, J = 4.7 Hz), 58.10, 
54.07, 27.83, 22.56, 19.96 (d, J = 3.2 Hz); 19F NMR (365 MHz, CDCl3)  − (d, J = 13.74 
13.7 Hz), −78.14, −114.39- (−)115.04 (m); 31P NMR (162 MHz, CDCl3)  ; m/z HRMS (ESI 





yl)phosphonium trifluoromethanesulfonate (3p) 
 
Chlorphenamine (412.2 mg, 1.50 mmol) was dissolved in Et2O (3 mL) and cooled to 0 oC. 
Trifluoromethanesulfonic acid (134 μL, 1.50 mmol) was added dropwise, the ice bath was 
removed and the solution was stirred for 10 minutes at room temperature. The solution was 
concentrated in vacuo and the resulting acid salt was subjected to general procedure B (except that 
after 4-(diphenylphosphino)-2-phenylpyridine was added, the reaction mixture was stirred for 30 
min at −78 °C) using Tf2O (252 μL, 1.50 mmol), 4-(diphenylphosphino)-2-phenylpyridine (560 
mg, 1.65 mmol), DBU (450 μL, 3.00 mmol) and CH2Cl2 (15 mL). After the purification procedure, 
the title compound was isolated as a white amorphous powder (714 mg, 0.95 mmol, 63% yield). 
mp 130-133 °C; IR υmax/cm-1 (film): 3060, 1574, 1489, 1468, 1440, 1378, 1259, 1223, 1150, 1124, 
1109, 1028, 729, 636; 1H NMR (400 MHz, CDCl3) δ: 9.05 (1H, d, J = 5.2 Hz), 9.00 (1H, t, J = 5.2 
Hz), 7.95-7.87 (4H, m), 7.80-7.77 (5H, m), 7.70-7.65 (4H, m), 7.52-7.45 (5H, m), 7.39 (1H, dd, J 
= 13.0, 4.8 Hz), 7.27 (2H, d, J = 8.3 Hz), 7.17 (2H, d, J = 8.3 Hz), 4.46 (1H, t, J = 7.4 Hz), 3.07-
2.93 (2H, m), 2.83-2.76 (1H, m), 2.69 (6H, s), 2.44-2.35 (1H, m); 13C NMR (100 MHz, CDCl3) δ: 
164.22 (d, J = 9.6 Hz), 159.31 (d, J = 10.3 Hz), 151.77 (d, J = 10.9 Hz), 151.36 (d, J = 10.5 Hz), 
139.50, 136.68 (d, J = 1.6 Hz), 136.48 (d, J = 2.5 Hz), 134.56 (d, J = 10.6 Hz), 133.05, 131.13, 
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130.99, 130.53, 129.42, 129.06, 128.98, 127.58 (d, J = 83.9 Hz), 127.27 (d, J = 83.6 Hz), 127.13, 
125.31 (d, J = 8.3 Hz), 125.09 (d, J = 8.2 Hz), 123.20 (d, J = 8.8 Hz), 120.40 (q, J = 318.7 Hz), 
114.01 (d, J = 88.9 Hz), 56.27, 49.15, 43.36, 29.65; 19F NMR (365 MHz, CDCl3) δ: −78.30; 31P 
NMR (162 MHz, CDCl3) δ: 22.06; m/z HRMS (ESI + APCI) found [M-OTf]+ 612.2328, 





Prepared according to general procedure B using loratadine (383 mg, 1.00 mmol), Tf2O (168 
L, 1.00 mmol), 2-(4-Bromophenyl)-4-(diphenylphosphaneyl)pyridine (460 mg, 1.10 mmol), 
DBU (149 L, 1.00 mmol) and CH2Cl2 (10 mL). After the purification procedure, the title 
compound was isolated as an off white solid (770 mg, 0.81 mmol, 81% yield). mp 159-164 ºC; IR 
max/cm-1 (film): 3055, 2981, 1687, 1438, 1262, 1223, 1109, 1030, 730; 1H NMR (400 MHz, 
CDCl3) : 9.01 (1H, app t, J = 5.1 Hz), 8.73 (1H, app t, J = 4.7 Hz), 8.05-7.62 (13H, m), 7.60-7.40 
(3H, m) 7.16 (1H, dd, J = 7.7, 5.1 Hz), 7.06 (2H, s), 6.63 (1H, s), 4.06 (2H, q, J = 6.8 Hz), 3.80-
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3.57 (2H, m), 3.40-3.16 (3H, m) 2.74 (1H, d, J = 17.4 Hz), 2.63-2.09 (5H, m), 1.60-1.39 (1H, m), 
1.20 (3H, t, J = 7.0 Hz); 13C NMR (100 MHz, CDCl3)  163.34 (d, J = 8.5 Hz), 158.14 (d, J = 
10.5 Hz), 155.15, 151.83 (d, J = 10.9 Hz), 149.26 (d, J = 11.6 Hz), 139.30, 136.53, 136.46-136.12 
(2C, m), 135.45 (d, J = 1.4 Hz), 134.26 (d, J = 10.6 Hz), 133.83, 133.37, 132.17-131.89 (2C, m), 
131.41, 131.20 (d, J = 13.2 Hz), 129.64, 128.71, 128.64 (d, J = 83.6 Hz), 127.54 (d, J = 10.3 Hz), 
126.28, 125.35 (d, J = 8.3 Hz), 125.14 (d, J = 82.3 Hz), 122.94 (d, J = 8.9 Hz), 120.48 (q, J = 
321.4 Hz), 114.84 (d, J = 88.2 Hz), 114.39 (d, J = 88.1 Hz),  61.17, 44.48, 44.34, 30.52, 30.43-
30.10 (2C, m), 29.30, 14.45; 19F NMR (365 MHz, CDCl3)  −78.15 P (162 MHz, CDCl3) 
 20.87; m/z HRMS (ESI + APCI) found [M-OTf]+ 798.1693, C45H39BrClN3O2P+ requires  
798.1652.  
(2-(2-Chloro-5-(2-chloro-4-(methylsulfonyl)benzamido)phenyl)pyridin-4-yl)(4-
methylquinolin-2-yl)diphenylphosphonium trifluoromethanesulfonate (3r) 
 
Prepared according to general procedure B (except the stirring time after the addition of Tf2O 
was 2 hours instead of 30 minutes, the stirring time after the addition of the phosphine was 1.5 
hours instead of 30 minutes, and after the addition of DBU the reaction was allowed to slowly 
warm from –78 ºC to 0 ºC over 3 hours instead of warming from –78 ºC to room temperature over 
approximately 15-30 minutes) using vismodegib (506 mg, 1.20 mmol), Tf2O (200 L, 1.20 mmol), 
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2-(diphenylphosphaneyl)-4-methylquinoline (432 mg, 1.32 mmol), DBU (180 L, 1.20 mmol) and 
CH2Cl2 (30 mL). After the purification procedure (concentrated CH2Cl2 solution was added 
dropwise to an excess of Et2O at room temperature. The resulting suspension was immediately 
filtered on a frit and the solid was washed with room temperature Et2O. The solid was dissolved 
in approximately 5 mL CH2Cl2 and this process was repeated (4x) before the solid was dried in 
vacuo to provide the pure phosphonium salt), the title compound was isolated as a pale yellow 
solid (592 mg, 0.66 mmol, 55% yield). mp 119-125 ºC; IR max/cm-1 (film): 3255, 3062, 1681, 
1575, 1539, 1439, 1364, 1315, 1274, 1246, 1152, 1029, 726; 1H NMR (400 MHz, CDCl3) : 9.90 
(1H, s), 8.98 (1H, app t, J = 5.1 Hz), 8.24-8.09 (3H, m), 8.01-7.59 (18H, m), 7.56 (1H, d, J = 4.8 
Hz), 7.31-7.23 (1H, m), 2.93 (3H, s), 2.77 (3H, s) ; 13C NMR (100 MHz, CDCl3)  164.27, 157.96 
(d, J = 10.9 Hz), 150.87 (d, J = 10.6 Hz), 148.76 (d, J = 10.9 Hz), 148.46 (d, J = 23.0 Hz), 142.65 
(d, J = 118.3), 142.04, 140.23, 137.66, 136.79 (d, J = 1.6 Hz), 136.05 (d, J = 2.7 Hz), 134.58 (d, J 
= 10.3 Hz), 132.23, 131.83, 130.92-130.42 (2C, m), 130.29, 129.85, 128.77 (d, J = 3.1 Hz), 128.46 
(d, J = 83.7 Hz), 128.59-128.24 (3C, m), 126.35, 125.82 (d, J = 7.6 Hz), 125.59, 125.10 (d, J = 
27.0 Hz), 124.31, 123.07, 122.38, 120.24 (d, J = 320.9 Hz), 115.31 (d, J = 87.8 Hz), 44.14, 19.05 
(d, J = 1.4 Hz); 19F NMR (365 MHz, CDCl3)  −78.30 P (162 MHz, CDCl3)  13.30; m/z 
HRMS (ESI + APCI) found [M-OTf]+ 746.1185, C41H31Cl2N3O3PS+ requires  746.1201. 
(5,7-Dichloro-4-(4-fluorophenoxy)quinolin-2-yl)(4-ethoxyquinolin-2-
yl)diphenylphosphonium trifluoromethanesulfonate (3s) 
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Prepared according to general procedure B, using 5,7-dichloro-4-(4-fluorophenoxy)quinoline 
(308 mg, 1.00 mmol), Tf2O (168 L, 1.00 mmol), 2-(diphenylphosphaneyl)-4-ethoxyquinoline 
(392 mg, 1.10 mmol), DBU (150 L, 1.00 mmol), and EtOAc (10 mL). After the purification 
procedure (concentrated CH2Cl2 solution of crude product was added dropwise to an excess of 
50% Et2O in hexanes instead of Et2O), the title compound was provided as a brown amorphous 
solid (400 mg, 0.49 mmol, 49% yield). IR max/cm-1 (film): 3070, 2989, 2248, 855, 834, 646, 594, 
572; 1H NMR (400 MHz, CDCl3) : 8.31 (1H, d, J = 8.1 Hz), 8.02 (1H, d, J = 2.1 Hz), 7.87-7.64 
(14H, m), 7.16-7.04 (3H, m), 7.00 (1H, d, J = 6.4 Hz), 6.96-6.88 (2H, m), 4.14 (2H, q, J = 7.0 Hz), 
1.47 (3H, t, J = 7.0 Hz); 13C NMR (100 MHz, CDCl3)   164.34 (d, J = 12.9 Hz), 153.30 (d, J = 
14.0 Hz), 160.27 (d, J = 246.1 Hz), 151.68 (d, J = 25.5 Hz), 149.24 (d, J = 25.4 Hz), 148.30 (d, J 
= 117.4 Hz), 148.14 (d, J = 2.8 Hz), 144.56 (d, J = 116.9 Hz), 136.97, 135.54 (d, J = 2.9 Hz), 
134.68 (d, J = 10.0 Hz), 132.24, 131.67, 131.09 (d, J = 1.2 Hz), 130.27 (d, J = 13.0 Hz), 129.13, 
127.99, 122.77 (d, J = 8.6 Hz), 122.45, 121.56 (d, J = 2.3 Hz), 120.64 (q, J = 321.3 Hz), 118.17 
(d, J = 2.3 Hz), 117.21, 116.96, 116.51 (d, J = 87.5 Hz), 110.93 (d, J = 26.9 Hz), 105.92 (d, J = 
29.0 Hz), 65.51, 13.93; 19F NMR (365 MHz, CDCl3)  −78.19, −- (−)115.01 (m); 31P NMR 
(162 MHz, CDCl3)  8.41; m/z HRMS (ESI + APCI) found [M-OTf]+ 663.1166, 
C38H27Cl2FN2O2P
+ requires  663.1199. 
289 
(5-Chloro-6'-methyl-3-(4-(methylsulfonyl)phenyl)-[2,3'-bipyridin]-4'-yl)(4-methylquinolin-
2-yl)diphenylphosphonium trifluoromethanesulfonate (3t) 
 
Prepared according to general procedure B except with NaOAc added with phosphine, using 
5-chloro-6'-methyl-3-(4-(methylsulfonyl)phenyl)-2,3'-bipyridine (538 mg, 1.50 mmol), Tf2O (255 
L, 1.50 mmol), 2-(diphenylphosphaneyl)-4-methylquinoline (540 mg, 1.65 mmol), DBU (225 
L, 1.50 mmol), NaOAc (123 mg, 1.50 mmol) and CH2Cl2 (15 mL). After the purification 
procedure (concentrated CH2Cl2 solution was added dropwise to an excess of Et2O at room 
temperature. The resulting suspension was immediately filtered on a frit and the solid was washed 
with room temperature Et2O. The solid was dissolved in approximately 5 mL CH2Cl2 and this 
process was repeated (3x) before the solid was dried in vacuo to provide the pure phosphonium 
salt), the title compound was provided as a yellow crystalline solid (840 mg, 1.04 mmol, 69% 
yield). mp 165-170 oC; IR max/cm-1 (film): 3060, 1576, 1312, 770, 721, 547; 1H NMR (400 MHz, 
CDCl3) : 8.24 (1H, d, J = 7.0 Hz), 8.12-7.93 (8H, m), 7.87-7.67 (9H, m), 7.62-7.55 (3H, m), 7.30-
7.23 (2H, m), 3.17 (3H, s), 2.74 (3H, s), 2.60 (3H, s); 13C NMR (100 MHz, CDCl3)   160.87 (d, 
J = 11.1 Hz), 152.08 (d, J = 7.2 Hz), 148.24 (d, J = 11.1 Hz), 147.98 (d, J = 2.1 Hz), 147.32 (d, J 
= 24.0 Hz), 147.15 (d, J = 125.9 Hz), 146.15, 141.55, 141.15, 138.54, 135.30, 135.29, 135.13 (d, 
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J = 3.0 Hz), 134.85 (d, J = 9.4 Hz), 133.39 (d, J = 3.2 Hz), 131.95, 131.71, 130.71 (d, J = 10.1 
Hz), 130.23, 130.07 (d, J = 6.3 Hz), 129.74 (d, J = 1.3 Hz), 128.92 (d, J = 87.0 Hz), 128.36, 128.12 
(d, J = 3.1 Hz), 124.45, 123.53 (d, J = 26.9 Hz), 120.83 (q, J = 321.2 Hz), 119.37 (d, J = 88.5 Hz), 
44.14, 24.62, 18.84 (d, J = 1.6 Hz); 19F NMR (365 MHz, CDCl3)  −78.15; 31P NMR (162 MHz, 




yl)diphenylphosphonium trifluoromethanesulfonate (3u) 
 
Prepared according to general procedure B (except that the stirring time after addition of Tf2O 
was 2 hours instead of 30 minutes, the stirring time after addition of 2-(diphenylphosphino)-4-
methylquinoline was 1.5 hours instead of 30 minutes, and after the addition of DBU the reaction 
was allowed to slowly warm from –78 ºC to 0 ºC over 3 hours instead of warming from –78 ºC to 
room temperature over approximately 15-30 minutes) using (1S,2S,4S,5R)-2-((R)-
(benzyloxy)(quinolin-4-yl)methyl)-5-vinylquinuclidine (592 mg, 1.20 mmol), Tf2O (200 μL, 1.20 
mmol), 2-(diphenylphosphino)-4-methylquinoline (432 mg, 1.32 mmol), DBU (180 μL, 1.20 
mmol) and CH2Cl2 (30 mL). After the purification procedure (concentrated CH2Cl2 solution was 
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added dropwise to an excess of Et2O at room temperature. The resulting suspension was 
immediately filtered on a frit and the solid was washed with room temperature Et2O. The solid 
was dissolved in approximately 5 mL CH2Cl2 and this process was repeated (3x) before the solid 
was dried in vacuo to provide the pure phosphonium salt), the title compound was isolated as a 
yellow amorphous powder (710 mg, 0.73 mmol, 61% yield). mp 155-158 °C; IR υmax/cm-1 (film): 
3316, 3056, 2795, 1662, 1568, 1527, 1505, 1474, 1450, 1406, 1254, 1222, 1149, 1104, 1028, 857, 
815, 752, 726, 689; 1H NMR (400 MHz, CDCl3) δ: 9.52 (1H, d, J = 6.4 Hz), 9.04 (1H, dd, J = 4.8, 
4.4 Hz), 8.53 (1H, s), 8.23 (1H, d, J = 5.1 Hz), 8.01‒7.99 (1H, m), 7.87-7.59 (15H, m), 7.52 (1H, 
d, J = 4.8 Hz), 7.45 (1H, dd, J = 4.3, 2.0 Hz), 7.39 (2H, d, J = 8.2 Hz), 7.28 (1H, dd, J = 15.7, 5.1 
Hz), 7.22 (1H, d, J = 5.2 Hz), 7.06 (1H, d, J = 1.9 Hz), 6.92 (1H, d, J = 8.5 Hz), 5.51 (1H, s), 3.54 
(2H, s), 2.77-2.51 (14H, m), 1.50 (3H, s); 13C NMR (100 MHz, CD3CN) δ: 166.21, 161.17, 159.55 
(d, J = 1.1 Hz), 159.01, 154.33 (d, J = 1.1 Hz), 152.10 (d, J = 6.3 Hz), 149.77 (d, J = 11.3 Hz), 
149.43, 148.63, 148.38, 148.10, 142.66, 137.94, 136.82, 136.06 (d, J = 2.1 Hz), 135.71 (d, J = 9.3 
Hz), 135.33 (d, J = 85.6 Hz), 132.86 (d, J = 9.8 Hz), 132.23, 131.02 (d, J = 12.7 Hz), 130.44 (d, J 
= 4.4 Hz), 129.85, 129.45 (d, J = 3.0 Hz), 128.45, 126.72, 126.06 (d, J = 84.5 Hz), 125.56 (d, J = 
1.0 Hz), 123.30, 123.04, 122.31 (d, J = 90.6 Hz), 122.01 (q, J = 319.1 Hz), 117.99, 115.59, 110.10, 
62.06, 55.02, 51.51, 44.62, 18.95 (d, J = 1.6 Hz), 17.29; 19F NMR (365 MHz, CDCl3) δ: −78.13; 
31P NMR (162 MHz, CDCl3) δ: 18.51; m/z HRMS (ESI + APCI) found [M-OTf]+ 819.3695, 





A 2.3.4 General Procedure C (Ligand-coupling Reactions to Make Heterobiaryls) 
 
An oven dried 8 mL vial with a septa cap was charged with the phosphonium salt (1.0 equiv) 
and EtOH or TFE (0.4 M). The vial was subjected to three rapid cycles of vacuum / nitrogen 
backfill and then HCl or TfOH (2.0 equiv) was added via a syringe. The septa cap was quickly 
replaced with an unpierced one and the reaction was heated to 80 ºC for the stated time. The 
reaction was quenched with a saturated aqueous solution of Na2CO3 and the aqueous layer was 
extracted with CH2Cl2 (3x). The combined organic extracts were washed with a saturated aqueous 
solution of brine, dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by 
flash column chromatography under the stated conditions to provide the heterobiaryl.  
2-Phenyl-4,4'-bipyridine (4a) 
 
Prepared according to general procedure C using diphenyl(2-phenylpyridin-4-yl)(pyridin-4-
yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol), 4.0 M HCl in dioxanes (250 L, 
1.00 mmol), and EtOH (1.25 mL). The was reaction was heated to 80 ºC for 14 hours. Flash column 
chromatography (silica gel, gradient elution: 40% EtOAc in hexanes to 50% EtOAc in hexanes) 
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afforded the title compound as an off white solid (102 mg, 0.44 mmol, 88% yield). mp 64-65 ºC; 
IR max/cm-1 (film): 3029, 1590, 1532, 1472, 1444, 1389, 1225, 808, 770, 731, 687; 1H NMR (400 
MHz, CDCl3) : 8.87-8.59 (3H, m), 8.02 (2H, d, J = 7.2 Hz), 7.88 (1H, s), 7.62-7.32 (6H, m) ; 13C 
NMR (100 MHz, CDCl3)  158.34, 150.51, 150.34, 146.25, 145.67, 138.78, 129.21, 128.71, 




Prepared according to general procedure C using (2-(4-bromophenyl)pyridin-4-yl)(3-
chloropyridin-4-yl)diphenylphosphonium trifluoromethanesulfonate (340 mg, 0.50 mmol), 4.0 M 
HCl in dioxanes (250 L, 1.00 mmol), and EtOH (1.25 mL). The was reaction was heated to 80 
ºC for 17 hrs. Flash column chromatography (silica gel: 25% EtOAc in hexanes) afforded the title 
compound as a white solid (111 mg, 0.32 mmol, 64% yield). mp 153-154 ºC; IR max/cm-1 (film): 
3053, 1603, 1579, 1552, 1461, 1412, 1376, 1111, 1006, 831, 741; 1H NMR (400 MHz, CDCl3) : 
8.79 (1H, d, J = 5.0 Hz), 8.74 (1H, s), 8.60 (1H, d, J = 4.9 Hz), 7.91 (2H, d, J = 8.5 Hz), 7.77 (1H, 
s), 7.61 (2H, d, J = 8.5 Hz), 7.37-7.28 (2H, m); 13C NMR (100 MHz, CDCl3)  156.61, 150.35, 
149.96, 148.15, 145.03, 144.91, 137.56, 131.92, 129.72, 128.46, 124.53, 123.87, 122.03, 120.01; 
m/z HRMS (DART) found [M+H]+ 344.9812, C16H11BrN2+ requires  344.9789. 
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Ethyl 2'-(4-bromophenyl)-2-butyl-[4,4'-bipyridine]-3-carboxylate (4c) 
 
Prepared according to general procedure C using (2-(4-bromophenyl)pyridin-4-yl)(2-butyl-
3-(ethoxycarbonyl)pyridin-4-yl)diphenylphosphonium trifluoromethanesulfonate (155 mg, 0.20 
mmol), trifluoromethanesulfonic acid (36 μL, 0.40 mmol) and EtOH (0.5 mL) at 80 °C for 14 
hours. Flash column chromatography (silica gel: 16% EtOAc in hexanes to 33% EtOAc in 
hexanes) afforded the title compound as a colorless oil (67 mg, 0.15 mmol, 76% yield). IR υmax/cm-
1 (film): 3051, 2956, 2929, 2870, 1722, 1601, 1589, 1575, 1537, 1491, 1475, 1455, 1405, 1379, 
1258, 1138, 1099, 1071, 1045, 1008, 825; 1H NMR (400 MHz, CDCl3) δ: 8.73 (1H, d, J = 5.0 Hz), 
8.68 (1H, d, J = 5.0 Hz), 7.90 (2H, d, J = 8.3 Hz), 7.71 (1H, s), 7.60 (2H, d, J = 8.3 Hz), 7.26 (1H, 
d, J = 5.8 Hz), 7.18 (1H, d, J = 5.0 Hz), 4.11 (2H, q, J = 7.2 Hz), 2.89 (2H, t, J = 7.8 Hz), 1.76 
(2H, qn, J = 7.6 Hz), 1.42 (2H, sext, J = 7.4 Hz), 1.00 (3H, t, J = 7.2 Hz), 0.94 (3H, t, J = 7.4 Hz); 
13C NMR (100 MHz, CDCl3) δ: 167.97, 160.08, 156.52, 150.14, 149.95, 147.22, 145.26, 137.49, 
131.99, 128.40, 127.85, 123.92, 121.29, 120.68, 119.21, 61.69, 36.02, 31.93, 22.66, 13.86, 13.60; 




Prepared according to general procedure C using (5-chloro-2-methylpyridin-4-yl)(3-
methoxypyridin-4-yl)diphenylphosphonium trifluoromethanesulfonate (285 mg, 0.50 mmol), 
trifluoromethanesulfonic acid (89 μL, 1.00 mmol) and EtOH (1.25 mL) at 80 °C for 14 hours. 
Flash column chromatography (silica gel: 50% EtOAc in hexanes) afforded the title compound as 
a colorless crystalline solid (77 mg, 0.33 mmol, 65% yield). mp 105-108 °C; IR υmax/cm-1 (film): 
3029, 2968, 2938, 2842, 1582, 1556, 1506, 1492, 1469, 1441, 1379, 1360, 1312, 1306, 1291, 1269, 
1256, 1239, 1213, 1195, 1101, 1017, 846, 833; 1H NMR (400 MHz, CDCl3) δ: 8.52 (1H, s), 8.39 
(1H, s), 8.33 (1H, d, J = 4.7 Hz), 7.09 (1H, d, J = 4.7 Hz), 7.05 (1H, s), 3.88 (3H, s), 2.54 (3H, s); 
13C NMR (100 MHz, CDCl3) δ: 156.62, 152.18, 148.70, 142.83, 142.52, 134.21, 133.11, 128.01, 




Prepared according to general procedure C using (3-chloro-pyridin-4-yl)(3-fluoropyridin-4-
yl)diphenylphosphonium trifluoromethanesulfonate (136 mg, 0.25 mmol), 4.0M HCl in dioxane  
(125 μL, 0.50 mmol) and EtOH (0.625 mL) at 80 °C for 23 hours. Flash column chromatography 
(silica gel: 40% EtOAc in hexanes to 50% EtOAc in hexanes) followed by flash column 
chromatography (neutral alumina: 20% EtOAc in hexanes to 40% EtOAc in hexanes) afforded the 
title compound as a white crystalline solid (34 mg, 0.16 mmol, 65% yield). mp 92-94 °C; IR 
υmax/cm-1 (film): 3021, 1578, 1470, 1413, 1398, 1268, 1217, 1202, 1176, 1110, 1027, 830, 752; 1H 
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NMR (400 MHz, CDCl3) δ: 8.69 (1H, s), 8.60-8.44 (3H, m), 7.29-7.17 (2H, m); 13C NMR (100 
MHz, CDCl3) δ: 155.86 (d, J = 259.5 Hz), 150.15, 147.84, 145.81 (d, J = 5.4 HZ), 139.81, 139.05 
(d, J = 24.1 Hz), 131.57 (d, J = 13.0 Hz), 130.70, 124.97, 124.63; 19F NMR (365 MHz, CDCl3) δ: 




Prepared according to general procedure C using (2-((4-bromo-3-
fluorophenoxy)methyl)pyridin-4-yl)(2-butyl-5-(trifluoromethyl)pyridin-4-
yl)diphenylphosphonium trifluoromethanesulfonate (204 mg, isolated as a mixture see 3f), 
Trifluoromethanesulfonic acid (45 μL, 0.50 mmol) and EtOH (0.625 mL) at 80 °C for 12 hours. 
Flash column chromatography (silica gel: 2% EtOAc in CH2Cl2 to 5% EtOAc in CH2Cl2) afforded 
the title compound as a white amorphous powder (63 mg, 0.13 mmol, 29% yield over two steps). 
mp 79-81 °C; IR υmax/cm-1 (film): 3027, 2958, 2924, 2875, 2860, 1597, 1589, 1564, 1539, 1492, 
1467, 1452, 1426, 1415, 1380, 1323, 1292, 1268, 1249, 1189, 1177, 1153, 1130, 1101, 1089, 1057, 
1032, 974, 942, 902, 855, 843, 820; 1H NMR (400 MHz, CDCl3) δ: 8.88 (1H, s), 8.68 (1H, d, J = 
5.0 Hz), 7.44-7.38 (2H, m), 7.22 (1H, d, J = 4.8 Hz), 7.08 (1H, s), 6.78 (1H, dd, J = 10.2, 2.8 Hz), 
6.69 (1H, dd, J = 8.9, 2.8 Hz), 5.22 (2H, s), 2.88 (2H, t, J = 7.7 Hz), 1.74 (2H, qn, J = 7.3 Hz), 
1.40 (2H, sext, J = 7.5 Hz), 0.94 (3H, t, J = 7.3 Hz); 13C NMR (100 MHz, CDCl3) δ: 166.90, 
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159.44 (d, J = 245.7 Hz), 158.68 (d, J = 9.7 Hz), 156.50, 149.21, 147.06 (q, J = 5.5 Hz), 146.29, 
146.23 (q, J = 1.8 Hz), 133.47 (d, J = 1.7 Hz), 123.90, 123.50 (q, J = 272.3 Hz), 122.27 (d, J = 1.1 
Hz), 121.38 (q, J = 30.6 Hz), 120.59, 111.98 (d, J = 3.2 Hz), 103.98 (d, J = 25.6 Hz), 100.11 (d, J 
= 21.2 Hz), 70.86, 37.99, 31.58, 22.44, 13.83; 19F NMR (365 MHz, CDCl3) δ: −56.55, −104.87 (t, 
J = 8.4 Hz); m/z HRMS (DART) found [M+H]+ 483.0690, C22H20BrF4N2O+ requires 483.0695. 
2-(3-Fluoropyridin-4-yl)-4-methylquinoline (4g) 
 
Prepared according to general procedure C, using (3-fluoropyridin-4-yl)(4-methylquinolin-2-
yl)diphenylphosphonium trifluoromethanesulfonate (286 mg, 0.50 mmol), 4.0M HCl in dioxane 
(250 L, 1.00 mmol), and EtOH (1.25 mL) at 80 oC for 12 hours. The crude material was purified 
by flash chromatography (silica gel gradient elution: 25% EtOAc in hexanes to 50% EtOAc in 
hexanes) to provide the title compound as a white crystalline solid (68 mg, 0.31 mmol, 57% yield). 
mp 94-95 oC; IR max/cm-1 (film): 3038, 2968, 1464, 1350, 1277, 1235, 746; 1H NMR (400 MHz, 
CDCl3) : 8.62 (1H, d, J = 2.8 Hz), 8.59 (1H, dd, J = 4.9, 0.9 Hz), 8.19 (1H, dd, J = 8.4, 0.5 Hz), 
8.10 (1H, dd, J = 7.3, 5.0 Hz), 8.05 (1H, dd, J = 8.4, 0.9 Hz), 7.80-7.75 (2H, m), 7.66-7.62 (1H, 
m), 2.80 (3H, d, J = 0.8 Hz); 13C NMR (100 MHz, CDCl3)   (d, J = 258.8 Hz); 158.84 (d, 
J = 2.0 Hz), 148.09, 146.25 (d, J = 5.1 Hz), 145.16, 139.33 (d, J = 26.1 Hz), 134.60 (d, J = 9.5 
Hz), 130.50, 129.74, 127.79, 127.20, 124.58, 123.74, 122.69 (d, J = 8.2 Hz), 19.00; 19F NMR (365 
MHz, CDCl3)  −131.61 (d, J = 7.5 Hz); m/z HRMS (DART) found [M+H]+ 239.0973, 
C15H12FN2+ requires  239.0979. 
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Ethyl 2-(4-ethoxyquinolin-2-yl)isonicotinate (4h) 
 
Prepared according to general procedure C, using (4-(ethoxycarbonyl)pyridin-2-yl)(4-
ethoxyquinolin-2-yl)diphenylphosphonium trifluoromethanesulfonate (164 mg, 0.25 mmol), 
trifluoromethanesulfonic acid (42 L, 0.50 mmol), and EtOH (0.63 mL) at 80 oC for 12 hours. The 
crude material was purified by flash chromatography (silica gel: 10% EtOAc in hexanes to 25% 
EtOAc in hexanes) to provide the title compound as a white crystalline solid (38 mg, 0.12 mmol, 
47% yield). mp 102-104 oC; IR max/cm-1 (film): 3038, 2968, 1464, 1350, 1277, 1235, 746; 1H 
NMR (400 MHz, CDCl3) : 9.18 (1H, s), 8.84 (1H,d, J = 5.0 Hz), 8.26 (1H,dd, J = 3.16 3.2, 1.2 
Hz), 8.15 (1H, d, J = 8.4 Hz), 7.97 (1H, s), 7.97 (1H, dd, J = 5.0, 1.6 Hz), 7.71-7.70 (1H, m), 7.56-
7.49 (1H, m), 4.55-4.38 (4H, m), 1.62 (3H, t, J = 7.0 Hz), 1.47 (3H, t, J = 7.1 Hz); 13C NMR (100 
MHz, CDCl3) : 
            
       m/z HRMS (DART) found [M+H]+ 323.1386, 









Prepared according to general procedure C, using (7-chloro-4-(3-fluorophenoxy)quinolin-2-
yl)(4-methylquinolin-2-yl)diphenylphosphonium trifluoromethanesulfonate (187 mg, 0.25 mmol), 
trifluoromethanesulfonic acid (42 L, 0.50 mmol), and (2,2,2)-Trifluoroethanol (0.63 mL) at 80oC 
for 12 hours. The crude material was purified by flash chromatography (silica gel, 10% EtOAc in 
hexanes) to provide the title compound as a white crystalline solid (70 mg, 0.17 mmol, 67% yield). 
mp 208-210 oC; IR max/cm-1 (film): 3068, 1615, 1094, 947, 831, 755, 526; 1H NMR (400 MHz, 
CDCl3) : 8.60 (1H, d, J = 0.8 Hz), 8.28 (1H, d, J = 8.9 Hz), 8.25 (1H, d, J = 1.8 Hz), 8.13 (1H, 
s), 8.07 (1H, dd, J = 8.4, 0.7 Hz), 8.03 (1H, dd, J = 8.3, 0.9 Hz), 7.69 (1H, m), 7.60-7.53 (2H, m), 
7.47 (1H, td, J = 12.2, 7.5 Hz), 7.10-6.99 (3H, m), 2.83 (3H, d, J = 0.9 Hz); 13C NMR (100 MHz, 
CDCl3)   (d, J = 248.4 Hz), 161.43, 158.99, 155.76 (d, J = 10.6 Hz), 154.93, 150.04, 
147.57, 145.07, 136.33, 131.10, (d, J = 9.6 Hz), 130.50, 129.22, 128.57, 128.54, 127.50, 126.90, 
123.75, 123.26, 120.13, 119.70, 116.32 (d, J = 3.4 Hz), 112.44 (d, J = 21.1 Hz), 108.65 (d, J = 
24.2 Hz), 108.65 (d, J = 24.2 Hz), 103.43, 18.95; 19F NMR (365 MHz, CDCl3)  −109.72-







Prepared according to general procedure C using (4-Methylquinolin-2-yl)diphenyl(2-
(propylthio)pyrimidin-4-yl)phosphonium trifluoromethanesulfonate (149 mg, 0.25 mmol), 
trifluoromethanesulfonic acid (44 L, 0.50 mmol), and EtOH (0.63 mL). The was reaction was 
heated to 80 ºC for 5.5 hours. Flash column chromatography (silica gel: 5% EtOAc in hexanes) 
followed by a second flash column (silica gel, gradient elution: 3% EtOAc in hexanes to 5% EtOAc 
in hexanes) afforded the title compound as a white solid (27 mg, 0.091 mmol, 37% yield). mp 57-
58 ºC; IR max/cm-1 (film): 2925, 1557, 1539, 1505, 1417, 1352, 1317, 1194, 1160, 782; 1H NMR 
(400 MHz, CDCl3) : 8.67 (1H, d, J = 4.7 Hz), 8.40 (1H, s), 8.23 (1H, d, J = 4.7 Hz), 8.17 (1H, d, 
J = 8.1 Hz), 8.03 (1H, d, J = 8.1 Hz), 7.75 (1H, t, J = 7.0 Hz), 7.61 (1H, t, J = 7.0 Hz), 3.26 (2H, 
t, J = 7.1 Hz), 2.80 (3H, s), 1.88 (2H, sext, J = 7.1 Hz), 1.13 (3H, t, J = 7.1 Hz); 13C NMR (100 
MHz, CDCl3)  172.21, 163.22, 158.12, 153.22, 147.70, 145.37, 130.61, 129.53, 128.96, 127.37, 
123.80, 119.29, 112.97, 33.04, 22.72, 19.02, 13.62; m/z LRMS (ESI + APCI) found [M+ H]+ 




Prepared according to general procedure C using (5,6-dimethylpyrazin-2-yl)(4-
ethoxyquinolin-2-yl)diphenylphosphonium trifluoromethanesulfonate (154 mg, 0.25 mmol), 
trifluoromethanesulfonic acid (67 μL, 0.75 mmol) and EtOH (625 L) at 100 °C for 14 hours. 
Flash column chromatography (silica gel: 33% EtOAc in hexanes) afforded the title compound as 
a gray amorphous powder (16 mg, 0.06 mmol, 23% yield). mp 189-191 °C; IR υmax/cm-1 (film): 
3080, 2999, 2977, 2919, 1615, 1586, 1500, 1472, 1460, 1445, 1420, 1402, 1376, 1359, 1347, 1273, 
1249, 1232, 1185, 1156, 1114, 1105, 1089, 1027, 993, 953, 919, 861, 837, 818, 784, 777, 767; 1H 
NMR (400 MHz, CDCl3) δ: 9.52 (1H, s), 8.24 (1H, d, J = 8.2 Hz), 8.10 (1H, d, J = 8.4 Hz), 7.86 
(1H, s), 7.71 (1H, dd, J = 7.2, 7.1 Hz), 7.50 (1H, dd, J = 7.8, 7.3 Hz), 4.42 (2H, q, J = 7.0 Hz), 
2.64 (3H, s), 2.62 (3H, s), 1.61 (3H, t, J = 7.0 Hz); 13C NMR (100 MHz, CDCl3) δ: 162.28, 156.03, 
152.39, 150.85, 149.00, 148.17, 140.21, 129.87, 129.28, 125.77, 121.89, 121.37, 97.86, 64.26, 








trifluoromethanesulfonate (106 mg, 0.10 mmol), trifluoromethanesulfonic acid (25 L, 0.30 
mmol), and EtOH (0.25 mL) at 80 oC for 72 hours. The crude material was purified by flash 
chromatography (silica gel: 2% MeOH in CH2Cl2) followed by a second flash chromatography 
column (silica gel: 2% MeOH in CH2Cl2) to provide the title compound as a faint brown oil (43 
mg, 0.06 mmol, 60% yield). IR max/cm-1 (film): 3055, 2928, 2872, 1689, 1629, 1604, 1586, 1564, 
1502, 964, 766, 645, 619, 534; 1H NMR (400 MHz, CDCl3) : 8.40 (1H, d, J = 5.5 Hz), 8.35-8.25 
(2H, m), 7.62 (1H, s), 7.40-7.34 (1H, s), 7.40-7.34 (3H, m), 7.24 (1H, t, J = 1.7 Hz), 7.22 (2H, m), 
6.93-6.85 (2H, m), 5.60 (1H, s), 4.05 (2H, q, J = 7.1 Hz), 3.95 (2H, d, J = 5.4 Hz), 3.79-3.62 (3H, 
m), 3.57 (1H, m), 3.17-3.04 (3H, m), 2.86-2.72 (2H, m), 2.10 (1H, q, J = 8.4 Hz), 1.96-1.47 (5H, 
m), 1.25-1.12 (6H, m); 13C NMR (100 MHz, CDCl3)    (dq, J = 255.5, 2.3 Hz), 
155.47, 151.76 (m), 148.82, 147.49 (d, J = 7.2 Hz), 144.64, 143.16, 140.14, 135.40, 134.77, 
133.47, 128.65, 128.08, 126.75 (2C, m), 122.64 (dq, J = 270.5, 1.1 Hz), 123.86 (m), 123.22 (d, J 
= 3.4 Hz), 122.58, 116.09 (d, J = 20.7 Hz), 72.80, 62.61, 61.28, 58.75, 54.74, 41.07, 40.99, 31.16, 
31.01, 29.67, 28.59, 23.26, 14.66; 19F NMR  −61.13 (d, J = 12.8 Hz), −114.89-(−)115.21 (m); 





Prepared according to general procedure C using (S)-(2-((4-chlorophenyl)((1-
(ethoxycarbonyl)piperidin-4-yl)oxy)methyl)pyridin-4-yl)(3-(3-fluoro-5-(6-methylpyridin-2-
yl)phenyl)pyridin-4-yl)diphenylphosphonium trifluoromethanesulfonate (97 mg, 0.10 mmol), 
trifluoromethanesulfonic acid (26.5 L, 0.30 mmol), and EtOH (0.25 mL). The was reaction was 
heated to 80 ºC for 26 hours. Flash column chromatography (the crude reaction mixture was 
dissolved in 5 mL of CH2Cl2 and then 1 mL of trifluoroacetic acid was added, the mixture was 
loaded onto a silica column and then gradient elution: CH2Cl2 to 3% MeOH in CH2Cl2) followed 
by a second flash column (the crude reaction mixture was dissolved in 5 mL of CH2Cl2 and then 1 
mL of trifluoroacetic acid was added, the mixture was loaded onto a silica column and then 
gradient elution: CH2Cl2 to 2% MeOH in CH2Cl2) followed by preparatory thin layer 
chromatography (silica gel: 3% MeOH in CH2Cl2 afforded the title compound as a colorless oil 
(41 mg, 0.07 mmol, 65% yield). IR max/cm-1 (film): 3060, 2953, 2925, 1690, 1585, 1576, 1432, 
1384, 1228, 1087, 751; 1H NMR (400 MHz, CDCl3) : 8.74 (2H, br s), 8.54 (1H, d, J = 5.0 Hz), 
7.69 (1H, d, J = 9.9 Hz), 7.60-7.50 (2H, m), 7.35 (1H, d, J = 4.2 Hz), 7.24-7.15 (3H, m), 7.13-7.04 
(5H, m), 6.84 (1H, d, J = 8.7 Hz), 5.47 (1H, s), 4.09 (2H, q, J = 7.2 Hz), 3.63-3.49 (2H, m), 3.49-
3.38 (1H, m), 3.16-3.03 (2H, m), 2.58 (3H, s), 1.72-1.55 (2H, m), 1.54-1.36 (2H, m), 1.23 (3H, t, 
J = 7.2 Hz); 13C NMR (100 MHz, CDCl3)  162.95 (d, J = 246.7 Hz), 161.95, 158.64, 155.38, 
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154.23 (d, J = 2.9 Hz), 151.02, 149.66-149.29 (2C, m), 147.16, 145.05, 142.20 (d, J = 7.8 Hz), 
139.54, 138.93 (d, J = 8.3 Hz), 136.94, 134.56, 133.30, 128.52, 127.81, 124.11-123.81 (2C, m), 
122.47, 122.44, 120.99, 117.20, 116.54 (d, J = 22.6 Hz), 113.28 (d, J = 22.7 Hz), 80.38, 72.19, 
61.19, 40.78, 40.72, 30.88, 30.68, 24.62, 14.66; 19F NMR (365 MHz, CDCl3)  -112.23; m/z 




Prepared according to general procedure C (except an additional 18 L, 0.20 mmol of 
trifluoromethanesulfonic acid was added after 40.5 hours) using (4-(((2R, 6S)-2,6-
dimethylmorpholino)methyl)quinolin-2-yl)(3-(3-fluoro-5-(6-methylpyridin-2-yl)phenyl)pyridin-
4-yl)diphenylphosphonium trifluoromethanesulfonate (85 mg, 0.10 mmol), 
trifluoromethanesulfonic acid (35 L, 0.40 mmol), and EtOH (0.25 mL). The was reaction was 
heated to 80 ºC for 58.5 hours. Flash column chromatography (silica gel: 60% EtOAc in hexanes) 
followed by a second flash column (silica gel, gradient elution: 1% MeOH in CH2Cl2 to 2.5% 
MeOH in CH2Cl2) afforded the title compound as a colorless oil (23.7 mg, 0.046 mmol, 46%). IR 
max/cm-1 (film): 3063, 2972, 2928, 1586, 1455, 1430, 1344, 1083, 757; 1H NMR (400 MHz, 
CDCl3) : 8.81 (2H, br s), 8.27-8.15 (2H, m), 7.85-7.73 (3H, m), 7.68 (1H, d, J = 9.9 Hz), 7.58 
(1H, t, J = 7.6 Hz), 7.51 (1H, t, J = 7.7 Hz), 7.23 (1H, d, J = 7.7 Hz), 7.15-7.03 (2H, m), 6.92 (1H, 
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d, J = 9.0 Hz), 3.63 (2H, s), 3.54-3.38 (2H, m), 2.50 (3H, s), 2.40 (2H, d, J = 11.5 Hz), 1.63 (2H, 
t, J = 10.5 Hz), 1.00 (6H, d, J = 6.3 Hz) 13C NMR (100 MHz, CDCl3)  162.86 (d, J = 246.4), 
158.62, 156.36, 154.36 (d, J = 2.7 Hz), 150.76, 149.56, 148.57, 146.77, 143.77, 142.18 (d, J = 8.6 
Hz), 139.74 (d, J = 8.2 Hz), 136.94, 134.58, 130.19, 129.63, 126.87, 126.64, 124.68, 124.24, 
123.95 (d, J = 2.7 Hz), 122.63, 122.40, 117.22, 116.79 (d, J = 22.5 Hz), 113.16 (d, J = 22.7 Hz), 
71.51, 59.81, 59.38, 24.51, 18.83; 19F NMR (365 MHz, CDCl3)  -112.28 (t, J = 9.3 Hz) m/z 




Prepared according to general procedure C, using (4-(((2S, 6R)-2,6-
dimethylmorpholino)methyl)quinolin-2-yl)(3-(((R)-1-(3-fluoro-4-
(trifluoromethyl)benzyl)pyrrolidin-2-yl)methoxy)pyridin-4-yl)diphenylphosphonium 
trifluoromethanesulfonate (94 mg, 0.10 mmol), 4.0M HCl in dioxane (100 L, 0.40 mmol), and 
EtOH (0.25 mL) at 80 oC for 72 hours. The crude material was purified by flash chromatography 
(silica gel: 2% MeOH in CH2Cl2) to provide the title compound as a brown amorphous solid (30 
mg, 0.05 mmol, 49% yield). IR max/cm-1 (film): 3063, 2971, 2930, 2871, 2813, 1629, 1587, 1545, 
693, 653, 602, 550, 531, 526; 1H NMR (400 MHz, CDCl3) : 8.50-8.39 (2H, m), 8.23 (1H, d, J = 
8.3 Hz), 8.11 (1H, d, J = 8.4 Hz), 7.85 (1H, s), 7.75 (1H, d, J = 4.8 Hz), 7.71 (1H, m), 7.56 (1H, 
306 
m), 7.29 (1H, t, J = 7.7 Hz), 6.97-6.87 (2H, m), 4.21-4.06 (2H, m), 4.01 (1H, d, J = 14.16 14.2 
Hz), 3.80 (2H, d, J = 1.8 Hz), 3.73-3.61 (2H, m), 3.30 (1H, d, J = 14.2 Hz), 3.08-2.97 (1H, m), 
2.91-2.80 (1H, m), 2.79 (2H, d, J = 11.5 Hz), 2.15 (1H, q, J = 6.2 Hz), 2.06-1.94 (1H, m), 1.86 
(2H, q, J = 10.6 Hz), 1.78-1.65 (3H, m), 1.14 (6H, d, J = 6.2 Hz); 13C NMR (100 MHz, CDCl3)  
159.57 (dq, J = 253.8, 2.1 Hz), 154.01, 152.42, 148.39, 147.22 (d, J = 5.5 Hz), 143.38, 143.23, 
136.59, 135.72, 130.16, 129.47, 126.94-126.32 (m, 4C), 124.75, 124.17, 123.30 (d, J = 3.3 Hz), 
122.97, 122.62 (dq, J = 273.1, 1.0 Hz), 116.89 (d, J = 20.6 Hz), 73.11, 71.67 (d, J = 2.2 Hz), 62.43, 
60.13, 59.69 (d, J = 8.4 Hz), 58.86, 54.66, 28.60, 23.29, 19.88 (d, J = 1.1 Hz) 19F NMR  −61.10 
(d, J = 12.9 Hz), −114.67- (−)115.23 (m); m/z HRMS (DART) found [M+H]+ 609.2839, 
C34H37F4N4O2+ requires  609.2847. 
3-(4-Chlorophenyl)-N,N-dimethyl-3-(2'-phenyl-[4,4'-bipyridin]-2-yl)propan-1-amine (4p) 
 
Prepared according to general procedure C using (2-(1-(4-chlorophenyl)-3-
(dimethylamino)propyl)pyridin-4-yl)diphenyl(2-phenylpyridin-4-yl)phosphonium 
trifluoromethanesulfonate (381 mg, 0.50 mmol), trifluoromethanesulfonic acid (134 μL, 1.50 
mmol) and EtOH (1.25 mL) at 80 °C for 12 hours. Flash column chromatography (silica gel: 9% 
MeOH in CH2Cl2) afforded the title compound as a light yellow oil (179 mg, 0.42 mmol, 84% 
yield). IR υmax/cm-1 (film): 3410, 3027, 2940, 2856, 2815, 2766, 2430, 2203, 1590, 1533, 1488, 
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1467, 1445, 1379, 1261, 1089, 1025, 1014, 907, 829, 775, 756, 727, 694; 1H NMR (400 MHz, 
CDCl3) δ: 8.74 (1H, d, J = 4.9 Hz), 8.68 (1H, d, J = 4.9 Hz), 8.01 (2H, d, J = 7.4 Hz), 7.87 (1H, 
s), 7.49‒7.33 (8H, m), 7.25 (2H, d, J = 8.6 Hz), 4.29 (1H, t, J = 7.4 Hz), 2.70‒2.34 (10H, m); 13C 
NMR (100 MHz, CDCl3) δ: 163.01, 158.27, 150.26, 150.06, 146.48, 146.27, 141.11, 138.76, 
132.47, 129.21, 129.15, 128.66, 126.88, 120.96, 119.79, 119.49, 118.23, 56.90, 49.98, 44.25, 




Prepared according to general procedure C using (2-(4-bromophenyl)pyridin-4-yl)(8-chloro-
11-(1-(ethoxycarbonyl)piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-
b]pyridin-4-yl)diphenylphosphonium trifluoromethanesulfonate (237 mg, 0.25 mmol), 
trifluoromethanesulfonic acid (44 L, 0.50 mmol), and EtOH (625 L). The was reaction was 
heated to 80 ºC for 30 hrs. Flash column chromatography (basic alumina, gradient elution: 20% 
EtOAc in hexanes to 40% EtOAc in hexanes) afforded the title compound as a white solid (133 
mg, 0.22 mmol, 87% yield). mp 95-98 ºC; IR max/cm-1 (film): 3050, 2972, 2922, 1690, 1578, 
1473, 1428, 1222, 1008, 826, 729; 1H NMR (400 MHz, CDCl3) : 8.77 (1H, d, J = 5.0 Hz), 8.49 
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(1H, d, J = 5.0 Hz), 7.91 (2H, d, J = 8.6 Hz), 7.66-7.58 (3H, m), 7.21-7.14 (3H, m), 7.12 (1H, s) 
7.06 (1H, d, J = 5.0 Hz), 4.14 (2H, q, J = 7.2 Hz), 3.82 (2H, br s), 3.41-3.29 (1H, m), 3.27-3.12 
(3H, m), 2.88-2.72 (2H, m), 2.56-2.35 (3H, m), 2.34-2.20 (1H, m), 1.26 (3H, t, J = 7.2 Hz); 13C 
NMR (100 MHz, CDCl3)  159.73, 156.58, 155.34, 149.87, 147.81, 147.09, 146.77, 138.50, 
137.53, 137.34, 135.89, 134.11, 133.01, 131.90, 131.21, 130.30, 129.60, 128.41, 126.07, 123.84, 
122.53, 121.87, 119.70, 61.24, 44.69, 44.57, 32.12, 30.60, 30.51, 27.48, 14.48; m/z HRMS 




Prepared according to general procedure C using (2-(2-chloro-5-(2-chloro-4-
(methylsulfonyl)benzamido)phenyl)pyridin-4-yl)(4-methylquinolin-2-yl)diphenylphosphonium 
trifluoromethanesulfonate (224 mg, 0.25 mmol), 4.0 M HCl in dioxanes (125 L, 0.50 mmol), and 
(2,2,2)-Trifluoroethanol (625 L). The was reaction was heated to 80 ºC for 37 hours.  Flash 
column chromatography (silica gel was packed in hexanes and neutralized with NEt3 then gradient 
elution: CH2Cl2 to 1.5% MeOH in CH2Cl2) followed by a second flash column (basic alumina, 
gradient elution: CH2Cl2 to 2% MeOH in CH2Cl2) and the resulting solid was washed on a frit with 
200 mL of Et2O and then 25 mL of chilled CH2Cl2 (0 ºC). The title compound was isolated as a 
white solid (73 mg, 0.13 mmol, 52% yield). decomp. 270-275 ºC; IR max/cm-1 (film): 3318, 3018, 
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2992, 2914, 1689, 1539, 1299, 1152, 1030, 816, 751; 1H NMR (400 MHz, CDCl3) : 10.99, (1H, 
s), 8.89 (1H, d, J = 5.2 Hz), 8.28 (1H, d, J = 5.2 Hz), 8.21 (1H, s), 8.18-8.07 (4H, m), 8.02 (1H, 
dd, J = 8.0, 1.5 Hz), 7.94 (1H, d, J = 8.0 Hz), 7.87-7.76 (2H, m), 7.72-7.59 (2H, m), 3.36 (3H, s), 
2.79 (3H, s); 13C NMR (100 MHz, CDCl3)   163.87, 156.84, 152.95, 150.28, 147.31, 146.12, 
146.03, 143.13, 140.84, 139.31, 137.65, 130.97, 130.44, 130.08-129.82 (3C, m), 128.10, 127.60, 
127.16, 125.99, 125.91, 124.21, 122.35, 121.81, 125.99, 125.91, 124.21, 122.35, 121.81, 121.07, 
120.42, 119.31, 43.09, 18.39; m/z HRMS (ESI + APCI) found [M+H]+ 562.0766, 
C29H22Cl2N3O3S+ requires  562.0753. 
5,7-Dichloro-4'-ethoxy-4-(4-fluorophenoxy)-2,2'-biquinoline (4s) 
 
Prepared according to general procedure C, using (5,7-dichloro-4-(4-
fluorophenoxy)quinolin-2-yl)(4-ethoxyquinolin-2-yl)diphenylphosphonium 
trifluoromethanesulfonate (203 mg, 0.25 mmol), trifluoromethanesulfonic acid (42 L, 0.50 
mmol), and (2,2,2)-Trifluoroethanol (625 L) at 80 oC for 36 hours. The crude material was 
suspended in a 5mL CH2Cl2 and filtered over a frit with cold CH2Cl2 to provide the title compound 
as a white crystalline solid (69 mg, 0.15 mmol, 58% yield). mp 235-238 oC; IR max/cm-1 (film): 
3065, 2978, 1430, 1296, 1214, 1117, 733; 1H NMR (400 MHz, CDCl3) : 8.24 (1H, d, J = 8.2 Hz), 
8.19-8.12 (2H, m), 8.10 (1H, s), 7.97 (1H, d, J = 8.4 Hz), 7.67 (1H, t, J = 7.3 Hz), 7.60 (1H, d, J = 
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1.8 Hz), 7.51 (1H, t, J = 15.0 Hz), 7.24 (4H, m), 4.47 (2H, q, J = 7.0 Hz), 1.64 (3H, t, J = 7.0 Hz); 
13C NMR (100 MHz, CDCl3)     (d, J = 243.8 Hz), 158.99, 155.89, 151.37, 
150.39 (d, J = 2.7 Hz), 148.69, 134.94, 130.24, 129.86, 129.67, 129.42, 128.18, 126.26, 122.87 (d, 
J = 8.5 Hz), 121.94, 121.77, 118.42, 116.98 (d, J = 23.6 Hz), 105.31, 98.17, 64.38, 14.55; 19F 





Prepared according to general procedure C, using (5-chloro-6'-methyl-3-(4-
(methylsulfonyl)phenyl)-[2,3'-bipyridin]-4'-yl)(4-methylquinolin-2-yl)diphenylphosphonium 
trifluoromethanesulfonate (83 mg, 0.10 mmol), trifluoromethanesulfonic acid (26 L, 0.30 mmol), 
and EtOH (0.25 mL) at 80 oC for 22 hours. The crude material was purified by flash 
chromatography (silica gel gradient elution: 3% MeOH in CH2Cl2 to 4% MeOH in CH2Cl2) to 
provide the title compound as a white crystalline solid (40 mg, 0.08 mmol, 80% yield). mp 286-
290 oC; IR max/cm-1 (film): 3034, 2926, 1506, 1264, 1034, 873, 863; 1H NMR (400 MHz, CDCl3) 
: 8.69-8.59 (2H, m), 7.96 (1H, d, J = 8.0 Hz), 7.68-7.43 (6H, m), 7.35 (1H, s), 6.94-6.81 (3H, m), 
3.00 (3H, s), 2.67 (3H, s), 2.61 (3H, s); 13C NMR (100 MHz, CDCl3)  
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Prepared according to general procedure C using (3-(2-((2-methyl-5-(4-((4-methylpiperazin-
1-yl)methyl)benzamido)phenyl)amino)pyrimidin-4-yl)pyridin-4-yl)(4-methylquinolin-2-
yl)diphenylphosphonium trifluoromethanesulfonate (97 mg, 0.10 mmol), 
trifluoromethanesulfonic acid (36 μL, 0.40 mmol) and EtOH (0.25 mL) at 80 °C for 48 hours. 
Flash column chromatography by three times (silica gel: 30% toluene, 3% MeOH and 1% Et3N in 
CH2Cl2) afforded the title compound as a colorless oil (26 mg, 0.04 mmol, 41% yield). IR υmax/cm-
1 (film): 3249, 3036, 2933, 2796, 1663, 1572, 1553, 1525, 1505, 1446, 1406, 1349, 1287, 1204, 
1162, 1138, 1010, 906, 816, 758, 730; 1H NMR (400 MHz, CDCl3) δ: 9.02 (1H, s), 8.83 (1H, d, J 
= 5.0 Hz), 8.26 (1H, d, J = 5.1 Hz), 8.09 (1H, s), 7.96‒7.87 (5H, m), 7.72 (1H, d, J = 5.0 Hz), 7.66 
(1H, t, J = 7.5 Hz), 7.55 (1H, t, J = 7.4 Hz), 7.48‒7.44 (3H, m), 7.09‒7.06 (2H, m), 6.83 (1H, s), 
6.62 (1H, d, J = 5.1 Hz), 3.56 (2H, s), 2.57‒2.29 (14H, m), 2.13 (3H, s); 13C NMR (100 MHz, 
CDCl3) δ: 165.33, 164.51, 160.07, 157.95, 156.20, 150.85, 150.62, 147.78, 147.57, 144.55, 142.50, 
137.36, 136.47, 133.86, 132.78, 130.60, 129.99, 129.67, 129.24, 127.14, 127.12, 126.91, 124.53, 
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123.66, 123.51, 122.41, 115.13, 112.72, 112.53, 62.52, 55.08, 53.12, 45.99, 18.74, 17.32; m/z 
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Bis-Heterobiaryl Formation from Chloroazines: Experimental 
(Combined Work of Ben Boyle and Michael Hilton) 
 
A 3.1 General Methods and Materials 
 HPPh2 (99%) was purchased from Oakwood Chemicals and stored in a glovebox. (2,2,2)- 
Trifluoroethanol (TFE) was purchased from Oakwood Chemicals and used without further 
purification. Anhydrous chlorobenzene (>99.8%) was purchased from Sigma Aldrich chemical 
company and used without further purification. HCl (4.0 M in dioxanes) and 
trifluoromethanesulfonic acid (98%) were purchased from Sigma Aldrich chemical company and 
used without further purification but were routinely stored in a –20 ºC fridge. KPF6 (>99%) was 
purchased from Sigma Aldrich chemical company and used without further purification but was 
routinely stored in a desiccator. NaOTf was purchased from Oakwood Chemicals and used without 
further purification but was routinely stored in a desiccator. All reactions were run under a nitrogen 
atmosphere unless otherwise noted.  
A 3.2 Instrumentation 
 1H NMR spectra were recorded using a Bruker Ultrashield–400, a Varian 400 MR or an 
Agilent Inova 400 spectrometer. The chemical shifts (δ) were reported in ppm and referenced to 
the corresponding NMR solvent: CDCl3 (7.26 ppm), (CD3)2SO (2.50 ppm), or CD3OD (3.31 
ppm). Coupling constants (J) were reported in Hertz (Hz) and the multiplicity was reported as 




= multiplet, br = broad. 13C NMR spectra were recorded using a Bruker Ultrashield–400, a 
Varian 400 MR or an Agilent Inova 400 spectrometer. The chemical shifts (δ) were reported in 
ppm and referenced to the corresponding NMR solvent: CDCl3 (77.16 ppm), (CD3)2SO (39.51 
ppm), or CD3OD (49.00 ppm). Low–resolution mass spectra were recorded on an Agilent 6310 
Quadrupole Mass Spectrometer. Infrared spectra were recorded on a Bruker Tensor 27 FT–IR 
spectrometer with absorptions reported in wavenumbers (cm–1). Melting points were recorded 
using a Büchi B–450 melting point apparatus.  
A 3.3. General Procedures 
A 3.3.1 General Procedure A (2,4′ or 4,4′-bipyridine synthesis) 
 
An oven dried 8 mL vial with a septa cap was charged with the heterocyclic phosphine (1.0 
equiv), sodium trifluoromethanesulfonate (3.2 equiv) and heteroaryl chloride 2 (1.2 equiv). The 
vial was subjected to three rapid cycles of vacuum/nitrogen backfill and then dioxane (2.0M) and 
4.0M HCl in dioxane (1.0 equiv) were added via a syringe. The septa cap was quickly replaced 
with an unpierced one and the reaction was heated to 120 ºC and allowed to stir for the stated time. 
The reaction was allowed to cool to room temperature before the septa cap was removed and 4.0M 
HCl in dioxanes (1.0 equiv), H2O (10 equiv), and TFE (dilute to 0.4M) were quickly added. The 
reaction vial was heated to 80 oC and allowed to stir for the stated time. The reaction was quenched 
with a saturated aqueous solution of Na2CO3 and the aqueous layer was extracted with CH2Cl2 




(MgSO4), filtered, and concentrated in vacuo. The residue was purified by flash column 
chromatography under the stated conditions to provide the heterobiaryl.  
3'-Chloro-6-methyl-2,4'-bipyridine (5a) 
 
Prepared according to general procedure A using 2-(diphenylphosphaneyl)-6-methylpyridine 
(69 mg, 0.25 mmol), 3,4-dichloropyridine (44 mg,  0.30 mmol), sodium trifluoromethanesulfonate 
(138 mg, 0.80 mmol), 4.0M HCl in dioxanes (63 L, 0.25 mmol), and dioxanes (0.13 mL) at 120 
C for 17 hours; then H2O (45 L, 2.5 mmol), 4.0M HCl in dioxanes (63 L, 0.25 mmol), and TFE 
(0.50 mL) at 80 C for 22 hours. Flash column chromatography (silica gel: 45% EtOAc in hexanes) 
afforded the title compound as a white crystalline solid (41 mg, 0.20 mmol, 81% yield). mp 59-60 
C; IR max/cm-1 (film): 3063, 3035, 3014, 3002, 2958, 1371, 1248, 980, 750, 742, 613; 1H NMR 
(400 MHz, CDCl3) : 8.68 (1H, s), 8.57 (1H, d, J = 5.0 Hz), 7.70 (1H, t, J = 7.8 Hz), 7.57 (1H, d, 
J = 4.9 Hz), 7.52 (1H, d, J = 7.7 Hz), 7.23 (1H, d, J = 7.7 Hz), 2.64 (3H, s); 13C NMR (100 MHz, 
CDCl3)  159.1, 153.6, 150.4, 148.2, 146.3, 136.6, 129.9, 125.5, 123.3, 121.7, 24.8; m/z LRMS 






Prepared according to general procedure A except with additional 4.0M HCl in dioxanes (1.2 
equiv.) using 2-(diphenylphosphaneyl)pyridine (66 mg, 0.25 mmol), 4-chloro-N-
methylpicolinamide (51 mg,  0.30 mmol), sodium trifluoromethanesulfonate (138 mg, 0.80 mmol), 
4.0M HCl in dioxanes (75 L, 0.3 mmol), and dioxanes (0.13 mL) at 120 C for 22 hours; then 
H2O (45 L, 2.5 mmol), 4.0M HCl in dioxanes (63 L, 0.25 mmol), and TFE (0.50 mL) at 80 C 
for 25.5 hours. Flash column chromatography (silica gel: 70% EtOAc in hexanes) afforded the 
title compound as a colorless oil (42 mg, 0.20 mmol, 79% yield). IR max/cm-1 (film): 3404, 3053, 
2926, 1670, 1603, 1587, 1533, 1461, 1433, 1412, 1265, 735; 1H NMR (400 MHz, CDCl3) : 8.73 
(1H, d, J = 4.9 Hz), 8.69 (1H, d, J = 1.8 Hz), 8.63 (1H, d, J = 5.1 Hz), 8.16 (1H, dd, J = 5.1, 1.9 
Hz), 8.08 (1H, br s), 7.91 (1H, d, J = 7.9 Hz), 7.86–7.77 (1H, m), 7.34 (1H, ddd, J = 7.5, 4.8, 1.1 
Hz), 3.05 (3H, d, J = 5.1 Hz); 13C NMR (100 MHz, CDCl3)   164.9, 153.9, 150.6, 150.1, 148.8, 
147.9, 137.1, 124.1, 123.5, 121.1, 119.2, 26.1; m/z LRMS (ESI + APCI) found [M+H]+ 214.1, 
C12H12N3O+ requires  214.1. 
5-(Thiophen-2-yl)-2'-(trifluoromethyl)-2,4'-bipyridine (5c) 
 
Prepared according to general procedure A using 2-(diphenylphosphaneyl)-5-(thiophen-2-
yl)pyridine (86 mg, 0.25 mmol), 4-chloro-2-(trifluoromethyl)pyridine (31 L,  0.30 mmol), 




mmol), and dioxanes (0.13 mL) at 120 C for 24 hours; then H2O (45 L, 2.5 mmol), 4.0M HCl 
in dioxanes (63 L, 0.25 mmol), and TFE (0.50 mL) at 80 C for 22 hours. Flash column 
chromatography (silica gel: 10% EtOAc in hexanes) afforded the title compound as a faint yellow 
crystalline solid (44 mg, 0.14 mmol, 57% yield). mp 93-94 C; IR max/cm-1 (film): 3071, 3046, 
2954, 2922, 2851, 1606, 1572, 1471, 958, 856, 749; 1H NMR (400 MHz, CDCl3) : 9.03 (1H, dd, 
J = 2.4, 0.9 Hz), 8.84 (1H, d, J = 5.1 Hz), 8.37 (1H, dd, J = 1.7, 0.8 Hz), 8.12 (1H, dd, J = 5.1, 1.7 
Hz), 8.03 (1H, dd, J = 8.3, 2.4 Hz), 7.88 (1H, dd, J = 8.3, 0.9 Hz), 7.51-7.41 (2H, m), 7.18 (1H, 
dd, J = 5.1, 3.6 Hz); 13C NMR (100 MHz, CDCl3)  151.7, 150.9, 149.4 (d, J = 34.54 Hz), 147.8, 
147.5, 139.7, 134.1, 131.5, 128.8, 127.2, 125.2, 123.4, 123.3, 121.9 (q, J = 274.34 Hz), 117.9 (d, 
J = 2.57 Hz); 19F NMR (365 MHz, CDCl3)  − m/z LRMS (ESI + APCI) found [M+H]+ 
307.1, C15H10F3N2S+ requires  307.1. 
7-(5-(Thiophen-2-yl)pyridin-2-yl)thieno[3,2-b]pyridine (5d) 
 
Prepared according to general procedure A using 2-(diphenylphosphaneyl)-5-(thiophen-2-
yl)pyridine (86 mg, 0.25 mmol), 7-chlorothieno[3,2-b]pyridine (51 mg,  0.30 mmol), sodium 
trifluoromethanesulfonate (138 mg, 0.80 mmol), 4.0M HCl in dioxanes (63 L, 0.25 mmol), and 
dioxanes (0.13 mL) at 120 C for 12 hours; then H2O (45 L, 2.5 mmol), 4.0M HCl in dioxanes 




(silica gel: 50% EtOAc in hexanes) afforded the title compound as a bright yellow crystalline solid 
(55 mg, 0.19 mmol, 75% yield). mp 129-130 C; IR max/cm-1 (film): 3089, 3063, 3041, 3004, 
2975, 2923, 2852, 2520, 2157, 1555, 1389, 1139, 1026, 832, 674; 1H NMR (400 MHz, CDCl3) : 
9.15 (1H, dd, J = 2.1, 1.1 Hz), 8.83 (1H, d, J = 4.9 Hz), 8.12-8.02 (2H, m), 7.90 (1H, d, J = 5.7 
Hz), 7.76 (1H, d, J = 4.9 Hz), 7.64 (1H, d, J = 5.7 Hz), 7.50 (1H, dd, J = 3.6, 1.1 Hz), 7.43 (1H, 
dd, J = 5.0 Hz), 7.18 (1H, dd, J = 5.1, 3.6 Hz); 13C NMR (100 MHz, CDCl3)  158.4, 152.5, 147.5, 
146.0, 140.0, 139.9, 134.6, 133.7, 130.5, 129.8, 128.7, 126.8, 124.9, 124.8, 121.2, 115.0; m/z 
LRMS (ESI + APCI) found [M+H]+ 295.1, C16H11N2S2+ requires  295.0. 
7-(1H-pyrrolo[2,3-b]pyridin-4-yl)thieno[3,2-b]pyridine (5e) 
 
Prepared according to general procedure A using 4-(diphenylphosphaneyl)-1H-pyrrolo[2,3-
b]pyridine (76 mg, 0.25 mmol), 7-chlorothieno[3,2-b]pyridine (51 mg,  0.30 mmol), sodium 
trifluoromethanesulfonate (138 mg, 0.80 mmol), 4.0M HCl in dioxanes (63 L, 0.25 mmol), and 
dioxanes (0.13 mL) at 120 C for 18.5 hours; then H2O (45 L, 2.5 mmol), 4.0M HCl in dioxanes 
(63 L, 0.25 mmol), and TFE (0.50 mL) at 80 C for 24 hours. Flash column chromatography 
(silica gel: 50% EtOAc in hexanes) afforded the title compound as an white crystalline solid (37 
mg, 0.15 mmol, 58% yield). mp 250-251 C; IR max/cm-1 (film): 3122, 2996, 2924, 2860, 2762, 
2710, 2215, 2041, 1557, 1541, 1325; 1H NMR (400 MHz, CDCl3) : 9.79 (1H, s), 8.85 (1H, d, J 
= 4.8 Hz), 8.50 (1H, d, J = 5.0 Hz), 7.81 (1H, d, J = 5.6 Hz), 7.68 (1H, d, J = 5.6 Hz), 7.52 (1H, d, 




 157.4, 149.5, 147.8, 143.4, 141.8, 138.5, 132.3, 131.3, 126.0, 125.7, 118.8, 118.3, 115.2, 100.7; 
m/z LRMS (ESI + APCI) found [M+H]+ 252.1, C14H10N3S+ requires  252.1. 
A 3.3.2 General Procedure B (Couplings involving quinolines/diazines) 
 
An oven dried 8 mL vial with a septa cap was charged with the heterocyclic phosphine (1.0 
equiv), sodium trifluoromethanesulfonate (2.2 equiv) and heteroaryl chloride 2 (1.2 equiv). The 
vial was subjected to three rapid cycles of vacuum/nitrogen backfill and then TFE (0.4M), H2O 
(10 equiv), and HCl (1.2 equiv) were added via a syringe. The septa cap was quickly replaced with 
an unpierced one and the reaction was heated to 80 ºC and allowed to stir for the stated time. The 
reaction was quenched with a saturated aqueous solution of Na2CO3 and the aqueous layer was 
extracted with CH2Cl2 (3x). The combined organic extracts were washed with a saturated aqueous 
solution of brine, dried (MgSO4), filtered, and concentrated in vacuo. The residue was purified by 






Prepared according to general procedure B using 2-(diphenylphosphaneyl)-6-methylpyridine 
(69 mg, 0.25 mmol), 4-chloro-7-(trifluoromethyl)quinoline (69 mg,  0.30 mmol), sodium 
trifluoromethanesulfonate (95 mg, 0.55 mmol), 4.0M HCl in dioxanes (75 L, 0.30 mmol), H2O 
(45 L, 2.5 mmol), and TFE (0.63 mL) at 80 C for 15.5 hours. Flash column chromatography 
(silica gel: 25% EtOAc in hexanes) afforded the title compound as an white crystalline solid (53 
mg, 0.19 mmol, 73% yield). mp 54-55 C; IR max/cm-1 (film): 3053, 2954, 2856, 1655, 1637, 
1623, 1574, 1555, 1368, 1080, 872, 662; 1H NMR (400 MHz, CDCl3) : 9.09 (1H, d, J = 4.4 Hz), 
8.48 (1H, dd, J = 2.0, 1.0 Hz), 8.32-8.26 (1H, m), 7.80 (1H, t, J = 7.7 Hz), 7.71 (1H, dd, J = 8.9, 
1.9 Hz), 7.62 (1H, d, J = 4.4 Hz), 7.42 (1H, d, J = 7.6 Hz), 7.31 (1H, d, J = 7.8 Hz), 2.70 (3H, s); 
13C NMR (100 MHz, CDCl3)  159.2, 155.4, 151.5, 148.1, 146.7, 137.3, 131.3 (q, J = 32.85 Hz), 
128.0-127.7 (2C, m), 127.5, 124.1 (q, J = 272.54 Hz), 123.2, 123.1, 122.7-122.5 (m), 121.9, 24.8; 
19F NMR (365 MHz, CDCl3)  − m/z LRMS (ESI + APCI) found [M+H]+ 289.2, 
C16H12F3N2+ requires  289.1. 
7-Chloro-4-(2,6-dimethylpyridin-4-yl)quinoline (5g) 
 
Prepared according to general procedure B using 4-(diphenylphosphaneyl)-2,6-
dimethylpyridine (73 mg, 0.25 mmol), 4,7-dichloroquinoline (60 mg,  0.30 mmol), sodium 
trifluoromethanesulfonate (95 mg, 0.55 mmol), 4.0M HCl in dioxanes (75 L, 0.30 mmol), H2O 
(45 L, 2.5 mmol), and TFE (0.63 mL) at 80 C for 14 hours. Flash column chromatography (silica 




mmol, 69% yield). mp 88-90 C; IR max/cm-1 (film): 3361, 3087, 3040, 3026, 2961, 2857, 1551, 
1349, 822, 735, 656, 591; 1H NMR (400 MHz, CDCl3) : 8.96 (1H, s), 8.19 (1H, d, J = 2.1 Hz), 
7.77 (1H, d, J = 9.0 Hz), 7.49 (1H, dd, J = 9.0, 2.2 Hz), 7.30 (1H, d, J = 4.4 Hz), 7.07 (2H, s), 2.64 
(6H, s); 13C NMR (100 MHz, CDCl3)  158.5, 151.1, 149.2, 146.5, 146.1, 135.8, 129.1, 128.2, 
126.9, 124.6, 121.1, 120.8, 24.7; m/z LRMS (ESI + APCI) found [M+H]+ 269.1, C16H14ClN2+ 
requires  269.1. 
(2-(4-Methylpyridin-2-yl)quinolin-4-yl)methanol (5h) 
 
Prepared according to general procedure B using 2-(diphenylphosphaneyl)-4-methylpyridine 
(69 mg, 0.25 mmol), (2-chloroquinolin-4-yl)methanol (58 mg, 0.30 mmol), sodium 
trifluoromethanesulfonate (95 mg, 0.55 mmol), 4.0M HCl in dioxanes (75 L, 0.30 mmol), H2O 
(45 L, 2.5 mmol), and TFE (0.63 mL) at 80 ºC for 43 hours. Flash column chromatography (silica 
gel: 4% MeOH in CH2Cl2) followed by a second flash column (silica gel: 3% MeOH in CH2Cl2) 
afforded the title compound as an off-white powder (26 mg, 0.10 mmol, 42% yield). mp 154-157 
ºC; IR max/cm-1 (film): 3292, 2923, 2852, 1602, 1555, 1509, 1480, 1447, 1332, 1093, 1080, 826, 
763; 1H NMR (400 MHz, CDCl3) : 8.59 (1H, s), 8.56 (1H, d, J = 5.0 Hz), 8.41 (1H, d, J = 1.7 
Hz), 8.17 (1H, dd, J = 8.4, 1.3 Hz), 7.95 (1H, dd, J = 8.4, 1.4 Hz), 7.70 (1H, ddd, J = 8.4, 6.8, 1.4 
Hz), 7.52 (1H, ddd, J = 8.2, 6.8, 1.3 Hz), 7.18 (1H, dd, J = 5.1, 1.7 Hz), 5.20 (2H, s), 3.14 (1H, br 




129.4, 126.9, 126.0, 125.2, 123.1, 122.7, 116.7, 62.4, 21.3; m/z LRMS (ESI + APCI) found 
[M+H]+ 251.1, C16H15N2O+ requires  251.1.  
4-(4-(7-Chloroquinolin-4-yl)pyridin-2-yl)phenol (5i) 
 
Prepared according to general procedure B using 4-(4-(diphenylphosphaneyl)pyridin-2-
yl)phenol (71 mg, 0.20 mmol), 4,7-dichloroquinoline (48 mg,  0.24 mmol), sodium 
trifluoromethanesulfonate (76 mg, 0.44 mmol), 4.0M HCl in dioxanes (60 L, 0.24 mmol), H2O 
(36 L, 2.0 mmol), and TFE (0.5 mL) at 80 ºC for 44.5 hours. Flash column chromatography 
(silica gel: 60% EtOAc in hexanes) afforded the title compound as an off-white powder (50 mg, 
0.15 mmol, 75% yield). mp 258-260 ºC; IR max/cm-1 (film): 3033, 2921, 2850, 1608, 1580, 1539, 
1520, 1451, 1419, 1382, 1274, 1240, 1179, 878, 833, 822; 1H NMR (400 MHz, DMSO-d6) δ: 9.78 
(1H, s), 9.04 (1H, d, J = 4.4 Hz), 8.77 (1H, dd, J = 4.9, 0.8 Hz), 8.20 (1H, d, J = 2.2 Hz), 8.07–
8.00 (2H, m), 7.98 (1H, s), 7.89 (1H, d, J = 9.0 Hz), 7.71–7.57 (2H, m), 7.42 (1H, dd, J = 4.9, 1.5 
Hz), 6.87 (2H, d, J = 8.7 Hz); 13C NMR (100 MHz , CDCl3)   158.8, 156.8, 151.5, 149.7, 148.4, 
145.5, 145.4, 134.4, 129.2, 128.3, 128.1, 128.0, 127.3, 124.0, 121.8, 119.4, 115.5; m/z LRMS (ESI 








Prepared according to general procedure B using 2-(diphenylphosphaneyl)-5-(thiophen-2-
yl)pyridine (86 mg, 0.25 mmol), 2-chloro-8-methoxy-4-methylquinoline (62 mg,  0.30 mmol), 
sodium trifluoromethanesulfonate (95 mg, 0.55 mmol), 4.0M HCl in dioxanes (75 L, 0.30 mmol), 
H2O (45 L, 2.5 mmol), and TFE (0.63 mL) at 80 C for 18 hours. Flash column chromatography 
(silica gel: 60% EtOAc in Et2O) followed by a second flash column (silica gel neutralized with 
NEt3: gradient elution: 5% EtOAc in hexanes to 10% EtOAc in hexanes) afforded the title 
compound as a yellow amorphous solid (42 mg, 0.13 mmol, 50% yield). IR max/cm-1 (film): 3070, 
2956, 2934, 2832, 1600, 1567, 1546, 1126, 958, 814, 663, 647; 1H NMR (400 MHz, CDCl3) : 
8.98 (1H, dd, J = 2.4, 0.8 Hz), 8.74 (1H, dd, J = 8.3, 0.8 Hz), 8.48 (1H, s), 8.04 (1H, dd, J = 8.3, 
2.4 Hz), 7.61 (1H, dd, J = 8.5, 1.2 Hz), 7.55-7.44 (2H, m), 7.40 (1H, dd, J = 5.1, 1.1 Hz), 7.16 (1H, 
dd, J = 5.1, 3.6 Hz), 7.09 (1H, dd, J = 7.7. 1.2 Hz), 4.13 (3H, s), 2.80 (3H, d, J = 1.0 Hz); 13C NMR 
(100 MHz, CDCl3)  156.1, 155.3, 154.1, 146.1, 145.1, 145.2, 140.6, 139.9, 133.8, 130.6, 129.6, 
128.5, 126.8, 126.3, 124.5, 122.2, 120.1, 115.9, 107.9, 56.4, 19.6; m/z LRMS (ESI + APCI) found 






Prepared according to general procedure B using 2-(diphenylphosphaneyl)-4-
methoxypyrimidine (74 mg, 0.25 mmol), 4-chloro-2-(methylthio)pyrimidine (35 L,  0.30 mmol), 
sodium trifluoromethanesulfonate (95 mg, 0.55 mmol), 4.0M HCl in dioxanes (75 L, 0.30 mmol), 
H2O (45 L, 2.5 mmol), and TFE (0.63 mL) at 80 ºC for 13 hours. Flash column chromatography 
(silica gel, gradient elution: 20% EtOAc in hexanes to 40% EtOAc in hexanes) afforded the title 
compound as a white powder (23 mg, 0.10 mmol, 38% yield). mp 93-95 ºC; IR max/cm-1 (film): 
3068, 3035, 2993, 2952, 2923, 2852, 1567, 1553, 1536, 1469, 1370, 1337, 1286, 1207, 843, 788; 
1H NMR (400 MHz, CDCl3) : 8.71 (1H, d, J = 5.1 Hz), 8.65 (1H, d, J = 5.7 Hz), 7.99 (1H, d, J = 
5.1 Hz), 6.81 (1H, d, J = 5.8 Hz), 4.10 (3H, s), 2.66 (3H, s); 13C NMR (100 MHz , CDCl3) 
          ; m/z LRMS (ESI + APCI) 
found [M+H]+ 235.1, C10H11N4OS+ requires  235.1. 
4-(5-Ethylpyrimidin-2-yl)-6,7-dimethoxyquinazoline (5l) 
 
Prepared according to general procedure B using 2-(diphenylphosphaneyl)-5-ethylpyrimidine 




trifluoromethanesulfonate (95 mg, 0.55 mmol), 4.0M HCl in dioxanes (75 L, 0.30 mmol), H2O 
(45 L, 2.5 mmol), and TFE (0.63 mL) at 80 C for 12 hours. Flash column chromatography (silica 
gel: 4% MeOH in CH2Cl2) afforded the title compound as a yellow crystalline solid (40 mg, 0.14 
mmol, 54% yield). mp 163-164 C; IR max/cm-1 (film): 3090, 3043, 3009, 2928, 1557, 1341, 940, 
827, 630, 599, 562; 1H NMR (400 MHz, CDCl3) : 9.34 (1H, s), 8.89 (2H, s), 8.21 (1H, s), 7.42 
(1H, s), 4.09 (3H, s), 4.01 (3H, s), 2.82 (2H, q, J = 7.6 Hz), 1.40 (3H, t, J = 7.6 Hz); 13C NMR (100 
MHz, CDCl3)  162.2, 159.0, 157.1 (2C), 156.1, 153.7, 151.0, 151.0, 137.6, 119.1, 107.1, 104.4, 




Prepared according to general procedure B using 2-(diphenylphosphaneyl)-5-(thiophen-2-
yl)pyridine (86 mg, 0.25 mmol), 2-chloro-8-methoxy-4-methylquinoline (62 mg,  0.30 mmol), 
sodium trifluoromethanesulfonate (95 mg, 0.55 mmol), 4.0M HCl in dioxanes (75 L, 0.30 mmol), 
H2O (45 L, 2.5 mmol), and TFE (0.63 mL) at 80 C for 18 hours. Flash column chromatography 
(silica gel: 60% EtOAc in hexanes) followed by a second flash column (silica gel: gradient elution: 
CH2Cl2 to 2% MeOH in CH2Cl2) afforded the title compound as an orange crystalline solid (60 
mg, 0.16 mmol, 63% yield). mp 173-174 C; IR max/cm-1 (film): 3496, 3061, 3010, 2969, 2941, 
2835, 1592, 1560, 1546, 1402, 1318, 1160, 884; 1H NMR (400 MHz, CDCl3) : 8.92 (1H, dd, J = 




2.1 Hz), 7.81 (1H, dt. J = 9.1, 2.1 Hz), 7.63 (1H, d, J = 8.4 Hz), 7.54 (1H, dt, J = 8.0, 1.9 Hz), 7.12 
(1H, d, J = 7.7 Hz), 4.15 (3H, d, J = 1.9 Hz), 2.84 (3H, d, J = 1.8 Hz); 13C NMR (100 MHz, CDCl3) 
 157.0, 156.2, 154.1, 146.6, 145.3, 139.9, 135.7, 133.0, 131.6, 129.9, 129.8, 129.6, 127.2, 120.8, 
120.8, 120.4, 115.9, 108.0, 56.4, 19.6; m/z LRMS (ESI + APCI) found [M+H]+ 379.1, 
C20H16BrN2O+ requires  379.0. 
A 3.3.3 General Procedure C (2,2′-bipyridines synthesis) 
 
An oven dried 8 mL vial with a septa cap was charged with the heterocyclic phosphine (1.0 
equiv), potassium hexafluorophosphate (1.0 equiv), and heteroaryl chloride 2 (2.0 equiv). The vial 
was subjected to three rapid cycles of vacuum/nitrogen backfill and then chlorobenzene (2.0M) 
and trifluoromethanesulfonic acid (1.2 equiv) were added via a syringe. The septa cap was quickly 
replaced with an unpierced one and the reaction was heated to 130 ºC for the stated time. The 
reaction was then allowed to cool to room temperature. The septa cap was removed and 4.0M HCl 
in dioxanes (1.0 equiv), H2O (10 equiv), and TFE (dilute to 0.4M) were quickly added. The 
reaction vial was then heated at 80 oC for the stated time. The reaction was quenched with a 
saturated aqueous solution of Na2CO3 and the aqueous layer was extracted with CH2Cl2 (3x). The 
combined organic extracts were washed with a saturated aqueous solution of brine, dried (MgSO4), 
filtered, and concentrated in vacuo. The residue was purified by flash column chromatography 






Prepared according to general procedure C using 2-(diphenylphosphaneyl)-6-methylpyridine 
(69 mg, 0.25 mmol), 2-chloro-5-(pyrrolidin-1-ylmethyl)pyridine (98 mg,  0.50 mmol), potassium 
hexafluorophosphate (46 mg, 0.25 mmol), trifluoromethanesulfonic acid (71 L, 0.80 mmol), and 
chlorobenzene (0.13 mL) at 130 ºC for 39.5 hours; then H2O (45 L, 2.5 mmol), 4.0M HCl in 
dioxanes (63 L, 0.25 mmol), and TFE (0.50 mL) at 80 ºC for 24 hours. Flash column 
chromatography (silica gel was packed in hexanes and neutralized with NEt3 then gradient elution: 
30% EtOAc in hexanes to 70% EtOAc in hexanes) afforded the title compound as an orange oil 
(22 mg, 0.09 mmol, 35% yield). IR max/cm-1 (film): 3057, 2960, 2786, 1593, 1573, 1560, 1454 
1410, 1347, 1080, 1025, 800, 759; 1H NMR (400 MHz, CDCl3) : 8.59 (1H, d, J = 1.7 Hz), 8.35 
(1H, d, J = 8.1 Hz), 8.14 (1H, d, J = 7.8 Hz), 7.81 (1H, dd, J = 8.1, 2.1 Hz), 7.68 (1H, t, J = 7.7 
Hz), 7.15 (1H, d, J = 7.6 Hz), 3.69 (2H, s), 2.62 (3H, s), 2.58-2.50 (4H, m), 1.83-1.77 (4H, m); 13C 
NMR (100 MHz, CDCl3) 
              ; m/z 






Prepared according to general procedure C using 2-(diphenylphosphaneyl)-4-methylpyridine 
(69 mg, 0.25 mmol), 2-chloro-5-(3-(pentafluoro-6-sulfaneyl)phenyl)pyridine (158 mg,  0.50 
mmol), potassium hexafluorophosphate (46 mg, 0.25 mmol), trifluoromethanesulfonic acid (27 
L, 0.30 mmol), and chlorobenzene (0.13 mL) at 130 ºC for 39 hours; then H2O (45 L, 2.5 mmol), 
4.0M HCl in dioxanes (63 L, 0.25 mmol), and TFE (0.50 mL) at 80 ºC for 22 hours. Flash column 
chromatography (silica gel: 40% EtOAc in hexanes) afforded the title compound as a light tan 
powder (48 mg, 0.13 mmol, 51% yield). mp 129-131 ºC; IR max/cm-1 (film): 3022, 2923, 2852, 
1606, 1595, 1465, 1435, 1368, 1115, 859, 825; 1H NMR (400 MHz, CDCl3) : 8.89 (1H, s), 8.66-
8.44 (2H, m), 8.29 (1H, s), 8.11-7.93 (2H, m), 7.89-7.72 (2H, m), 7.60 (1H, t, J = 7.8 Hz), 7.17 
(1H, d, J = 3.6 Hz), 2.46 (3H, s); 13C NMR (100 MHz , CDCl3)     (app t, J = 
17.4 Hz), 149.2, 148.5, 147.7, 139.0, 135.6, 134.8, 130.3, 129.7, 125.6 (app qn, J = 4.5 Hz), 125.2, 
124.8 (app qn, J = 4.5 Hz), 122.2, 121.4, 21.4; 19F NMR (365 MHz, CDCl3)  83.77 (qn, J = 151.8 







Prepared according to general procedure C using 2-(diphenylphosphaneyl)-5-
(trifluoromethyl)pyridine (83 mg, 0.25 mmol), 2-chloro-5-(thiophen-2-yl)pyridine (98 mg,  0.50 
mmol), potassium hexafluorophosphate (46 mg, 0.25 mmol), trifluoromethanesulfonic acid (27 
L, 0.30 mmol), and chlorobenzene (0.13 mL) at 130 C for 45 hours; then H2O (45 L, 2.5 mmol), 
4.0M HCl in dioxanes (63 L, 0.25 mmol), and TFE (0.50 mL) at 80 C for 19 hours. Flash column 
chromatography (silica gel: 2% EtOAc in hexanes) afforded the title compound as a white 
crystalline solid (41 mg, 0.13 mmol, 53% yield). IR max/cm-1 (film): 3124, 3067, 2921, 1599, 
1579, 1548, 1530, 1468, 1209, 782, 751, 644; 1H NMR (400 MHz, CDCl3) :  ( dd, J = 
2.4, 0.8 Hz), 8.93 (1H, dt, J = 2.5, 0.9 Hz), 8.58 (1H, dt, J = 8.4, 0.8 Hz), 8.49 (1H, dd, J = 8.3, 0.8 
Hz), 8.09-7.99 (2H, m), 7.47 (1H, dd, J = 3.6, 1.1 Hz), 7.42 (1H, dd, J = 5.1, 1.1 Hz), 7.17 (1H, 
dd, J = 5.1, 3.6 Hz); 13C NMR (100 MHz, CDCl3)  158.9, 153.4, 146.6, 146.3 (q, J = 4.1 Hz), 
140.2, 134.2, (q, J = 3.5 Hz), 134.0, 131.4, 128.6, 126.8, 126.4 (q, J = 33.00 Hz), 124.9, 123.9 (q, 
J = 272.1 Hz), 121.9, 120.7; 19F NMR (365 MHz, CDCl3)  −  m/z LRMS (ESI + APCI) 




Prepared according to general procedure C using 2-(diphenylphosphaneyl)-5-
(trifluoromethyl)pyridine (66 mg, 0.20 mmol), 6-chloro-N-(3-fluoro-4-




mg, 0.20 mmol), trifluoromethanesulfonic acid (21 L, 0.24 mmol), and chlorobenzene (0.13 mL) 
at 130 C for 45 hours; then H2O (45 L, 2.5 mmol), 4.0M HCl in dioxanes (63 L, 0.25 mmol), 
and TFE (0.50 mL) at 80 C for 19 hours. Preparatory thin layer chromatography (40% EtOAc in 
hexanes) followed by flash column chromatography (silica gel: 1% MeOH in CH2Cl2) afforded 
the title compound as a white amorphous solid (40 mg, 0.09 mmol, 47% yield). IR max/cm-1 (film): 
3853, 3750, 2923, 2852, 2359, 2342, 1733, 1652, 1598, 1540, 1468, 1426, 1132, 1083, 820, 552, 
532; 1H NMR (400 MHz, DMSO-d6) :  ( s), 9.27 (1H, d, J = 2.2 Hz), 9.15 (1H, s), 8.67 
(1H, d, J = 8.4 Hz), 8.61 (1H, d, J = 8.3 Hz), 8.54 (1H, dd, J = 8.3, 2.2 Hz), 8.43 (1H, dd, J = 8.5, 
2.4 Hz), 8.02 (1H, dd, J = 13.6, 1.9 Hz), 7.86-7.74 (2H, m); 13C NMR (100 MHz, DMSO-d6) 
 164.4, 160.3, 157.8, 156.2, 149.1, 146.4 (d, J = 4.1 Hz), 144.6 (d, J = 11.9 Hz), 137.3, 135.2 (d, 
J = 3.7 Hz), 130.7, 127.9 (2C, m), 125.7 (d, J = 32.5 Hz), 123.7 (q, J = 272.3 Hz), 122.8 (q, J = 
270.59 Hz), 121.1 (d, J = 41.7 Hz), 115.8 (d, J = 3.0 Hz), 110.9 (d, J = 32.8 Hz), 107.7 (d, J = 25.4 
Hz); 19F NMR (365 MHz, CDCl3)  − (d, J = 12.0 Hz), −60.89, −114.19 (tt, J = 13.0, 6.7 
Hz)  m/z LRMS (ESI + APCI) found [M+H]+ 430.2, C19H11F7N3O+ requires  430.1. 
4-(3,5-Dichlorophenyl)-4'-methyl-2,2'-bipyridine (5r) 
 
Prepared according to general procedure C using 2-(diphenylphosphaneyl)-4-methylpyridine 
(69 mg, 0.25 mmol), 2-chloro-4-(3,5-dichlorophenyl)pyridine (129 mg,  0.50 mmol), potassium 
hexafluorophosphate (46 mg, 0.25 mmol), trifluoromethanesulfonic acid (27 L, 0.30 mmol), and 




dioxanes (63 L, 0.25 mmol), and TFE (0.50 mL) at 80 C for 20 hours. Flash column 
chromatography (silica gel: 2% MeOH in Et2O) followed by a second flash column (silica gel: 2% 
MeOH in CH2Cl2) afforded the title compound as a white amorphous solid (46 mg, 0.15 mmol, 
58% yield). IR max/cm-1 (film): 3054, 3011, 2922, 2855, 1670, 1595, 1556, 1490, 1138, 849, 720, 
650, 533; 1H NMR (400 MHz, CDCl3) :  ( dd, J = 5.0, 0.8 Hz), 8.53 (1H, dd, J = 4.9, 0.8 
Hz), 8.44 (1H, dd, J = 1.7, 0.8 Hz), 8.28 (1H, dt, J = 1.6, 0.8 Hz), 7.52 (1H, dd, J = 1.8, 0.7 Hz), 
7.42-7.32 (3H, m), 7.15 (1H, ddd, J = 5.0, 1.7, 0.8 Hz), 2.45 (3H, s); 13C NMR (100 MHz, CDCl3) 
 156.7, 155.7, 149.2, 149.1, 148.4, 147.2, 136.8, 135.2, 133.1, 131.9, 130.1, 127.6, 125.1, 124.2, 
122.2 121.8, 21.4; m/z LRMS (ESI + APCI) found [M+H]+ 315.1, C17H13Cl2N2+ requires  315.0. 
6'-Methyl-4-(4-(trifluoromethoxy)phenyl)-2,2'-bipyridine (5s) 
 
Prepared according to general procedure C using 2-(diphenylphosphaneyl)-6-methylpyridine 
(69 mg, 0.25 mmol), 2-chloro-4-(4-(trifluoromethoxy)phenyl)pyridine (137 mg,  0.50 mmol), 
potassium hexafluorophosphate (46 mg, 0.25 mmol), trifluoromethanesulfonic acid (27 L, 0.30 
mmol), and chlorobenzene (0.13 mL) at 130 ºC for 39.5 hours; then H2O (45 L, 2.5 mmol), 4.0M 
HCl in dioxanes (63 L, 0.25 mmol), and TFE (0.50 mL) at 80 ºC for 27 hours. Flash column 
chromatography (silica gel was packed in hexanes and neutralized with NEt3: 10% EtOAc in 
hexanes) afforded the title compound as colorless crystals (47 mg, 0.14 mmol, 57% yield). mp 46-
48 ºC; IR max/cm-1 (film): 3055, 3012, 2920, 1587, 1511, 1459, 1271, 1208, 1150, 1106, 1086, 




(1H, d, J = 7.8 Hz), 7.84-7.75 (2H, m), 7.73 (1H, t, J = 7.7), 7.48 (1H, dd, J = 5.1, 1.9 Hz), 7.36 
(2H, dq, J = 8.6, 1.0 Hz), 7.20 (1H, d, J = 7.6 Hz), 2.66 (3H, s); 13C NMR (100 MHz , CDCl3) 
     (q, J = 1.9 Hz), 149.9, 148.0, 137.4, 137.3, 128.8, 124.5, 121.5, 
121.4, 120.6 (q, J = 257.7 Hz), 119.2, 118.4, 24.8; 19F NMR (365 MHz, CDCl3)  −57.76; m/z 
LRMS (ESI + APCI) found [M+H]+ 331.2, C18H14F3N2O+ requires  331.1.  
A 3.3.4 General Procedure A’ (Heterocyclic Phosphine Synthesis: Pyridines) 
 
An oven dried 8 mL vial equipped with a stir bar was charged with the heterocycle (1.0 equiv). 
The vial was subjected to three rapid cycles of vacuum/nitrogen backfill, chlorobenzene (2.0 M) 
was added, followed by diphenylphosphine (1.2 equiv), and trifluoromethanesulfonic acid (1.0 
equiv). The reaction was heated to 130 oC and allowed to stir for the stated time. The reaction was 
quenched with a saturated aqueous solution of Na2CO3 and the aqueous layer was extracted with 
CH2Cl2 (3x). The combined organic extracts were washed with a saturated aqueous solution of 
brine, dried (MgSO4), filtered, and concentrated in vacuo. The residue was purified by flash 
column chromatography under the stated conditions to provide the heteroaryl phosphine product. 
2-(Diphenylphosphaneyl)-6-methylpyridine (6a) 
 
Prepared according to general procedure A’ using 2-chloro-6-methylpyridine (0.22 mL, 2.00 




mmol), and chlorobenzene (1.0 mL) at 130 ºC for 21 hours. Flash column chromatography (silica 
gel, gradient elution: 5% EtOAc in hexanes to 10% EtOAc in hexanes) afforded the title compound 
as a white powder (522 mg, 1.88 mmol, 94% yield). mp 80-82 ºC; IR max/cm-1 (film): 3048, 3001, 
2961, 1576, 1555, 1443, 1433, 1094, 796, 754, 698; 1H NMR (400 MHz, CDCl3) : 7.44 (1H, td, 
J = 7.2, 1.2 Hz), 7.40-7.29 (10H, m), 7.03 (1H, d, J = 7.8 Hz), 6.82 (1H, d, J = 7.6 Hz), 2.57 (3H, 
s); 13C NMR (100 MHz, CDCl3)  163.2 (d, J = 7.3 Hz), 159.1 (d, J = 14.5 Hz), 136.7 (d, J = 11.2 
Hz), 136.0, 134.2 (d, J = 19.5 Hz), 129.0, 128.6 (d, J = 7.1 Hz), 125.0 (d, J = 11.6 Hz), 122.1, 
24.8; P NMR (162 MHz, CDCl3)  −4.96; m/z LRMS (ESI + APCI) found [M+H]+ 278.1, 
C18H17NP+ requires  278.1. 
2-(Diphenylphosphaneyl)-4-methylpyridine (6b) 
 
Prepared according to general procedure A’ using 2-chloro-4-methylpyridine (0.22 mL, 2.00 
mmol), diphenylphosphane (0.42 mL, 2.40 mmol), trifluoromethanesulfonic acid (177 μL, 2.00 
mmol), and chlorobenzene (1.0 mL) at 130 ºC for 14 hours. Flash column chromatography (silica 
gel, gradient elution: 10% EtOAc in hexanes to 15% EtOAc in hexanes) afforded the title 
compound as a white powder (523 mg, 1.89 mmol, 94% yield). mp 69-71 ºC; IR max/cm-1 (film): 
3066, 3045, 2922, 1584, 1547, 1477, 1457, 1434, 1388, 1373, 1311, 1089, 1025, 999, 826, 752 ; 
1H NMR (400 MHz, CDCl3) : 8.58 (1H, d, J = 4.6 Hz), 7.44-7.29 (10H, m), 7.00 (1H, d, J = 4.1 
Hz), 6.93 (1H, s), 2.25 (3H, s); 13C NMR (100 MHz, CDCl3)  163.4 (d, J = 4.6 Hz), 150.2 (d, J 




J = 16.4 Hz), 128.7 (d, J = 6.9 Hz), 123.4, 21.2; P NMR (162 MHz, CDCl3)  −4.06; m/z LRMS 
(ESI + APCI) found [M+H]+ 278.2, C18H17NP+ requires  278.1. 
4-(Diphenylphosphaneyl)-2,6-dimethylpyridine (6c) 
 
Prepared according to general procedure A’ using 4-chloro-2,6-dimethylpyridine (283 mL, 
2.00 mmol), diphenylphosphane (0.42 mL, 2.40 mmol), trifluoromethanesulfonic acid (177 L, 
2.00 mmol), and chlorobenzene (1.0 mL) at 130 C for 20 hours. Flash column chromatography 
(silica gel: 25% EtOAc in hexanes) afforded the title compound as a white crystalline solid (582 
mg, 2.00 mmol, 99% yield). mp 118-119 C; IR max/cm-1 (film): 3069, 3052, 3000, 2984, 2954, 
2916, 2361, 1739, 1675, 1158, 831, 618, 542; 1H NMR (400 MHz, CDCl3) : 7.47-7.29 (10H, m), 
6.79 (2H, d, J = 7.2 Hz), 2.46 (6H, s); 13C NMR (100 MHz, CDCl3)  157.5 (d, J = 5.1 Hz),149.0 
(d, J = 16.2 Hz), 135.4 (d, J = 10.0 Hz), 134.3 (d, J = 20.3 Hz), 129.5, 128.9 (d, J = 7.5 Hz), 123.9 
(d, J = 15.9 Hz), 24.6; P NMR (162 MHz, CDCl3)  −6.96; m/z LRMS (ESI + APCI) found 
[M+H]+ 292.2, C19H19NP+ requires  292.1. 
4-(Diphenylphosphaneyl)-1H-pyrrolo[2,3-b]pyridine (6d) 
 
Prepared according to general procedure A’ using 4-chloro-1H-pyrrolo[2,3-b]pyridine (305 




L, 2.00 mmol), and chlorobenzene (1.0 mL) at 130 C for 20 hours. Flash column 
chromatography (silica gel: 50% EtOAc in hexanes) afforded the title compound as a faint yellow 
crystalline solid (550 mg, 1.82 mmol, 91% yield). mp 146-148 C; IR max/cm-1 (film): 3119, 3069, 
3054, 2902, 2802, 2763, 1592, 1182, 792, 611; 1H NMR (400 MHz, CDCl3) : 9.76 (1H, s), 8.20 
(1H, d, J = 4.9 Hz), 7.46-7.31 (11H, m), 6.71-6.57 (1H, m), 6.28 (1H, s); 13C NMR (100 MHz, 
CDCl3)  147.6 (d, J = 6.9 Hz), 142.2, 140.5 (d, J = 17.2 Hz), 135.2 (d, J = 20.3 Hz), 134.4 (d, J 
= 20.3 Hz), 129.4, 128.8 (d, J = 7.7 Hz), 125.4, 123.3, 119.2 (d, J = 4.4 Hz), 101.2 (d, J = 6.9 Hz); 
P NMR (162 MHz, CDCl3)  −12.55; m/z LRMS (ESI + APCI) found [M+H]+ 303.1, 
C19H16N2P+ requires  303.1. 
2-(Diphenylphosphaneyl)-5-(trifluoromethyl)pyridine (6e) 
 
Prepared according to general procedure A’ using 2-chloro-5-trifluoromethylpyridine (363 
mg, 2.00 mmol), diphenylphosphane (0.42 mL, 2.40 mmol), trifluoromethanesulfonic acid (177 
L, 2.00 mmol), and chlorobenzene (1.0 mL) at 130 C for 15.5 hours. Flash column 
chromatography (silica gel, gradient elution: 1% EtOAc in hexanes to 2% EtOAc in hexanes) 
afforded the title compound as a yellow oil (590 mg, 1.78 mmol, 89% yield). IR max/cm-1 (film): 
3055, 3003, 2359, 1955, 1881, 1684, 1594, 1558, 1479, 1281, 938, 578; 1H NMR (400 MHz, 
CDCl3) : 8.95 (1H, s), 7.76 (1H, d, J = 8.1), 7.48-7.31 (10H, m), 7.19 (1H, d, J = 8.1 Hz); 13C 
NMR (100 MHz, CDCl3)  169.7 (d, J = 2.2 Hz), 146.8 (dd, J = 11.7, 4.0 Hz), 135.2 (d, J = 9.9), 
134.5 (d, J = 20.3 Hz), 132.9-132.6 (m), 132.3 (d, J = 9.6 Hz), 129.7, 129.0 (d, J = 7.5 Hz), 127.3 








Prepared according to general procedure A’ using 2-chloro-5-(thiophen-2-yl)pyridine (391 
mg, 2.00 mmol), diphenylphosphane (0.42 mL, 2.40 mmol), trifluoromethanesulfonic acid (177 
μL, 2.00 mmol), and chlorobenzene (1.0 mL) at 130 ºC for 21 hours. Flash column 
chromatography (silica gel, gradient elution: 5% EtOAc in hexanes to 10% EtOAc in hexanes) 
afforded the title compound as a white powder (610 mg, 1.77 mmol, 88% yield). mp 89-91 ºC; IR 
max/cm-1 (film): 3053, 1544, 1478, 1458, 1432, 1378, 1267, 1206, 1095, 1025, 850, 828; 1H NMR 
(400 MHz, CDCl3) : 8.99(1H, d, J = 2.0 Hz), 7.74 (1H, dt, J = 8.1, 2.0 Hz), 7.47-7.32 (12H, m), 
7.14-7.07 (2H, m); 13C NMR (100 MHz, CDCl3)  162.6 (d, J = 3.1 Hz), 147.4 (d, J = 13.0 Hz), 
140.3, 136.2 (d, J = 10.7 Hz), 134.3 (d, J = 19.8 Hz), 132.5 (d, J = 2.3 Hz), 129.2, 128.9, 128.8 (d, 
J = 6.9 Hz), 128.4, 128.0 (d, J = 16.8 Hz), 126.3, 124.4; P NMR (162 MHz, CDCl3)  −4.05; 






Prepared according to general procedure A’ using 4-(4-chloropyridin-2-yl)phenol (206 mg, 
1.00 mmol), diphenylphosphane (0.21 mL, 1.20 mmol), trifluoromethanesulfonic acid (88 μL, 1.00 
mmol), and chlorobenzene (0.5 mL) at 130 ºC for 2 hours. Flash column chromatography (silica 
gel, gradient elution: 30% EtOAc in hexanes to 40% EtOAc in hexanes) afforded the title 
compound as a white powder (293 mg, 0.83 mmol, 83% yield). mp 196-198 ºC; IR max/cm-1 
(film): 3004, 2794, 2663, 2591, 2479, 1608, 1579, 1518, 1435, 1376, 1278, 1241, 1174, 1000, 824; 
1H NMR (400 MHz, DMSO-d6) δ: 9.76 (1H, s), 8.54 (1H, dd, J = 5.1, 2.5 Hz), 7.76 (2H, d, J = 8.7 Hz), 
7.53 (1H, d, J = 7.6 Hz), 7.50–7.41 (m, 6H), 7.41–7.29 (m, 4H), 6.91 (1H, ddd, J = 6.2, 4.9, 1.4 Hz), 6.82 
(2H, d, J = 8.7 Hz); 13C NMR (100 MHz, DMSO-d6) δ: 158.7, 155.9 (d, J = 5.4 Hz), 149.2 (d, J = 
4.1 Hz), 148.6 (d, J = 17.3 Hz), 134.7 (d, J = 10.4 Hz), 133.8 (d, J = 20.3 Hz), 129.7, 129.3–128.6 
(2C, m), 127.9, 124.3 (d, J = 13.0 Hz), 122.1 (d, J = 18.8 Hz), 115.6; P NMR (162 MHz, CDCl3) 
 −6.32; m/z LRMS (ESI + APCI) found [M+H]+ 356.2, C23H19NOP+ requires  356.1. 
A 3.3.5 General Procedure B’ (Heterocyclic Phosphine Synthesis: Quinolines and Diazines) 
 
An oven dried 8 mL vial (< 1.0 mmol) or 15 mL pressure tube (1.0-4.0 mmol) equipped with 
a stir bar was charged with the heterocycle (1.0 equiv). The vial was subjected to three rapid cycles 
of vacuum/nitrogen backfill, and TFE (0.4 M) was added, followed by diphenylphosphine (1.2 
equiv). The reaction was heated to 80 oC and allowed to stir for the stated time. The reaction was 
quenched with a saturated aqueous solution of Na2CO3 and the aqueous layer was extracted with 




brine, dried (MgSO4), filtered, and concentrated in vacuo. The residue was purified by flash 




Prepared according to general procedure B’ using 4-chloro-7-(trifluoromethyl)quinoline (926 
mg, 4.00 mmol), diphenylphosphane (0.84 mL, 4.80 mmol), and TFE (10.0 mL) at 80 C for 16 
hours. Flash column chromatography (silica gel: 10% EtOAc in hexanes) afforded the title 
compound as an faint yellow solid (1.30 g, 3.41 mmol, 85% yield). mp 86-89 C; IR max/cm-1 
(film): 3074, 3052, 3016, 1569, 1505, 1478, 1433, 1206, 856, 600, 529; 1H NMR (400 MHz, 
CDCl3) : 8.84 (1H, dd, J = 4.4, 1.2 Hz), 8.44 (1H, s), 8.34 (1H, dd, J = 8.8, 3.4 Hz), 7.62 (1H, dd, 
J = 8.8, 2.0 Hz), 7.46-7.27 (10H, m), 6.93 (1H, t, J = 4.2 Hz); 13C NMR (100 MHz, CDCl3) 
 151.1, 147.6 (d, J = 22.5 Hz), 146.8 (d, J = 2.7 Hz), 134.5 (d, J = 20.5 Hz), 133.9 (d, J = 8.3 
Hz), 131.5 (d, J = 3.5 Hz), 131.4 (d, J = 47.7 Hz), 129.2, 129.2 (d, J = 7.6 Hz), 128.2-127.9 (m), 
127.6 (d, J = 22.0 Hz), 127.1, 124.0 (q, J = 272.5 Hz), 122.6-122.2 (m); F NMR (365 MHz, 
CDCl3)  −62.75  P NMR (162 MHz, CDCl3)  −; m/z LRMS (ESI + APCI) found 






Prepared according to general procedure B using 2-chloro-6-bromoquinoline (485 mg, 2.00 
mmol), diphenylphosphane (0.42 mL, 2.40 mmol), and TFE (5.0 mL) at 80 C for 19 hours. Flash 
column chromatography (silica gel: 5% EtOAc in hexanes) afforded the title compound as an 
orange viscous oil (748 mg, 1.90 mmol, 95% yield). IR max/cm-1 (film): 3047, 3006, 2967, 2929, 
2872, 223, 1963, 1575, 1537, 1286, 999; 1H NMR (400 MHz, CDCl3) : 7.98 ( 1H, d, J = 9.01), 
7.95-7.88 (2H, m), 7.76 (1H, dd, J = 9.0, 2.2 Hz), 7.52-7.30 (10H, m), 7.20 (1H, d, J = 8.5 Hz); 
13C NMR (100 MHz, CDCl3)  165.9 (d, J = 1.54 Hz), 147.2 (d, J = 14.4 Hz), 136.1 (d, J = 11.1 
Hz), 134.4 (d, J = 19.8 Hz) 134.4 (d, J = 2.6 Hz), 133.3, 131.5, 129.8, 129.3, 128.8 (d, J = 7.2 Hz), 
128.0, 125.2 (d, J = 14.7 Hz), 120.9; P NMR (162 MHz, CDCl3)  −; m/z LRMS (ESI + 
APCI) found [M+H]+ 392.1, C21H16BrNP+ requires  392.0. 
1-(diphenylphosphaneyl)isoquinoline (6j) 
 
Prepared according to general procedure B using 1-chloro-isoquinoline (328 mg, 2.00 mmol), 
diphenylphosphane (0.42 mL, 2.40 mmol), and TFE (5.0 mL) at 80 C for 16.5 hours. Flash 
column chromatography (silica gel: 10% EtOAc in hexanes) afforded the title compound as an 
white crystalline solid (579 mg, 1.86 mmol, 93% yield). mp 143-145; C IR max/cm-1 (film): 3069, 
3046, 3004, 2924, 2361, 2340, 1577, 1543, 1492, 1434, 1304, 828, 694, 672, 546, 539, 527; 1H 
NMR (400 MHz, CDCl3) : 8.66-8.56 (2 H, m), 7.82 (1H, d, J = 8.2 Hz), 7.65 (1H, t, J = 7.5 Hz), 
7.58 (1H, d, J = 5.6 Hz), 7.52 (1H, ddd, J = 8.3, 6.8, 1.3 Hz), 7.45-7.29 (10H, m); 13C NMR (100 
MHz, CDCl3)   (d, J = 10.0 Hz), 143.4 (d, J = 4.1 Hz), 136.1 (d, J = 6.9 Hz), 135.5 (d, J = 




7.6 Hz), 127.5 (d, J = 2.0 Hz), 127.3 (d, J = 1.8 Hz), 127.1 (d, J = 23.0 Hz), 120.5; P NMR (162 
MHz, CDCl3)  −; m/z LRMS (ESI + APCI) found [M+H]+ 314.2, C21H17NP+ requires  314.1. 
2-(Diphenylphosphaneyl)-5-ethylpyrimidine (6k) 
 
Prepared according to general procedure B using 2-chloro-5-ethylpyrimidine (243 L, 2.00 
mmol), diphenylphosphane (0.42 mL, 2.40 mmol), and TFE (5.0 mL) at 80 C for 19 hours. Flash 
column chromatography (silica gel: 20% EtOAc in hexanes) afforded the title compound as a white 
crystalline solid (478 mg, 1.64 mmol, 82% yield). mp 78-80 C; IR max/cm-1 (film): 3070, 3045, 
3006, 2929, 1962, 1536, 1208, 1100, 816; 1H NMR (400 MHz, CDCl3) : 8.57 (2H, s), 7.59-7.43 
(4H, m), 7.42-7.30 (6H, m), 2.62 (2H, q, J = 7.63 Hz), 1.27 (3H, t, J = 7.63 Hz); 13C NMR (100 
MHz, CDCl3)  173.8 (d, J  = 12.4 Hz), 156.3 (d, J = 6.7 Hz), 135.9 (d, J = 20.1 Hz), 134.6 (d, J 
= 20.1 Hz), 134.1, 129.3, 128.6 (d, J = 7.6 Hz), 23.6, 14.9; P NMR (162 MHz, CDCl3)  −0.70; 
m/z LRMS (ESI + APCI) found [M+H]+ 293.2, C18H18N2P+ requires  293.2. 
2-(Diphenylphosphaneyl)-4-methoxypyrimidine (6l) 
 
Prepared according to general procedure B using 2-chloro-4-methoxypyrimidine (723 mg, 5.00 mmol), 
diphenylphosphane (1.04 mL, 6.00 mmol, and TFE (13.50 mL) at 80 C for 19.5 hours. Flash column 




mmol, 75% yield). IR max/cm-1 (film): 3052, 3002, 2950, 2363, 2153, 1963, 1907, 1825, 1683, 1610, 782, 
617, 578; 1H NMR (400 MHz, CDCl3) : 8.40 (1H, dd, J = 5.8, 0.7 Hz), 7.59-7.47 (4H, m), 7.40-7.30 (6H, 
m), 6.54 (1H, dd, J = 5.8, 0.9 Hz), 3.75 (3H, s); 13C NMR (100 MHz, CDCl3)  176.0 (d, J = 12.4 Hz), 
168.2 (d, J = 6.2 Hz), 156.8 (d, J = 7.6 Hz), 135.7 (d, J = 7.6 Hz), 134.7 (d, J = 19.8 Hz), 129.1, 128.3 (d, 
J = 7.6 Hz), 106.1 (d, J = 2.0 Hz), 53.7; 31P NMR (162 MHz, CDCl3)  −1.62; m/z LRMS (ESI + APCI) 
found [M+H]+ 295.1, C17H16N2OP
+ requires  295.1. 
2-(Diphenylphosphaneyl)-3-methoxypyrazine (2m) 
 
Prepared according to general procedure B using 2-chloro-3-methoxypyrazine (434 mg, 3.00 
mmol), diphenylphosphane (0.63 mL, 3.60 mmol, and TFE (7.5 mL) at 80 C for 2 hours. Flash 
column chromatography (silica gel, gradient elution: 5% EtOAc in hexanes to 10% EtOAc in 
hexanes) afforded the title compound as a white powder (549 mg, 1.87 mmol, 62% yield). mp 104-
105 C; IR max/cm-1 (film): 3052, 2943, 1515, 1479, 1454, 1434, 1368, 1353, 1297, 1220, 1179, 
1157, 1099, 999, 866, 747; 1H NMR (400 MHz, CDCl3) : 8.19 (1H, d, J = 2.7 Hz), 8.01 (1H, d, 
J = 2.8 Hz), 7.44–7.29 (10H, m), 3.86 (3H, s); 13C NMR (100 MHz, CDCl3)  161.7 (d, J = 21.8 
Hz), 148.6 (d, J = 13.4 Hz), 139.6, 137.6, 134.6 (d, J = 7.2 Hz), 134.3 (d, J = 20.2 Hz), 129.0, 
128.3 (d, J = 7.6 Hz), 53.7; P NMR (162 MHz, CDCl3)  −0.32; m/z LRMS (ESI + APCI) 
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